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Group testing is the process of combining items into groups to test for a binary
characteristic. One of its most widely used applications is infectious disease
testing. In this context, specimens (e.g., blood, urine) are amalgamated into
groups and tested. For groups that test positive, there are many algorith-
mic retesting procedures available to identify positive individuals. The appeal
of group testing is that the overall number of tests needed is significantly less
than for individual testing when disease prevalence is small and an appropriate
algorithm is chosen. Group testing has a number of applications beyond in-
fectious disease testing, such as drug discovery, food contamination detection,
and diagnosis of faulty network sensors.
An important decision that needs to be made prior to implementation is
the group sizes to use. In best practice, an objective function is minimized
to determine the optimal set of group sizes, known as the optimal testing
configuration (OTC). We examine several different objective functions and
show that the OTCs and corresponding results (e.g., number of tests, accuracy)
are largely the same for these functions when using standard group testing
algorithms.
Both estimating the probability of disease and identifying positive individ-
uals are goals of group testing. We present the first general R functions for
identification and make these available in the new binGroup2 package. We
also include in this package estimation functions from the binGroup package
by creating a unified framework for them.
We developed a web-based Shiny application to assist laboratory personnel
in determining how well a group testing algorithm is expected to perform
before implementation. The app utilizes binGroup2 functions to calculate the
expected number of tests and diagnostic accuracy measures for a wide variety
of algorithms using one- and two-disease assays. The OTC can be found with
the app as well.
Most group testing research using one-disease assays makes the assumption
of equal sensitivity and equal specificity values across all stages of testing. We
present derivations of operating characteristics for group testing algorithms
that allow the diagnostic test accuracy to differ across stages of testing. These
resulting expressions are incorporated into the binGroup2 package.
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1Chapter 1
Introduction
1.1. Fundamentals of group testing
As fears of a German World War II victory spread throughout the United
States in 1940, Congress and President Franklin Delano Roosevelt worked to-
gether to pass the Selective Training and Service Act (Encyclopaedia Britan-
nica, Inc., 2017). The law established the first peacetime draft in U.S. history
and instituted screening to determine men's physical and mental fitness for
war. Part of the screening process involved testing for diseases such as syphilis.
With millions of people needing to be screened, Dorfman (1943) proposed a
new testing algorithm meant to reduce the total number of tests needed. In
his algorithm, Dorfman proposed that individual specimens be amalgamated
into groups instead of being tested individually. If a group tested negative, all
members of the group would be declared negative for the syphilitic antigen. If
a group tested positive, all individuals would be retested to determine which
were positive and which were negative. Because the prevalence of syphilis was
low, it was believed that group testing would result in much fewer tests than
testing each specimen separately (i.e., individual testing). Screening for dis-
eases such as syphilis is just one of many diverse group testing applications.
Throughout this dissertation, we will focus our terminology on the infectious
2disease testing setting. That is, group testing will be discussed in the con-
text of testing specimens (e.g., blood, urine) to identify which are positive or
negative for a disease of interest.
Since Dorfman's original proposal, there have been many other group test-
ing algorithms developed. Most of these can be categorized as either hierar-
chical or non-hierarchical in nature. Hierarchical algorithms involve testing
individuals in non-overlapping groups at a particular stage of testing. The
testing pattern at each subsequent stage is determined by the results in the
previous stage. The Dorfman technique is a two-stage hierarchical algorithm.
In contrast, non-hierarchical algorithms involve testing individuals in overlap-
ping groups within a stage. This is done to reduce the number of retests needed
at subsequent stages. The next subsections describe each of these algorithm
types in detail.
1.1.1. Hierarchical algorithms
Let p be the probability that an individual is truly positive for the disease
of interest. For a group of size I, the probability that the group is truly
negative (all individuals in the group are truly negative) is (1 − p)I . Thus,
the probability that the group is truly positive (at least one individual in the
group is truly positive) is 1− (1− p)I . The expected number of tests needed
to decode one group becomes 1 + I[1− (1− p)I ]. Across a population of size
N , the expected total number of tests is N/I + N
[
1− (1− p)I], assuming
that I divides evenly into N (Dorfman, 1943). In situations where I does
not divide evenly into N , any remaining individuals are usually combined in
another group so that the expected total number of tests is 1+b
[
1− (1− p)b]+
N/I +N
[
1− (1− p)I], where b is the size of the remainder group.
3Using these equations, Dorfman (1943) showed that when compared to
individual testing, group testing can lead to significant savings for the number
of tests, depending on I and p. Choosing too large of an I will result in too
many groups testing positive and consequently a large number of retests. On
the other hand, choosing too small of an I will lead to a larger number of tests
than would be needed if I was chosen better. There was an interest early in
this research then to find the optimal group size, one that was not too large or
too small for the corresponding p. For this reason, Dorfman provided tables to
find the optimal group size (i.e., the smallest expected number of tests) given
p and concluded that group testing is preferred to individual testing when the
disease has a small prevalence (i.e., p < 0.20).
The Dorfman algorithm is an example of a two-stage algorithm. Figure
1.1 shows a Dorfman algorithm with an initial group of size 10 followed by
individual testing. A natural extension of this technique involves repeatedly
dividing groups that test positive into smaller, non-overlapping subgroups un-
til all positive specimens are confirmed through individual testing. Finucan
(1964) presented a three-stage algorithm in which an initial group is tested
first, subgroups are tested second, and individual retesting is done in the third
and final stage of the algorithm. The expected number of tests and minimum
cost (associated with the optimal initial group size) were derived for the three-
stage algorithm. Finucan (1964) also presented the optimal number of stages
and minimum cost for S-stage algorithms in general.
Figure 1.2 illustrates a three-stage hierarchical algorithm used in practice
for acute HIV detection in San Francisco (Sherlock et al., 2007). The first stage
has an initial group of size 50, followed by five subgroups with 10 individuals
each, and finally, individual testing. In current practice, three- and four-stage
4Figure 1.1: Dorfman testing algorithm.
Figure 1.2: Three-stage hierarchical testing algorithm.
algorithms are often used (e.g. Sherlock et al., 2007; Quinn et al., 2000)
because they can be more efficient (i.e., result in fewer tests) than two-stage
algorithms in particular situations.
1.1.2. Non-hierarchical algorithms
The most common type of non-hierarchical algorithm is known as array testing.
Array testing (Phatarfod and Sudbury, 1994) involves arranging specimens in
a square grid, or array. Specimens are amalgamated by row and by column,
so that each individual's specimen is included in two groups, and tested. All
specimens located at the intersection of a positive row and a positive column
are retested separately. In the presence of testing error, retesting is also done
for all specimens in a positive row (column) where no column (row) tests
positive. Figure 1.3 displays an array testing algorithm where rows 1 and 9
5Figure 1.3: Array testing algorithm.
test positive, as do columns 1 and 8. Four individuals (indicated by red circles)
lie at the intersections of positive rows and positive columns, so those four
individuals are individually retested to determine whether they are positive or
negative.
The original array testing proposal by Phatarfod and Sudbury (1994) in-
volved just two stages of testing, the first for testing row and column groups,
and the second for individual retesting. Kim et al. (2007) incorporated the
possibility of testing error into the algorithm that would necessitate the retest-
ing of entire rows/columns as aforementioned. Kim et al. (2007) also examined
adding a master group test to the algorithm. Such an algorithm involves three
stages, where a master group of all specimens in the array is tested first, fol-
lowed by row and column testing in the second stage, and individual retesting
in the third and final stage. Kim et al. (2007) provided expressions for the
expected number of tests for array testing with and without master pooling.
Additional work in this area includes Hudgens and Kim (2011) that stud-
ied the optimal group sizes for square array testing without master pooling.
Also, Kim and Hudgens (2009) examined three-dimensional array-based test-
6ing algorithms, where specimens are arranged in a three-dimensional array for
testing.
1.2. Testing error for the overall algorithm
Most of the early group testing papers assumed that the assays were perfect,
although this is not the case in many real-life applications. It is now common
practice to incorporate testing error in infectious disease testing applications.
Individual testing error occurs when a specimen that is truly positive (nega-
tive) is incorrectly identified as negative (positive) by the assay. The sensitivity
(Se) is the proportion of true positives correctly identified by the test and the
specificity (Sp) is the proportion of true negatives correctly identified by the
test (Altman and Bland, 1994a).
Recognizing that the true status of a specimen is not usually known in
application, Altman and Bland (1994b) also defined values that describe the
proportion of specimens that are correctly diagnosed with individual testing.
The positive (negative) predictive value is the proportion of specimens testing
positive (negative) who are correctly identified as positive (negative). The
positive predictive value (PPV ) and negative predictive value (NPV ) can
then be calculated as
PPV =
Sep
Sep+ (1− Sp)(1− p)
and
NPV =
Sp(1− p)
(1− Se)p+ Sp(1− p)
for any probability of infection p (Altman and Bland, 1994b).
Throughout a group testing algorithm, an assay may be used several times
7on the same specimen (either in a group or individually) to determine whether
the specimen is positive or negative. For specimens that are tested multiple
times, the Se and Sp no longer describe the probability of being correctly diag-
nosed by the group testing algorithm though. Instead, Johnson et al. (1991)
defined the pooling sensitivity (PSe) as the probability that an individual is
identified as positive, given that the individual is truly positive. Similarly, the
pooling specificity (PSp) is the probability that an individual is identified as
negative, given that the individual is truly negative. Kim et al. (2007) de-
fined the pooling positive predictive value (PPPV ) as the probability that an
individual is truly positive, given that the individual is identified by the test
as positive. The pooling negative predictive value (PNPV ) is the probability
that an individual is truly negative, given that the individual is identified by
the test as negative. Applying Bayes' rule, the PPPV and PNPV can then
be expressed as
PPPV =
pPSe
(1− p)(1− PSp) + pPSe
and
PNPV =
(1− p)PSp
p(1− PSe) + (1− p)PSp .
1.3. Informative testing
While nearly all of the previously mentioned papers assume that every indi-
vidual has the same probability p of testing positive, this assumption is not
reasonable in most applications. We can easily imagine that different indi-
viduals may have different probabilities of testing positive for a given disease,
say pi for i = 1, . . . , N individuals to be tested. In many situations, covariate
information, such as medical history or risk behaviors, is available for individ-
8uals being tested and can be used to estimate each individual's probability of
testing positive. The number of tests needed for group testing can then be
reduced by taking advantage of these individual probabilities.
Hwang (1975) is likely the first group testing paper that considered testing
specimens that do not all have the same probability of being positive. While
the paper allows for individual probabilities to differ, it does not discuss how
to estimate these probabilities or account for testing error. The first paper to
propose a way to identify positive specimens using available covariate infor-
mation came decades later. Bilder et al. (2010) defined informative retesting
as an algorithm in which covariate information is used to inform how retest-
ing is implemented in groups that test positive when testing error is present.
This paper showed that significant reductions in the expected number of tests
for a group testing algorithm can occur when accounting for the differences
among individual probabilities. McMahan et al. (2012a) examined informa-
tive retesting in the context of Dorfman's algorithm and derived expressions
for the expected number of tests, PSe, PSp, PPPV , and PNPV . McMahan
et al. (2012b) did the same for informative retesting in the context of array
testing without master pooling. Both of these papers continued to show the
advantages of using the available covariate information, while also showing
that the informative algorithms resulted in similar or sometimes better ac-
curacy than their non-informative (pi = p for all i = 1, ..., N) counterparts.
Bilder and Tebbs (2012) compared a number of informative retesting algo-
rithms and found that no single algorithm was best overall in terms of the
number of tests and accuracy. Several factors including prevalence, accuracy
of the assay, availability of covariate information, and heterogeneity among in-
dividual probabilities all are important factors in determining which algorithm
9is best. Black et al. (2015) later provided an extension of informative testing
to hierarchical testing for three or more stages.
1.4. Multiplex testing
All of the aforementioned papers dealt with group testing in the context of
single-disease assays, assays that test for only one disease at a time. In re-
cent years, group testing research has expanded to the use of multiplex assays,
i.e., assays that test for more than one disease at a time. Tebbs et al. (2013)
examined a two-stage hierarchical algorithm used by the State Hygienic Lab-
oratory (SHL) at the University of Iowa to test for chlamydia and gonorrhea
simultaneously via the Aptima Combo 2 Assay. For this algorithm, individual
specimens are randomly assigned to groups of two or more, and each group
is tested for both diseases. If a group tests negative for both diseases, all
members are declared disease free. If a group tests positive for either disease,
all members are retested individually for both diseases using the same assay.
Tebbs et al. (2013) derived expressions for the expected number of tests and
accuracy measures. Using these expressions, they were able to identify opti-
mal group sizes for the two-stage algorithm. The authors found that pooling
for multiple infections results in fewer tests than both individual testing with
multiplex assays and group testing with single-disease assays.
Hou et al. (2017) generalized the methods in Tebbs et al. (2013) to hier-
archical testing with three or more stages and derived closed-form expressions
for the expected number of tests and accuracy measures. The authors showed
a reduction in the expected number of tests can occur when using these higher-
stage hierarchical algorithms rather than the two-stage algorithms. For their
contribution to the statistical science and its application, both Tebbs et al.
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(2013) and Hou et al. (2017) were awarded the Outstanding Statistical Appli-
cation award by the American Statistical Association, and Hou et al. (2017)
was also awarded the Biometrics paper of the year award. However, both of
these papers assumed that all individuals had the same probability of testing
positive. Bilder et al. (2019) provided the first group testing algorithms for
multiplex assays that take advantage of individual-specific probabilities. The
algorithms developed can be applied in hierarchical testing with two or more
stages, and the authors derived the expected number of tests and accuracy
measures for the algorithms. Bilder et al. (2019) showed that the combina-
tion of informative group testing and multiplex assays can significantly reduce
the number of tests required without loss of accuracy in comparison to non-
informative algorithms. Hou et al. (2020) further provided methods for array
testing with multiplex assays.
1.5. Assumptions about diagnostic accuracy
The sensitivity and specificity of a diagnostic test are often assumed to be the
same for each stage of testing. For example, this means that a three-stage
hierarchical algorithm would have Se = 0.95 for the initial group test, subse-
quent tests of smaller subgroups, and individual tests. This assumption may
not be realistic for two reasons: 1) when larger groups are used, positive indi-
viduals can be diluted by negative individuals past the threshold of detection
for an assay; and 2) different diagnostic tests may be used at different stages
of the testing algorithm. In situations where dilution effects are a cause for
concern, McMahan et al. (2013) removed the assumption that sensitivity and
specificity are constant for all groups (pools) and derived expressions for pool-
specific sensitivity and specificity that is dependent upon the size of the group,
11
improving prevalence estimation.
Usually though, properly calibrated assays will have the same diagnostic
accuracy for each test at each stage, especially for nucleic acid amplification
tests (NAATs). Kacena et al. (1998a; 1998b) found negligible loss in diagnos-
tic accuracy with as many as 10 samples when screening for chlamydia and
gonorrhea with a NAAT. Also, NAATs have been used to detect acute HIV
infection in groups of 90 or more specimens with no significant dilution effects
(Quinn et al., 2000; Pilcher et al., 2005). For other types of tests, Kline et al.
(1989) and Tu et al. (1995) found that groups of up to 15 specimens can be
used with negligible loss of diagnostic test accuracy for HIV screening with
an enzyme-linked immunosorbent assay (ELISA). Soroka et al. (2003) showed
the same for groups of up to size 20 with two different lateral flow rapid an-
tibody assays. These studies support Black et al. (2015), McMahan et al.
(2012a), McMahan et al. (2012b), and Kim et al. (2007) in their assumption
that sensitivity and specificity do not depend on the size of the group.
In some situations, different assays may be used within a testing algorithm.
For example, an ELISA test may be utilized to test an initial group size due
to its lower cost and NAATs may be used to test positive groups in subsequent
stages due to their frequently higher sensitivity values. For these situations,
Bilder et al. (2019) allowed for differences in the diagnostic accuracy across
stages of testing in their derivations of operating characteristics (e.g., expected
number of tests, accuracy measures) for hierarchical testing algorithms with
multiplex assays. Similarly, Hou et al. (2020) allowed for different values of
sensitivity and specificity for the master array, row/column tests, and indi-
vidual testing in their derivations of operating characteristics for array testing
algorithms with multiplex assays.
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1.6. Implementation in R
There are two primary objectives in group testing research. The first is the
estimation problem: estimate the overall prevalence of disease or individual
probabilities of testing positive. The binGroup package (Bilder et al., 2010)
was the first R package to provide functions for the estimation problem for
both homogeneous populations, where all individuals are assumed to have the
same probability of testing positive, and heterogeneous populations, where
each individual is allowed to have a different probability of testing positive. For
homogeneous populations, the package provides functions that estimate the
overall prevalence p, calculate a p-value and determine power for a hypothesis
test involving p, and find the optimal group size for a design. For heterogeneous
populations, the contributed functions fit group testing regression models and
simulate group testing data.
The second objective in group testing research is the identification problem:
identify all positive individuals being tested via a testing algorithm. Unfortu-
nately, the binGroup package did not provide functions for the identification
problem until a number of functions were added associated with this disser-
tation. For both the estimation and identification problems, the functions in
binGroup were contributed by a number of different researchers. This led to
an inconsistent style that can make it difficult for practitioners to use.
Several papers in the group testing literature provide R functions to calcu-
late operating characteristics for various group testing algorithms. For single-
disease assays, Black et al. (2015) provided functions for up to four-stage hier-
archical testing and McMahan et al. (2012a) provided functions for informative
two-stage hierarchical testing. McMahan et al. (2012b) supplied functions for
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array testing without master pooling. These R functions for single-disease as-
says utilized the assumption that sensitivity/specificity values are equal across
all stages of testing. For multiplex assays, Bilder et al. (2019) developed R
functions for up to five-stage hierarchical testing and Hou et al. (2020) de-
veloped R functions for array testing with and without master pooling. The
functions for hierarchical testing algorithms with multiplex assays allow sen-
sitivity/specificity values to differ across stages of testing, while the functions
for array testing with multiplex assays allow for only a single sensitivity/speci-
ficity value in the algorithm. All of the R functions mentioned here can be
accessed at www.chrisbilder.com/grouptesting.
1.7. Organization of the dissertation
The order of this dissertation is as follows. Chapter 2 is a paper published
in Statistics in Medicine. This paper compares objective functions that are
used to determine the optimal testing configuration (set of group sizes that
minimize an objective function) for a significant number of group testing al-
gorithms. The goal of this paper is to settle a controversy in group testing
research regarding which objective function is best to use in practice. Chapter
3 describes a new R package named binGroup2 that provides R functions for
both the estimation and identification problems of group testing. This package
is built upon the estimation functions in the binGroup package but performs
a large reorganization of these functions and creates a consistent framework
that researchers will find easier to use. The binGroup2 package also incor-
porates functions for the identification problem. Included are new functions
that enable practitioners to find an optimal testing configuration to imple-
ment group testing. Chapter 4 describes a new Shiny application to allow
14
researchers without R experience to access particular identification functions
from binGroup2 without having to understand code. Chapter 5 summarizes
the work completed and proposes ideas for future research.
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Chapter 2
The objective function controversy for group testing:
Much ado about nothing?
This chapter is published: Hitt, B., Bilder, C., Tebbs, J., and McMahan, C.
(2019). The objective function controversy for group testing: Much ado about
nothing? Statistics in Medicine 38(24), 4912-4923. Used with permission.
Abstract
Group testing is an indispensable tool for laboratories when testing high
volumes of clinical specimens for infectious diseases. An important decision
that needs to be made prior to implementation is determining what group sizes
to use. In best practice, an objective function is chosen and then minimized
to determine an optimal set of these group sizes, known as the optimal testing
configuration (OTC). There are a few options for objective functions, and they
differ based on how the expected number of tests, assay characteristics, and
testing constraints are taken into account. These varied options have led to a
recent controversy in the literature regarding which of two different objective
functions is better. In our paper, we examine these objective functions over
a number of realistic situations for infectious disease testing. We show that
this controversy may be much ado about nothing because the OTCs and cor-
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responding results (e.g., number of tests, accuracy) are largely the same for
standard testing algorithms in a wide variety of situations.
Keywords: Binary response; Infectious disease; Pooled testing; Screening; Sen-
sitivity; Specificity
2.1. Introduction
Laboratories throughout the world test high volumes of clinical specimens for
infectious diseases, including HIV, hepatitis C, and West Nile virus. In such
situations, it has become standard practice to test amalgamations of specimens
as a group or pool rather than to test individual specimens. The reason is
simple: members of a negative testing group can be declared negative all at
once. Thus, for a group of size I, say, just one test is needed to declare all
members negative, rather than the I separate tests that would be needed with
individual testing. Fortunately, when disease prevalence is small, the majority
of groups will test negatively when sensibly chosen group sizes are used. For
members of a positive testing group, there are many algorithmic retesting pro-
cedures available to determine which specific individuals are positive. The first
retesting procedure was proposed by Dorfman (1943) and simply involved in-
dividually retesting each member of a positive group. Since this seminal work,
group testing has been used to efficiently test for infectious diseases in a vast
number of human applications, including blood donation screening (American
Red Cross, 2020), antiretroviral treatment failure detection for HIV-positive
individuals (Kim et al., 2014; Tilghman et al., 2015), chlamydia and gonorrhea
testing (Papp et al., 2014), and influenza outbreak surveillance (Hourfar et al.,
2007). Outside of infectious disease testing in humans, group testing is used in
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an extensive number of applications, including cow milk surveillance (Græs-
bøll et al., 2017), disease detection in cattle and buffaloes (Abdellrazeq et al.,
2014), West Nile virus monitoring in mosquitoes (Khan et al., 2017), food
contamination detection (Pasquali et al., 2014), drug discovery (Kainkaryam
and Woolf, 2009), and diagnosis of faulty network sensors (Lo et al., 2013).
For all group testing applications, the choice of group sizes is extremely
important for success. Choosing group sizes too large will lead to exceedingly
many groups testing positively. This will subsequently lead to a large number
of retests, perhaps even a larger number of tests overall than what would be
needed for individual testing. Similarly, choosing group sizes too small will
lead to a larger number of tests than would be needed if the group sizes were
chosen better. In best practice, laboratories choose group sizes by minimizing
an objective function that takes into account the group testing algorithm to
be implemented. There are a number of different algorithms in use, and they
are best characterized as being either hierarchical or non-hierarchical in na-
ture. Hierarchical algorithms begin by testing individuals in non-overlapping
groups. For a group that tests positively, subsequent retesting stages occur in
smaller, non-overlapping groups. The previously described Dorfman algorithm
is a two-stage algorithm. Three- and four-stage algorithms are commonly used
in practice (Quinn et al., 2000; Sherlock et al., 2007) because they are often
more efficient (i.e., fewer tests). Non-hierarchical algorithms involve testing
each individual in overlapping groups to reduce the number of retests. The
most common type of non-hierarchical algorithm is known as array testing
(Phatarfod and Sudbury, 1994; Kim et al., 2007). For this algorithm, individ-
ual specimens are arranged in a two-dimensional grid. These specimens are
amalgamated by row and by column and then tested. Intersecting positive
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rows and columns indicate where retesting should be performed to determine
which individuals are positive. For a thorough review of hierarchical and array
testing algorithms, see Hughes-Oliver (2006) and Bilder (2019).
While there are many different types of group testing algorithms, all labo-
ratories are interested in minimizing the number of tests needed to assay their
specimens. For this reason, objective functions are based on the expected
number of tests, so that a set of group sizes for a testing algorithm, known
as the optimal testing configuration (OTC), can be found by minimizing this
function. Traditionally, group testing research has focused on objective func-
tions expressed solely as the expected number of tests per individual. This is
due to a close correspondence between the number of tests and testing costs.
However, using an objective function that contains only the expected number
of tests leaves out an important component of infectious disease testing: accu-
racy. Infectious disease testing is rarely perfect. Errors can occur for reasons
such as improper laboratory implementation or a specimen being collected dur-
ing the window period between disease contraction and the ability to detect
it. Fortunately, known mathematical expressions are available for the accuracy
of most group testing algorithms. This enables laboratories to calculate the
expected accuracy of a chosen testing configuration prior to implementation.
Malinovsky et al. (2016) recently proposed a new objective function that
includes the expected number of tests and a measurement of accuracy. This
allows laboratories to evaluate accuracy at the same time as the number of tests
when choosing an OTC. As may be expected when breaking with tradition, the
proposal generated controversy in the group testing research literature. Both
Hudgens (2016) and McMahan et al. (2016) offered rejoinders to Malinovsky
et al. (2016) that disagreed with this new objective function. All three of these
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works focused only on the Dorfman algorithm in their limited evaluations. The
purpose of our paper is to examine a significant number of other group testing
algorithms with respect to objective functions. This is important because other
algorithms are widely used and known to result in a smaller number of tests
and/or higher accuracy than the Dorfman algorithm. We present findings in
our paper that interestingly show both the traditional and the new objective
function are actually quite similar and very often lead to the same OTC in
realistic infectious disease testing situations.
The order of this paper follows. Section 2.2 explicitly defines the objective
functions and provides a mathematical comparison between them. Section
2.3 calculates the OTC for each objective function along with their operating
characteristics (expected number of tests and accuracy measures) in a wide
variety of settings. These calculations are performed for both hierarchical and
array testing algorithms. We show under what conditions these operating
characteristics will be the same and when they will be different. Section 2.4
examines the objective function controversy in the context of actual assays
used for infectious disease detection. To conclude, Section 2.5 summarizes our
findings, discusses alternative objective functions, and provides recommenda-
tions for practice. We also discuss R functions that we provide with our paper
to find the OTCs and to reproduce our work.
2.2. Objective Functions
Define T as a random variable representing the total number of tests for an
overall group of size I with a hierarchical algorithm. When using the tra-
ditional objective function, the OTC is found by minimizing the expected
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number of tests per individual:
OET = E(T )/I.
For example, the expected number of tests for three-stage hierarchical testing
is given by
E(T ) = 1 +m11P (G11 = 1) +
c2∑
j=1
m2jP (G11 = 1, G2j = 1),
where Gsj is the binary random variable (values of 1 and 0 indicate a positive
and a negative test result, respectively) representing the outcome for group j
at stage s, msj is the number of subgroups that would be created if group j at
stage s tests positively, and cs is the number of groups at stage s (see Black
et al. (2015); an example diagram is given in Appendix A). The probabilities
P (G11 = 1) and P (G11 = 1, G2j = 1) are both functions of the number of
groups and their respective sizes, the probability of being positive for each
individual, and the sensitivity Se and specificity Sp of the assay each time it
is applied. We do not provide further detailed expressions for E(T ) here to
avoid distraction from the main points of our paper and because expressions
are already provided elsewhere. For example, Kim et al. (2007) provides ex-
pressions for the case of each individual having the same true probability of
being positive, say p, and Black et al. (2015) provides expressions for the case
of each individual potentially having a different probability of being truly pos-
itive, say pi for i = 1, . . . , I. The latter case is known as informative group
testing (Bilder et al., 2010; Lewis et al., 2012; Bilder and Tebbs, 2012), be-
cause pi can be estimated with the help of disease-risk information that may
be available for each individual tested. We will refer to the former case then as
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non-informative group testing in our work here. Expressions for the expected
number of tests are known for array testing algorithms (Kim et al., 2007;
McMahan et al., 2012b) as well, where OET is still defined as the expected
number of tests per individual.
While OET is the most commonly utilized objective function, it does not
directly take into account the accuracy of the algorithm. However, one will still
examine separately the accuracy of the OTC to judge if it is satisfactory. As an
alternative approach, Malinovsky et al. (2016) proposed an objective function
that simultaneously takes into account accuracy and the expected number of
tests. To examine the accuracy aspect, define Yi as the final positive/negative
(1/0) outcome based on the group testing algorithm, and define Y˜i as the true
positive/negative (1/0) status of individual i, for i = 1, . . . , I. Commonly used
accuracy measures for a group testing algorithm as a whole are the pooling
sensitivity PSe,i = P (Yi = 1|Y˜i = 1) and the pooling specificity PSp,i =
P (Yi = 0|Y˜i = 0) for individual i. As an overall measure of accuracy, define
C as the number of correct classifications for a group of size I. The expected
number of correct classifications is
E(C) =
I∑
i=1
{
P (Yi = 0, Y˜i = 0) + P (Yi = 1, Y˜i = 1)
}
=
I∑
i=1
{PSp,i(1− pi) + PSe,ipi} , (2.2.1)
where P (Y˜i = 1) = pi is the probability that individual i is truly positive.
Malinovsky et al. (2016) proposed to find the OTC by maximizing the ex-
pected number of correct classifications per individual divided by the expected
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number of tests per individual. Equivalently, this results in minimizing
OMAR = E(T )/E(C).
Because C is never larger than the number of individuals I, E(C) ≤ I. By
comparing OMAR and OET , we see that
OET =
E(T )
I
≤ E(T )
E(C)
= OMAR
for the same initial group size I. In fact, OMAR and OET will be quite close
in value. This is because infectious disease assays will only be put into use if
they have high accuracy. Thus, E(C) will be quite close to I in practice.
To examine this closeness more precisely, consider minimizing the logarithm
of each objective function:
log(OET ) = log {E (T )} − log(I)
and
log(OMAR) = log {E (T )} − log {E (C)} . (2.2.2)
For hierarchical testing, the pooling sensitivity is always the same for every
individual tested in the same number of stages(Kim et al., 2007; Black et al.,
2015). The pooling specificity is the same for every individual as well, but only
for non-informative group testing with equal group sizes within a stage. Under
this scenario then, we can simplify the expression for the expected number of
correct classifications to be
E(C) = I {PSp(1− p) + PSep} , (2.2.3)
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where PSp and PSe are the pooling specificity and sensitivity, respectively,
but now equal for each individual. For array testing, the same simplification
for E(C) from Equation (2.2.1) to Equation (2.2.3) occurs when the number
of rows and the number of columns are the same (i.e., a square array), which
is how array testing is usually applied.
By substituting Equation (2.2.3) into Equation (2.2.2), we obtain
log(OMAR) = log {E(T )} − log [I {PSp(1− p) + PSep}]
= log(OET )− log {PSp(1− p) + PSep} .
Thus, any difference between the OTCs for the two objective functions is due
to the penalty of
log {PSp(1− p) + PSep} . (2.2.4)
Unfortunately, further definitive statements cannot be made regarding Equa-
tion (2.2.4), and we are left with making general statements regarding what
will happen most often. In particular, we see that the penalty places a large
weight on PSp in comparison to PSe because p is small for realistic group
testing applications. Also, because PSp and PSe tend to be close to 1 for
realistic applications, the penalty tends to be close to 0. Thus, log(OMAR) will
most often be close to log(OET ).
2.3. Comparisons
Because definitive statements are not possible for Equation (2.2.4) or for the
more general cases of unequal group sizes and informative group testing, we
provide in this section a thorough investigation of the OTCs when using the
objective functions over a very large number of situations. For each of these
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situations, we calculate the OTCs along with corresponding operating charac-
teristics. Our results for both non-informative and informative group testing
algorithms are described next.
2.3.1. Non-informative group testing
We include in this investigation the following group testing algorithms: two-
stage hierarchical, three-stage hierarchical, array testing without a master pool
(row and column groups are tested first, as described in Section 2.1), and array
testing with a master pool (all specimens in the array are tested together in
one group before any row or column groups are formed). For the first three
algorithms, we allow the initial group sizes to range from I = 3, ..., 40, but
allow higher initial group sizes when the overall prevalence is very small (e.g.,
p = 0.005) so that the OTC does not include our arbitrary upper bound for I.
For array testing with a master pool, we use the same range of group sizes for
the row and column groups, leading to a maximum master pool size of I2. All
array testing algorithms use square arrays, and we account for potential testing
ambiguities that can occur in arrays (e.g., a row tests positively without any
columns testing positively) by the methods described in Kim et al. (2007) We
apply these group testing algorithms over thirty different values of p ranging
from 0.005 to 0.150 by 0.005 and over five separate sets of accuracy levels (Se
and Sp values range from 0.90 to 0.99). These values of p, Se, and Sp are chosen
because they correspond to when group testing is used for infectious disease
testing. The assay accuracies are assumed to not change based on group size,
meaning that the assays have been properly tested and calibrated for group
testing.
Table 2.1 displays the results for p = 0.01. The OTCs are the same for
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both objective functions when using the hierarchical algorithms. Some small
differences between OTCs exist for the array testing algorithms, but the dif-
ferences are not of practical importance. For example, examine the results
for array testing without master pooling and Se = Sp = 0.90. The expected
number of tests and the pooling sensitivities are the same to four decimal
places. The pooling specificities are also quite close. In practical terms, for
a testing load of 100,000 individuals, there would be 98,267 correct negatives
found when using the OTC for OET and 98,307 correct negatives found when
using the OTC for OMAR. While 40 additional false positives would result
from the OTC for OET , these false positives would most likely be discovered
from follow-up confirmatory testing that normally would occur. We also pro-
vide similar tables for p = 0.05 and p = 0.10 in Appendix A. These tables
show only one case with differences between the OTCs.
Table 2.2 summarizes the largest differences among the operating charac-
teristics across all thirty different values of p included in our investigation.
Most often, the OTCs found are the same for the two objective functions.
When differences exist, these differences occur more often for smaller values
of Sp, but again are not of practical importance. Overall, these findings help
confirm what was strongly suspected in Section 2.2 through our mathematical
analysis. Namely, the objective functions lead to the same OTCs or OTCs
with similar operating characteristics when differences exist.
2.3.2. Informative group testing
We include in this investigation the following group testing algorithms: two-
stage hierarchical implemented via the pool-specific optimal Dorfman (PSOD)
method (McMahan et al., 2012a), three-stage hierarchical (Black et al., 2015),
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Table 2.1: OTC summary for p = 0.01 under non-informative group testing.
Equally sized groups are optimal at each stage; thus, an OTC of 24-6-1 means
that stage 1 has a group of size 24, stage 2 has four groups of size 6, and stage
3 has twenty-four groups of size 1. Differences between OET and OMAR are
highlighted.
Objective
Algorithm Se Sp function OTC E(T )/I PSe PSp
0.99 0.99
OET 11-1 0.2035 0.9801 0.9990
OMAR 11-1 0.2035 0.9801 0.9990
0.95 0.95
OET 11-1 0.2351 0.9025 0.9932
OMAR 11-1 0.2351 0.9025 0.9932
Two-stage
0.90 0.90
OET 12-1 0.2742 0.8100 0.9816
hierarchical OMAR 12-1 0.2742 0.8100 0.9816
0.99 0.90
OET 11-1 0.2841 0.9801 0.9815
OMAR 11-1 0.2841 0.9801 0.9815
0.90 0.99
OET 11-1 0.1941 0.8100 0.9990
OMAR 11-1 0.1941 0.8100 0.9990
0.99 0.99
OET 25-5-1 0.1354 0.9703 0.9996
OMAR 25-5-1 0.1354 0.9703 0.9996
0.95 0.95
OET 24-6-1 0.1443 0.8574 0.9973
OMAR 24-6-1 0.1443 0.8574 0.9973
Three-stage
0.90 0.90
OET 24-6-1 0.1562 0.7290 0.9938
hierarchical OMAR 24-6-1 0.1562 0.7290 0.9938
0.99 0.90
OET 24-6-1 0.1708 0.9703 0.9928
OMAR 24-6-1 0.1708 0.9703 0.9928
0.90 0.99
OET 25-5-1 0.1229 0.7290 0.9997
OMAR 25-5-1 0.1229 0.7290 0.9997
0.99 0.99
OET 25-1 0.1378 0.9703 0.9995
OMAR 25-1 0.1378 0.9703 0.9995
0.95 0.95
OET 25-1 0.1475 0.8575 0.9970
OMAR 24-1 0.1475 0.8575 0.9972
Array w/o
0.90 0.90
OET 25-1 0.1611 0.7291 0.9926
master pooling OMAR 24-1 0.1611 0.7291 0.9930
0.99 0.90
OET 23-1 0.1726 0.9703 0.9923
OMAR 23-1 0.1726 0.9703 0.9923
0.90 0.99
OET 27-1 0.1279 0.7292 0.9995
OMAR 27-1 0.1279 0.7292 0.9995
0.99 0.99
OET 625-25-1 0.1364 0.9606 0.9995
OMAR 625-25-1 0.1364 0.9606 0.9995
0.95 0.95
OET 625-25-1 0.1402 0.8146 0.9972
OMAR 576-24-1 0.1402 0.8146 0.9974
Array w/
0.90 0.90
OET 625-25-1 0.1450 0.6562 0.9934
master pooling OMAR 576-24-1 0.1450 0.6562 0.9937
0.99 0.90
OET 529-23-1 0.1708 0.9606 0.9924
OMAR 529-23-1 0.1708 0.9606 0.9924
0.90 0.99
OET 729-27-1 0.1151 0.6563 0.9996
OMAR 729-27-1 0.1151 0.6563 0.9996
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Table 2.2: Largest differences between operating characteristics for OTCs un-
der non-informative group testing. Values of p range from 0.005 to 0.150 by
0.005. The frequency column denotes the number of times a different OTC
was found for OET and OMAR among these values of p. Differences between
operating characteristics are rounded to four decimal places. Note that the
operating characteristic value for OET is always subtracted from the operating
characteristic value for OMAR. Thus, a negative value (indicated with paren-
theses) means that the value for OET was larger than the value for OMAR.
Largest difference
Algorithm Se Sp Frequency E(T )/I PSe PSp
Two-stage
hierarchical
0.99 0.99 0 - - -
0.95 0.95 3 0.0018 0.0000 0.0049
0.90 0.90 4 0.0023 0.0000 0.0054
0.99 0.90 7 0.0056 0.0000 0.0096
0.90 0.99 0 - - -
Three-stage
hierarchical
0.99 0.99 0 - - -
0.95 0.95 1 0.0014 0.0000 0.0051
0.90 0.90 3 0.0015 0.0000 0.0049
0.99 0.90 7 0.0041 (0.0098) 0.0136
0.90 0.99 1 0.0000 0.0000 0.0002
Array w/o
master
pooling
0.99 0.99 0 - - -
0.95 0.95 5 0.0010 0.0018 0.0026
0.90 0.90 8 0.0028 0.0022 0.0054
0.99 0.90 5 0.0043 0.0005 0.0076
0.90 0.99 1 0.0000 0.0006 0.0001
Array w/
master
pooling
0.99 0.99 2 0.0005 0.0006 0.0008
0.95 0.95 4 0.0012 0.0017 0.0026
0.90 0.90 8 0.0015 0.0018 0.0051
0.99 0.90 5 0.0048 0.0005 0.0077
0.90 0.99 2 0.0003 0.0026 0.0005
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and array testing without a master pool implemented via the gradient method
(McMahan et al., 2012b). For the PSOD method, we use a block size of 50
and replace its greedy optimization algorithm with examination of all possible
testing configurations. Array testing with a master pool is not included in our
investigations because there have been no informative group testing algorithms
proposed for it. We continue to allow the initial group sizes to range from
I = 3, ..., 40 and allow for higher initial group sizes when the overall prevalence
is very small.
To provide different levels of heterogeneity among the pi for i = 1, . . . , I,
we use the expected value of order statistics from Pi ∼ beta {α, α(1− p)/p} for
i = 1, . . . , I in the same manner as in Black et al. (2015) This beta distribution
has E(Pi) = p, and we once again consider values of p ranging from 0.005 to
0.150 by 0.005. The amount of heterogeneity is controlled by α, where lower
levels indicate a larger amount of heterogeneity (see Black et al. 2015 for
further discussion regarding the choice of α).
Table 2.3 displays the results for E(Pi) = 0.01, and Appendix A provides
the results for E(Pi) = 0.05 and E(Pi) = 0.10. The displayed pooling sensi-
tivity, PSWe , and pooling specificity, PS
W
p , are weighted averages of individual
pooling sensitivities and pooling specificities, respectively, for all individuals
within the initial group for a hierarchical algorithm or within the entire array
for an array testing algorithm. Expressions for these averages are provided
in Appendix A and are based on accuracy definitions given by Altman and
Bland (1994a). The largest differences for each operating characteristic across
all values of p are given in Table 2.4. Overall, while differences exist more
often for some algorithms than in the non-informative group testing setting,
OET and OMAR still result in the same or very similar OTCs the majority of
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the time, and, when differences exist, the vast majority of the differences likely
would not be of practical importance due to similar operating characteristic
values.
For three-stage hierarchical, the maximum difference in PSe for some set-
tings, such as Se = 0.90 and Sp = 0.99, may be somewhat concerning at a
first examination. Further investigation revealed that this occurred when the
OTC for OMAR had more sub-groups in the second stage of testing with a size
of 1 than did the OTC for OET . This is important because 1) a third stage
of testing is unnecessary for those individuals with a sub-group size of 1 in
the second stage of testing; 2) pooling sensitivity for each individual is SLe ,
where L is the number of stages that the individual is tested within (Black
et al., 2015); and 3) PSWe is a weighted average of each individual's pooling
sensitivity. Especially when p is large for three-stage hierarchical testing, the
initial group size can be quite small, so each individual's pooling sensitivity
plays a larger role in the weighted average. Thus, while there are some differ-
ences in the weighted averages of the pooling sensitivities, it is due to those
few individuals who are not tested in the third stage. The individuals tested
in the same number of stages still have the same pooling sensitivity values.
2.4. Applications
We present two different applications comparing the OTCs obtained from us-
ing OET or OMAR for infectious disease testing. To find the OTC for these and
other applications, the value of p or pi for i = 1, . . . , I is needed. Of course,
these quantities would most likely be unknown. Instead, some type of past
experience would be used by laboratories to estimate these quantities so that
an estimated OTC could be chosen. Also to find the OTC, the values of
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Table 2.4: Largest differences between operating characteristics for OTCs un-
der informative group testing. Values of E(Pi) = p range from 0.005 to 0.150
by 0.005. The frequency column denotes the number of times a different OTC
was found among these values of p. Differences between operating characteris-
tics are rounded to four decimal places. Note that the operating characteristic
value for OET is always subtracted from the operating characteristic value for
OMAR. Thus, a negative value (indicated with parentheses) means that the
value for OET was larger than the value for OMAR.
Largest difference
Algorithm α Se Sp Frequency E(T )/I PS
W
e PS
W
p
2
0.99 0.99 0 - - -
0.95 0.95 7 0.0006 (0.0023) 0.0011
0.90 0.90 12 0.0010 (0.0052) 0.0023
0.99 0.90 12 0.0011 (0.0008) 0.0022
Two-stage 0.90 0.99 2 0.0003 0.0052 0.0000
hierarchical
0.5
0.99 0.99 0 - - -
0.95 0.95 3 0.0003 (0.0035) 0.0011
0.90 0.90 15 0.0008 (0.0103) 0.0022
0.99 0.90 16 0.0012 (0.0011) 0.0022
0.90 0.99 11 0.0006 0.0078 (0.0002)
2
0.99 0.99 1 0.0000 (0.0019) 0.0002
0.95 0.95 2 0.0035 0.0219 0.0033
0.90 0.90 6 0.0044 0.0152 0.0062
0.99 0.90 4 0.0035 0.0006 0.0066
Three-stage 0.90 0.99 14 0.0180 0.0500 0.0003
hierarchical
0.5
0.99 0.99 1 0.0000 0.0001 0.0001
0.95 0.95 0 - - -
0.90 0.90 3 0.0010 0.0250 0.0033
0.99 0.90 5 0.0022 0.0034 0.0070
0.90 0.99 9 0.0057 0.0355 0.0003
2
0.99 0.99 1 0.0003 0.0004 0.0005
0.95 0.95 2 0.0011 0.0012 0.0027
0.90 0.90 5 0.0016 0.0012 0.0040
0.99 0.90 4 0.0028 0.0003 0.0053
Array w/o 0.90 0.99 0 - - -
master pooling
0.5
0.99 0.99 0 - - -
0.95 0.95 4 0.0003 0.0004 0.0015
0.90 0.90 14 0.0015 0.0004 0.0032
0.99 0.90 8 0.0024 0.0001 0.0041
0.90 0.99 1 0.0003 0.0005 0.0003
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Se and Sp are needed because E(T ) and the pooling sensitivities/specificities
depend upon them. Laboratories can obtain these values from a number of
sources, including internal validations, research articles, product inserts for as-
says, and summaries provided by organizations such as the Centers for Disease
Control and Prevention (CDC) and the Association of Public Health Labora-
tories. For each source, the sensitivity and specificity are actually observed
through taking a large sample. For instance, a set of known positive specimens
may be tested to evaluate the sensitivity of an assay. Alternatively, clinical-
based evaluations may be performed by applying the assay in practice and
using other means to validate true positive/negative statuses. The observed
sensitivities and specificities usually are treated as constants and sometimes
confidence intervals are stated along with them. Our purpose in this section
is not to evaluate these procedures but rather use the accuracy measures as
they are in practice to determine OTCs.
Group testing is used widely for HIV testing in applications including blood
donation screening (American Red Cross, 2020) and health surveillance via
public health clinics (Sherlock et al., 2007). Branson et al. (2014) provided
the CDC's recommendations for HIV testing by laboratories. To make these
recommendations, the authors examined over 30 research articles and product
inserts, and they included the sensitivities and specificities associated with
each assay examined. Observed sensitivities ranged from 96.3% to 100%, and
observed specificities ranged from 99.03% to 100%. For our investigation here,
we use the lowest values in these ranges to find the OTC. Our reason for
using these particular values is because differences between OTCs would most
likely occur with the lowest accuracies. Table 2.5 provides the OTCs from
non-informative group testing algorithms. For these calculations, we use an
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Table 2.5: OTC summary for HIV testing using p = 0.004, Se = 0.963, and
Sp = 0.9903, with non-informative group testing. Equally sized groups are
optimal at each stage; thus, an OTC of 24-6-1 means that stage 1 has a
group of size 24, stage 2 has four groups of size 6, and stage 3 has twenty-four
groups of size 1. There are no differences between the OTCs.
Objective
Algorithm function OTC E(T )/I PSe PSp
Two-stage hierarchical
OET 17-1 0.1313 0.9274 0.9993
OMAR 17-1 0.1313 0.9274 0.9993
Three-stage hierarchical
OET 49-7-1 0.0732 0.8931 0.9998
OMAR 49-7-1 0.0732 0.8931 0.9998
Array w/o master pooling
OET 44-1 0.0749 0.8931 0.9997
OMAR 44-1 0.0749 0.8931 0.9997
Array w/ master pooling
OET 1936-44-1 0.0721 0.8600 0.9998
OMAR 1936-44-1 0.0721 0.8600 0.9998
overall HIV prevalence of p = 0.004 based on CDC estimates of HIV (Centers
for Disease Control and Prevention, 2019) and Census Bureau estimates of
population (U.S. Census Bureau, Population Division, 2018) in the United
States from 2016. Overall, the table shows that OET and OMAR lead to the
same OTCs for all group testing algorithms considered. While the OTCs for
array testing with master pooling are the same for OET and OMAR, a master
pool with a 44×44 array may be too large to use in practice (the largest group
size that we have seen used for HIV testing is 128 (Sullivan et al., 2011)). A
laboratory may need to choose a sub-optimal array size for such a situation.
Group testing is used widely for chlamydia testing as well. High volumes
of clinical specimens are tested each year in this manner by public health
laboratories across the United States as part of statewide surveillance projects
(e.g., see Lewis et al. (2012) and Bilder et al. (2019)). Black et al. (2012)
examined the testing performed by the Nebraska Public Health Laboratory
(NPHL) with the BD ProbeTec ET CT/GC Amplified DNA Assay. A main
purpose of this paper was to evaluate how well an informative group testing
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algorithm could perform in comparison to their current implementation of
individual testing. For our purpose here, we use the observed data from the
urine specimen testing in 2009 to examine OTCs over a number of group
testing algorithms. The overall observed chlamydia prevalence was 0.080 for
females and 0.081 for males. We use these observed prevalences as our values
for p when performing non-informative group testing by gender. To implement
informative group testing, we used the beta distribution fits given by Black
et al. (2015) for the individual probabilities of being positive pi and implement
methods similar to those in Section 2.3.2. We limit our maximum group sizes to
be 20 due to large group sizes not being used in chlamydia testing (Mund et al.,
2008). The NPHL provided assay sensitivities of Se = 0.805 and Se = 0.93 and
specificities of Sp = 0.96 and Sp = 0.95 for females and males, respectively.
This assay had an unusually low sensitivity for female urine specimens, and
the laboratory eventually switched after that year to the Aptima Combo 2
Assay which has a much higher sensitivity (Se = 0.947) (Food and Drug
Administration, 2018). However, to be consistent with how the actual tests
were performed, we use the accuracies for the BD assay. Table 2.6 provides the
OTCs for non-informative and informative group testing algorithms. Overall,
the table shows that OET and OMAR lead to the same OTCs for all non-
informative group testing algorithms considered. While differences do exist
for females when using informative hierarchical testing algorithms, these small
differences likely would not be of practical importance.
2.5. Conclusion
We have shown that the choice between OET and OMAR most often does not
change the OTC, and even when the OTC is different, there are not practical
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differences in the operating characteristics. Therefore, our work helps to close
the case on the recent controversy regarding objective functions: both can be
used in practice because they lead to very similar results. Some individuals
may prefer to state that they used OMAR because it directly takes into account
accuracy at the beginning of the process. However, we tend to favor the
traditionally used OET for one main reason. Simply, laboratories need to know
the number of tests to be expected and the corresponding costs involved. In
many instances, the expected costs are directly proportional to the expected
number of tests. While the expected number of tests could also be stated
when using OMAR, this seems to be an unnecessary extra step, especially for
laboratory directors and technicians who choose the OTC.
It is important to emphasize that laboratories would not use OET with-
out still looking at accuracy. Rather than incorporating accuracy within the
objective function, they would find the OTC and then examine the accuracy
associated with it. If the accuracy resulting from OET (or OMAR) was un-
satisfactory, a new sub-optimal testing configuration would be chosen with
accuracies that are acceptable. To help laboratories and those performing re-
search in this area, we make available a set of R functions in the binGroup
package that can be used to find the OTC or other suitable testing configu-
rations by using OET and OMAR. Examples of how to use these functions are
available on our research website at www.chrisbilder.com/grouptesting and in
Appendix A.
Our evaluations of OET and OMAR focus on realistic settings for infectious
disease detection when group testing would be used. Thus, we focus on values
of Se and Sp close to 1 and small values of p. When smaller values of Se and
Sp and/or larger values of p are used, there can be differences in the OTCs
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and associated accuracy measures. For example, when Se = 0.75, Sp = 0.80,
and p = 0.10 for three-stage hierarchical testing, the OTC for OET has I = 15
and second-stage group sizes of 5 for each sub-group. For these same settings,
the OTC for OMAR has I = 12 and second-stage group sizes of 4 for each
sub-group. However, the pooling sensitivity is only PSe = 0.42 for both
testing configurations, which makes the use of group testing unrealistic for
this situation.
Laboratories may need to limit the particular values of I for which the
OTC is searched over, similar to what we did in Section 2.4 for the chlamydia
testing example. This may be due to physical constraints, such as a maximum
group size that can be incorporated into an automated pooling platform. Also,
this limit may be due to what is known as the dilution effect in group testing.
Because specimens are pooled together, each individual specimen becomes a
smaller part of the whole as the group size increases. This reduced portion can
make it more difficult for an assay to identify its target, which in turn lowers
its sensitivity. Laboratories may need to place an upper limit on I in this type
of situation. Properly calibrated tests are needed whenever group testing is
used to make sure the dilution effect does not become a problem. Fortunately,
the dilution effect is now much less likely to occur due to modern nucleic acid
amplification testing methods.
There are other objective functions that could be used. For example, Ma-
linovsky et al. (2016) considered maximizing E(C/T ), but concluded this to
be inferior to OMAR. Therefore, we focused only on their OMAR proposal in
our paper. Objective functions can include penalties for making classification
errors. For example, Graff and Roeloffs (1972) proposed using an objective
function that is a linear combination of the expected number of tests, the
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number of misclassified negatives, and the number of misclassified positives.
Subjectively chosen weights are used with the misclassification measures to
increase or decrease their importance. As would be expected, there will be
weights then that result in an OTC which is quite different than what would
be obtained from using OET and OMAR. We provide examples in Appendix A
illustrating these differences. However, the subjectiveness of these weights can
depend on the infectious disease, the laboratory, or even particular individuals
at a laboratory. Therefore, for general applications and research settings, it is
difficult to use this or similar types of objective functions. We say this by no
means to diminish the importance of taking into account the misclassification
type. Because of its importance for specific applications, we provide tools in
our binGroup package to find the OTC in those situations when this type of
control is necessary. Examples are provided again on our research website and
in Appendix A.
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Chapter 3
binGroup2: Identification and estimation using group
testing
3.1. Introduction
As discussed in Chapter 1, the two primary objectives of group testing re-
search are estimation and identification. The binGroup package (Bilder et al.,
2010) was created to provide researchers and practitioners functions to use
for estimation. Because functions for the identification problem did not exist
in the binGroup package, a primary purpose of this dissertation was to make
these types of functions available as well.
Over time, a number of additions have been made to binGroup by multi-
ple researchers (including myself). These additions resulted in many different
styles among functions in the package, making use of the package more diffi-
cult than necessary. For this reason, the binGroup2 package was created to
align the binGroup functions in style and format and to incorporate new func-
tions for the group testing identification problem. The identification functions
in binGroup2 include those that were written for the research in Chapter 2
and to incorporate new mathematical derivations that will be presented in
Appendix B. These functions focus on calculating operating characteristics
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(e.g., expected number of tests) and finding the optimal testing configuration
(OTC) for commonly used hierarchical and array-based group testing algo-
rithms. Minor modifications have also been made to repackage and improve
documentation for most of the estimation functions in binGroup to include
in binGroup2. Information on the original binGroup package is available in
Bilder et al. (2010).
In this chapter, we show how to use four main identification functions in
the binGroup2 package. The operatingCharacteristics1() (opChar1())
function calculates operating characteristics for a specified testing configura-
tion with a single-disease assay. The OTC1() function calculates the operating
characteristics and finds the OTC over a range of possible initial group sizes
and/or testing configurations with a single-disease assay. The
operatingCharacteristics2() (opChar2()) and OTC2() functions provide
the same calculations as their counterparts with a multiplex assay that tests
for two diseases. All four of these functions perform calculations for a number
of group testing algorithms. Appendix C contains the R documentation for
these functions and for the binGroup2 package.
In addition, we will briefly summarize the estimation functions included
in binGroup2 and provide tables illustrating the mapping of R functions from
binGroup to binGroup2. All of the functions written for this dissertation and
the supporting functions written for other papers (see Section 3.4) are included
in the binGroup2 package. This package is available from the Comprehensive
R Archive Network (CRAN).
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3.2. Operating characteristics for group testing algorithms
In Chapter 2, we examined operating characteristics for seven different group
testing algorithms, including hierarchical and array testing algorithms for both
homogeneous and heterogeneous populations. We have written an R function
to calculate operating characteristics for these group testing algorithms using
a single-disease assay. Also, we have written an analogous R function for
multiplex assays. We discuss both of these functions next.
3.2.1. Single-disease assays
The operatingCharacteristics1() (opChar1()) function calculates oper-
ating characteristics for group testing algorithms using a single-disease assay.
Suppose a laboratory wants to implement the simplest form of group testing,
two-stage hierarchical testing, to detect a single disease among a continuous
stream of specimens that arrive daily. The opChar1() function can be used to
determine the expected number of tests and corresponding diagnostic accuracy
for a specific initial group size.
To illustrate opChar1() in a simple setting, suppose a group size of 5 is
used in a situation with a disease prevalence of 0.05. Note that this is the
prevalence and group size used by the Nebraska Public Health Laboratory
in March 2020 for its calculations when planning to test for SARS-CoV-2,
the virus that causes COVID-19, via group testing (Nebraska Department of
Health and Human Services, 2020; Abdalhamid et al., 2020; Bilder et al., 2020).
If we assume a sensitivity of 0.99 and a specificity of 0.99 (good estimates are
not available as of March 2020), the opChar1() function can be used the
following way:
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> library(binGroup2)
> # Example 1 - non -informative two -stage hierarchical testing
> config.mat1 <- matrix(data = c(rep(1, 5), 1:5), nrow = 2,
ncol = 5, byrow = TRUE , dimnames = list(Stage = 1:2,
Individual = 1:5))
> config.mat1
Individual
Stage 1 2 3 4 5
1 1 1 1 1 1
2 1 2 3 4 5
> results1 <- opChar1(algorithm = "D2", p = 0.05, Se =
rep (0.99, 2), Sp = rep (0.99 , 2), hier.config = config.mat1)
Number of minutes running: 0
> names(results1)
[1] "algorithm" "prob" "Se" "Sp" "Config"
[6] "p.vec" "ET" "value" "Accuracy"
> results1$ET # One component of the returned list
[1] 2.158473
> names(results1$Config)
[1] "Stage1"
> names(results1$Accuracy)
[1] "Individual" "Overall"
> summary(results1)
Algorithm: Non -informative two -stage hierarchical testing
Testing configuration:
Stage 1: 5
Expected number of tests: 2.16
Expected number of tests per individual: 0.4317
Accuracy for individuals:
PSe PSp PPPV PNPV Individuals
1 0.9801 0.9981 0.9642 0.9990 All
Overall accuracy of the algorithm:
PSe PSp PPPV PNPV
1 0.9801 0.9981 0.9642 0.9990
PSe denotes the pooling sensitivity.
PSp denotes the pooling specificity.
PPPV denotes the pooling positive predictive value.
PNPV denotes the pooling negative predictive value.
We first define a matrix, config.mat1, that specifies the full testing configu-
ration for the hierarchical testing algorithm. This matrix, known as a group
membership matrix (Bilder et al., 2019), is provided in the hier.config ar-
gument of op.Char1(). The rows correspond to the stages of testing, the
columns correspond to each individual to be tested, and the cell values specify
the group number of each individual at each stage. For example, row 1 of the
matrix shows that each individual is being tested as one group in stage 1, and
row 2 of the matrix shows that each individual is tested separately in stage
2. While row and column names are used here for readability, these are not
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required. For array testing algorithms, the row/column size is provided in the
rowcol.sz argument of op.Char1() and the hier.config argument is not
used. Only square arrays are considered for array testing algorithms because
that is how array testing is most often applied.
Within the opChar1() function, we also specify the desired group testing
algorithm. While we specified algorithm = "D2" here for non-informative
two-stage hierarchical testing, other options include hierarchical testing up to
four stages and array testing with and without master pooling. The overall
prevalence of disease is specified with the p argument. The sensitivity and
specificity of the diagnostic test are specified by the Se and Sp arguments,
respectively. Their values are given in vectors, where one value is stated for
each stage of testing (in order). The values in Example 1 are specified as (stage
1, stage 2). As another example, values are specified as (stage 1, stage 2, stage
3) for three-stage hierarchical testing or (master group testing, row/column
testing, individual testing) for array testing with master pooling. If a single
value is provided, sensitivity/specificity values are assumed to be equal for all
stages of testing.
The list of results for opChar1() includes the algorithm (algorithm), over-
all probability of disease (prob), sensitivity (Se), specificity (Sp), and testing
configuration (Config) provided by the user. The Config result provides group
sizes for each stage of hierarchical testing algorithms or the row/column size
and array size for array testing algorithms. The vector of individual proba-
bilities (all of which are equal in Example 1) is provided by p.vec. Operat-
ing characteristics calculated are the expected number of tests (ET), expected
number of tests per individual (value), and accuracy measures (Accuracy) for
individuals and the overall algorithm.
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Accuracy measures include the pooling sensitivity, pooling specificity, pool-
ing positive predictive value, and pooling negative predictive value. Individual
accuracy measures (Accuracy$Individual) are calculated for each individual
specified (by number) in the optional a argument of op.Char1(). The a argu-
ment is not provided here, so individual accuracy measures for all individuals
in the algorithm are calculated. Individual accuracy measures are displayed
in a matrix, where each row is a unique set of individual accuracy measures.
The Individuals column lists which individuals share those measures. In
Example 1, the Individuals column displays All instead of listing every
individual in the algorithm because the accuracy measures for all individuals
are equal. Overall accuracy measures (Accuracy$Overall) for the algorithm
are displayed as well. These overall measures are weighted averages of the cor-
responding individual accuracy measures for all individuals in the algorithm.
Expressions for these averages are provided in Appendix A.
The summary.opChar() method function provides a concise summary for
objects of class opChar returned by opChar1(). Information displayed in-
cludes the specified testing configuration, expected number of tests, expected
number of tests per individual, individual accuracy measures, and overall accu-
racy measures of the algorithm. Note that R is referred to as an object-oriented
programming language. This is because generic functions, like summary(),
can produce different results due to the class of the object used with it. R
checks an object's class when a generic function is run and looks for a method
function with the name format <generic function>.<class name>. The
summary.opChar() function is the method function called when summary() is
used with an object of class opChar.
Additional features of opChar1() can be demonstrated with an informative
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group testing example. Suppose that, as is the case in most real-life applica-
tions, the probability of disease is not the same for all individuals being tested.
For example, the Nebraska Public Health Laboratory would like to categorize
specimens tested for SARS-CoV-2 as either high risk (high probability) or low
risk (low probability) to maximize the potential benefit from group testing. To
illustrate this approach, we will again use a two-stage hierarchical algorithm,
but this time with a heterogeneous probability vector. Informative two-stage
hierarchical testing is implemented in binGroup2 via the pool-specific optimal
Dorfman (PSOD) method described in McMahan et al. (2012a). Suppose a
block size of 25 represents the total number of specimens to be tested in a
laboratory in a single day. The first stage of the algorithm involves testing
specimens in five groups of five individuals each. We will again assume a sen-
sitivity of 0.99 and a specificity of 0.99. The opChar1() function can be used
the following way:
> # Example 2 - informative two -stage hierarchical testing
> config.mat2 <- matrix(data = c(rep(x = 1:5, each = 5),
1:25), nrow = 2, ncol = 25, byrow = TRUE , dimnames =
list(Stage = 1:2, Individual = 1:25))
> set.seed (1002)
> p.vec <- expectOrderBeta(p = 0.05, alpha = 0.1, grp.sz = 25)
> p.vec
[1] 1.709007e-11 5.071419e-10 7.221785e-09 6.573282e-08
[5] 4.299270e-07 2.155123e-06 8.632776e-06 2.849657e-05
[9] 7.953888e-05 1.923566e-04 4.133953e-04 8.108784e-04
[13] 1.490215e-03 2.622304e-03 4.534883e-03 7.483465e-03
[17] 1.224643e-02 1.966959e-02 3.108131e-02 4.847474e-02
[21] 7.493288e-02 1.154149e-01 1.785798e-01 2.817468e-01
[25] 4.702845e-01
> results2 <- opChar1(algorithm = "ID2", probabilities =
p.vec , Se = 0.99, Sp = 0.99, hier.config = config.mat2 , a
= 1:5, print.time = FALSE)
> names(results2)
[1] "algorithm" "prob" "alpha" "Se"
[5] "Sp" "Config" "p.vec" "ET"
[9] "value" "Accuracy"
> results2$alpha
[1] NA
> summary(results2)
Algorithm: Informative two -stage hierarchical testing
Testing configuration:
Block size: 25
Group sizes: 5,5,5,5,5
Expected number of tests: 9.50
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Expected number of tests per individual: 0.3802
Accuracy for individuals:
PSe PSp PPPV PNPV Individuals
1 0.9801 0.9999 0.0000 1.0000 1
2 0.9801 0.9999 0.0000 1.0000 2
3 0.9801 0.9999 0.0001 1.0000 3
4 0.9801 0.9999 0.0006 1.0000 4
5 0.9801 0.9999 0.0042 1.0000 5
Overall accuracy of the algorithm:
PSe PSp PPPV PNPV
1 0.9801 0.9986 0.9740 0.9990
PSe denotes the pooling sensitivity.
PSp denotes the pooling specificity.
PPPV denotes the pooling positive predictive value.
PNPV denotes the pooling negative predictive value.
The config.mat2 matrix provides the testing configuration and is specified in
the hier.config argument of opChar1().
The expectOrderBeta() function creates a heterogeneous vector of indi-
vidual probabilities that are the expected value of order statistics from a beta
distribution. This function is based on the beta.dist() function written for
Black et al. (2015), where we discuss our additions/changes to it shortly. The
p argument represents the overall disease prevalence. In the context of a beta
distribution, it is the expected value of a random variable with this distribu-
tion, p = α/ (α + β), where α > 0 and β > 0 are shape parameters (Casella
and Berger, 2002). The alpha argument represents the α shape parameter for
a beta distribution, and it specifies the degree of heterogeneity in the prob-
ability vector. Higher values of α correspond to lower levels of heterogeneity
among the generated individual probabilities. The number of probabilities
desired is given by the grp.sz argument.
Depending on the context that the function is used in, grp.sz may rep-
resent the initial group size for a group testing algorithm. Depending on the
specified p, α, and number of desired probabilities, simulation may be nec-
essary to determine the probabilities. For this reason, expectOrderBeta()
augments beta.dist() by checking whether simulation is necessary. An op-
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tional num.sim argument specifying the number of simulations can be passed
to expectOrderBeta() through the ... argument in opChar1(). While simu-
lation is not needed for Example 2, setting a seed is good practice and ensures
reproducibility of results in informative settings.
The sensitivity and specificity provided in Example 2 are single values
rather than vectors, meaning that the sensitivity values are equal, and the
specificity values are equal for all stages of testing. Example 2 utilizes the
optional a argument to calculate individual accuracy measures only for the
first 5 individuals. Because none of these individuals have equal accuracy
measures, measures for all 5 individuals are displayed in the output. The a
argument can also be used to specify a list of non-consecutive individuals. The
print.time argument is also optional and determines whether the length of
time for calculations to complete is printed. In Example 2, we have decided
not to print the time elapsed during calculations.
The components within the returned list of opChar1() are the same for
non-informative settings, but now with the addition of alpha for this infor-
mative group testing example. In Example 2, we generated a vector of in-
dividual probabilities outside the opChar1() function and specified it using
the probabilities argument. Because we did not use the optional alpha
argument, alpha in the list of results does not have a value. Another way to
generate individual risk probabilities is to do so inside the opChar1() function
by specifying an overall disease prevalence p and a shape parameter alpha for
the beta distribution. By using the same random seed value, p = 0.05, and
α = 0.1, we can produce the same results as in Example 2.
> set.seed (1002)
> results2a <- opChar1(algorithm = "ID2", p = 0.05, alpha =
0.1, Se = 0.99, Sp = 0.99, hier.config = config.mat2 , a =
1:5, print.time = FALSE)
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> results2a$p.vec
[1] 1.709007e-11 5.071419e-10 7.221785e-09 6.573282e-08
[5] 4.299270e-07 2.155123e-06 8.632776e-06 2.849657e-05
[9] 7.953888e-05 1.923566e-04 4.133953e-04 8.108784e-04
[13] 1.490215e-03 2.622304e-03 4.534883e-03 7.483465e-03
[17] 1.224643e-02 1.966959e-02 3.108131e-02 4.847474e-02
[21] 7.493288e-02 1.154149e-01 1.785798e-01 2.817468e-01
[25] 4.702845e-01
> summary(results2a)
<< OUTPUT EDITED >>
Expected number of tests: 9.50
Expected number of tests per individual: 0.3802
Accuracy for individuals:
PSe PSp PPPV PNPV Individuals
1 0.9801 0.9999 0.0000 1.0000 1
2 0.9801 0.9999 0.0000 1.0000 2
3 0.9801 0.9999 0.0001 1.0000 3
4 0.9801 0.9999 0.0006 1.0000 4
5 0.9801 0.9999 0.0042 1.0000 5
Overall accuracy of the algorithm:
PSe PSp PPPV PNPV
1 0.9801 0.9986 0.9740 0.9990
<< OUTPUT EDITED >>
The vector of individual probabilities (p.vec) in the results is the same as
the vector we generated using expectOrderBeta() outside the opChar1()
function.
3.2.2. Multiplex assays
Multiplex assays test for multiple diseases in a single application. If a group
tests negative for both diseases, all members of the group are declared negative.
If a group tests positive for at least one disease, retesting occurs according to
the group testing algorithm. With multiplex assays, we have a set of joint
probabilities of disease, one for each set of potential binary outcomes for the
diseases. For this dissertation, we focus only on the two disease case. In this
situation, there are four joint probabilities to consider: p00, the probability
that an individual tests negative for both diseases; p10, the probability that an
individual tests positive for only the first disease; p01, the probability that an
individual tests positive for only the second disease; and p11, the probability
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that an individual tests positive for both diseases. We use the ordering of
(p00, p10, p01, p11) throughout our discussion.
The operatingCharacteristics2() (opChar2()) function calculates op-
erating characteristics for group testing algorithms with a multiplex assay that
tests for two diseases. Calculations for hierarchical group testing algorithms
are performed as described in Bilder et al. (2019) and calculations for array-
based group testing algorithms are performed as described in Hou et al. (2020).
The required arguments are generally the same as for opChar1(), where we
describe exceptions during our discussion as needed. We show below how to
calculate operating characteristics for non-informative five-stage hierarchical
testing.
> # Example 3 - non -informative five -stage
> # hierarchical testing
> config.mat3 <- matrix(data = c(rep(1, 20), rep(1, 10),
rep(2, 10), rep(c(1, 2, 3, 4), each = 5), rep(1, 3),
rep(2, 2), rep(3, 3), rep(4, 2), rep(5, 3), rep(6, 2),
rep(7, 3), 8, 9, 1:18, NA, NA), nrow = 5, ncol = 20, byrow
= TRUE , dimnames = list(Stage = 1:5, Individual = 1:20))
> config.mat3
Individual
Stage 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2
3 1 1 1 1 1 2 2 2 2 2 3 3 3 3 3 4 4 4 4 4
4 1 1 1 2 2 3 3 3 4 4 5 5 5 6 6 7 7 7 8 9
5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 NA NA
> results3 <- opChar2(algorithm = "D5", p.vec = c(0.95, 0.02,
0.02, 0.01), Se = c(0.96 , 0.98), Sp = c(0.99, 0.99) ,
hier.config = config.mat3 , ordering = matrix(data = c(0,
1, 0, 1, 0, 0, 1, 1), nrow = 4, ncol = 2), print.time =
FALSE)
> names(results3)
[1] "algorithm" "prob.vec" "Se" "Sp" "Config"
[6] "p.mat" "ET" "value" "Accuracy"
> names(results3$Config)
[1] "Stage1" "Stage2" "Stage3" "Stage4"
> names(results3$Accuracy)
[1] "Disease 1 Individual" "Disease 2 Individual" "Overall"
> results3$Se
Stage
Disease 1 2 3 4 5
1 0.96 0.96 0.96 0.96 0.96
2 0.98 0.98 0.98 0.98 0.98
> results3$Sp
Stage
Disease 1 2 3 4 5
1 0.99 0.99 0.99 0.99 0.99
2 0.99 0.99 0.99 0.99 0.99
> summary(results3)
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Algorithm: Non -informative five -stage hierarchical testing
Testing configuration:
Stage 1: 20
Stage 2: 10,10
Stage 3: 5,5,5,5
Stage 4: 3,2,3,2,3,2,3,1,1
Expected number of tests: 7.96
Expected number of tests per individual: 0.3978
Disease 1 accuracy for individuals:
PSe PSp PPPV PNPV Individuals
1 0.8828 0.9989 0.9615 0.9964 1,2,3,6,7,8,11,12,13,16,17,18
2 0.8821 0.9993 0.9760 0.9964 4,5,9,10,14,15
3 0.9048 0.9981 0.9349 0.9971 19,20
Disease 2 accuracy for individuals:
PSe PSp PPPV PNPV Individuals
1 0.9388 0.9989 0.9641 0.9981 1,2,3,6,7,8,11,12,13,16,17,18
2 0.9385 0.9993 0.9778 0.9981 4,5,9,10,14,15
3 0.9507 0.9981 0.9381 0.9985 19,20
Overall accuracy of the algorithm:
PSe PSp PPPV PNPV
1 0.8848 0.9989 0.9630 0.9964
2 0.9399 0.9990 0.9654 0.9981
PSe denotes the pooling sensitivity.
PSp denotes the pooling specificity.
PPPV denotes the pooling positive predictive value.
PNPV denotes the pooling negative predictive value.
The config.mat3 matrix describes the testing configuration for the five-stage
algorithm. Note the use of NA to indicate that the 19th and 20th individuals
are not tested in the fifth stage because individual testing already occurred for
these individuals in the fourth stage of the algorithm.
Because this is a non-informative setting, a vector of overall joint probabil-
ities is specified using the p.vec argument. The ordering argument specifies
the ordering for the binary responses of the diseases. The columns of the
matrix correspond to each disease and the rows of the matrix correspond to
each of the four sets of binary outcomes. Together with the joint probabili-
ties provided in p.vec, this specifies p00 = 0.95, p10 = 0.02, p01 = 0.02, and
p11 = 0.01.
Because a vector of two values is specified for the sensitivity/specificity,
the sensitivity/specificity values for all stages are assumed to be equal. The
first value in the vector is used for the first disease and the second value in
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the vector is used for the second disease. The opChar2() function generates a
sensitivity/specificity matrix of appropriate size based on the specified group
testing algorithm, available in the Se and Sp results objects. Alternatively,
the sensitivity/specificity values can be specified by matrices, where one value
is given for each disease at each stage of testing. The rows of the matrix
correspond to each disease and the columns of the matrix correspond to each
stage of testing, s = 1, ..., S.
The same operating characteristics are calculated in opChar2() as in
opChar1(), and individual accuracy measures are now calculated for each
disease. The overall joint probabilities specified by the user are provided
by prob.vec and the matrix of joint probabilities for each individual are
provided by p.mat. Accuracy measures for each individual specified in
the a argument are provided in Accuracy$'Disease 1 Individual' and
Accuracy$'Disease 2 Individual'. Because we did not specify a list of
individuals in the a argument in Example 3, accuracy measures for all indi-
viduals are displayed. The overall accuracy of the algorithm is displayed in
a matrix of two rows. The first row corresponds to accuracy measures for
the first disease and the second row corresponds to the accuracy measures
for the second disease. The summary.opChar() function is compatible with
opChar2() and provides the specified testing configuration, expected number
of tests, expected number of tests per individual, individual accuracy measures
for each disease, and overall accuracy measures for the algorithm.
In Example 3, we assumed that all 20 individuals had the same set of joint
probabilities. For heterogeneous populations, users can specify a matrix of
individual probabilities in one of two ways: 1) a vector of length four containing
shape parameters for a Dirichlet distribution that leads to the simulation of the
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necessary joint probabilities, or 2) a matrix containing the joint probabilities
for each individual of interest. Consider a group of 5 individuals. We can
specify a matrix of individual probabilities in the following way:
> joint.p <- matrix(data = c(0.90, 0.04, 0.04, 0.02, 0.92,
0.03, 0.03, 0.02, 0.94, 0.03, 0.02, 0.01, 0.95, 0.02,
0.02, 0.01, 0.96, 0.02, 0.01, 0.01) , nrow = 4, ncol = 5,
byrow = FALSE)
> rownames(joint.p) <- c("00" , "10", "01", "11")
> colnames(joint.p) <- 1:5
> joint.p
1 2 3 4 5
00 0.90 0.92 0.94 0.95 0.96
10 0.04 0.03 0.03 0.02 0.02
01 0.04 0.03 0.02 0.02 0.01
11 0.02 0.02 0.01 0.01 0.01
The rows of the matrix correspond to the four joint probabilities and the
columns correspond to each individual in the algorithm. This matrix can be
specified in the probabilities argument of opChar2(). Alternatively, we can
use the alpha argument in opChar2() to specify a vector of shape parameters
for a Dirichlet distribution. Using the same testing configuration and diagnos-
tic accuracy as in Example 3, we can calculate operating characteristics for an
informative setting in the following way:
> results3a <- opChar2(algorithm = "ID5", alpha = c(18.25 ,
0.75, 0.75, 0.25), Se = c(0.96, 0.98) , Sp = c(0.99, 0.99),
hier.config = config.mat3)
> results3a$alpha.vec
[1] 18.25 0.75 0.75 0.25
> results3a$p.mat
1 2 3 4 5
00 0.9818650992 0.975220605 0.957523560 0.95518040 0.941661877
10 0.0107148978 0.002383102 0.035062204 0.01020303 0.002262310
01 0.0070155163 0.020264074 0.006309220 0.01744923 0.046596268
11 0.0004044867 0.002132218 0.001105015 0.01716733 0.009479545
<< OUTPUT EDITED >>
16 17 18 19 20
00 0.87651645 0.866355783 0.85353355 0.7804062963 0.7421553006
10 0.06069141 0.105318444 0.10013884 0.0052134818 0.0319714149
01 0.01564643 0.021725148 0.01673743 0.2140780373 0.2249153986
11 0.04714571 0.006600624 0.02959018 0.0003021846 0.0009578858
Additional details on the use of the Dirichlet distribution for this purpose are
provided in Bilder et al. (2019). The user-specified vector of shape parameters
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is provided in alpha.vec of the results. The matrix of joint probabilities for
each individual are provided in p.mat.
Additional examples using the opChar1() and opChar2() functions (e.g.,
array testing) are provided in the R documentation for the functions in
binGroup2. This documentation is also provided in Appendix C of this dis-
sertation.
3.3. Optimal testing configurations for group testing algorithms
In Chapter 2, we discussed the importance of choosing group sizes when im-
plementing group testing. In practice, group sizes are chosen by minimizing
an objective function, usually the expected number of tests per individual.
The set of group sizes corresponding to the minimum value of the objective
function is the optimal testing configuration (OTC). Chapter 2 examined sev-
eral different objective functions and provided comparisons for seven different
group testing algorithms, including hierarchical and array testing algorithms
for both homogeneous and heterogeneous populations. We have written an R
function to find the optimal testing configuration over every possible configu-
ration for those group testing algorithms using a single-disease assay. We have
also written a comparable R function for multiplex assays. We discuss both
of these functions next.
3.3.1. Single-disease assays
The OTC1() function (a.k.a., the OTC() function in Chapter 2 for binGroup)
finds the OTC for group testing algorithms with a single-disease assay and
computes the associated operating characteristics, as described in Chapter 2.
The required arguments are the same as for opChar1() with two exceptions: 1)
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initial group sizes are specified instead of a specific testing configuration and 2)
a list of objective functions is provided for finding the OTC. An initial group
size or range of initial group sizes (or row/column sizes) is specified using
the group.sz argument. The obj.fn argument specifies a list of objective
functions which are minimized to find the OTC.
Options for the objective functions include the expected number of tests
per individual; the expected number of tests divided by the expected number
of correct classifications (Malinovsky et al., 2016); and a linear combination of
the expected number of tests, the number of misclassified negatives, and the
number of misclassified positives (Graff and Roeloffs, 1972). These objective
functions are referred to as ET, MAR, and GR, respectively, where the latter
two objective functions are termed for the authors of the papers in which
the objective functions were presented. The GR objective function requires
a matrix of weights, specified in the weights argument, for the number of
misclassified negatives and misclassified positives. The rows of the matrix
correspond to each set of weights and up to six sets of weights are allowed.
The available group testing algorithms include up to three-stage hierarchical
testing and array testing with and without master pooling.
We show below how to use the OTC1() function to find the OTC for an
informative three-stage hierarchical group testing algorithm with sensitivity
and specificity that vary across stages of testing and individual probabilities
that are the expected values of order statistics from a beta(0.5, 49.5) distribu-
tion. Note that random variables from this beta distribution have an expected
value of E (Pi) = 0.01. Just as in the opChar1() function, we can alternatively
specify a vector of individual probabilities using the probabilities argument.
> # Example 4 - OTC for informative three -stage
> # hierarchical testing
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> set.seed (1234)
> results4 <- OTC1(algorithm = "ID3", p = 0.01, alpha = 0.5,
Se = c(0.95 , 0.95, 0.98), Sp = c(0.96 , 0.96, 0.99) ,
group.sz = 3:30, obj.fn = c("ET", "MAR", "GR"), weights =
matrix(data = c(1, 1, 10, 10, 1, 10), nrow = 3, ncol = 2,
byrow = TRUE))
Initial Group Size = 3
Initial Group Size = 4
<< OUTPUT EDITED >>
Initial Group Size = 29
Initial Group Size = 30
Number of minutes running: 0.34
> names(results4)
[1] "algorithm" "prob" "alpha" "Se"
[5] "Sp" "opt.ET" "opt.MAR" "opt.GR1"
[9] "opt.GR2" "opt.GR3" "Configs" "Top.Configs"
> names(results4$opt.ET)
[1] "OTC" "p.vec" "ET" "value" "Accuracy"
> names(results4$opt.ET$OTC)
[1] "Stage1" "Stage2"
> results4$Configs
I config ET value PSe PSp PPPV PNPV
1 28 13,7,5,3 3.5120 0.1254 0.8844 0.9996 0.9532 0.9988
2 29 14,7,5,3 3.6378 0.1254 0.8844 0.9995 0.9516 0.9988
3 30 15,7,5,3 3.7692 0.1256 0.8844 0.9995 0.9499 0.9988
4 27 13,7,4,3 3.3934 0.1257 0.8844 0.9996 0.9549 0.9988
5 26 13,6,4,3 3.2710 0.1258 0.8844 0.9996 0.9567 0.9988
<< OUTPUT EDITED >>
24 7 5,2 1.4067 0.2010 0.8844 0.9998 0.9780 0.9988
25 6 5,1 1.3339 0.2223 0.8935 0.9994 0.9339 0.9989
26 5 4,1 1.2604 0.2521 0.8944 0.9994 0.9362 0.9989
27 4 3,1 1.2011 0.3003 0.8955 0.9994 0.9358 0.9989
28 3 2,1 1.1553 0.3851 0.8970 0.9993 0.9303 0.9990
> head(results4$Top.Configs)
I config ET value PSe PSp PPPV PNPV
1 28 13,7,5,3 3.5120 0.1254 0.8844 0.9996 0.9532 0.9988
2 29 14,7,5,3 3.6378 0.1254 0.8844 0.9995 0.9516 0.9988
3 28 14,7,4,3 3.5132 0.1255 0.8844 0.9996 0.9531 0.9988
4 28 14,6,5,3 3.5146 0.1255 0.8844 0.9996 0.9531 0.9988
5 30 15,7,5,3 3.7692 0.1256 0.8844 0.9995 0.9499 0.9988
6 27 13,7,4,3 3.3934 0.1257 0.8844 0.9996 0.9549 0.9988
> summary(results4)
Algorithm: Informative three -stage hierarchical testing
Optimal testing configuration:
Stage 1 Stage 2
ET 28 13,7,5,3
MAR 28 13,7,5,3
GR1 28 13,7,5,3
GR2 23 11,5,4,3
GR3 28 13,7,5,3
Expected number of tests:
E(T) Value
ET 3.51 0.1254
MAR 3.51 0.1256
GR1 3.51 0.1270
GR2 2.91 0.1412
GR3 3.51 0.1373
E(T) denotes the expected number of tests.
Value denotes the objective function value per individual.
Overall accuracy of the algorithm:
PSe PSp PPPV PNPV
ET 0.8844 0.9996 0.9532 0.9988
MAR 0.8844 0.9996 0.9532 0.9988
GR1 0.8844 0.9996 0.9532 0.9988
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GR2 0.8844 0.9996 0.9616 0.9989
GR3 0.8844 0.9996 0.9532 0.9988
PSe denotes the pooling sensitivity.
PSp denotes the pooling specificity.
PPPV denotes the pooling positive predictive value.
PNPV denotes the pooling negative predictive value.
Because we specified a range of group sizes (I = 3, ..., 30) over which to find the
OTC, an appropriately-sized vector of individual probabilities is newly gen-
erated for each initial group size in the range using the expectOrderBeta()
function described in Section 3.2.1. We compare OTCs for all three objec-
tive functions by specifying obj.fn = c("ET","MAR","GR"), where the GR
objective function from Graff and Roeloffs (1972) uses three different sets of
weights specified in the weights argument.
The results produced by the OTC1() function are similar to those produced
by the opChar1() function, and include the algorithm, overall probability of
disease, α shape parameter for the beta distribution (for informative testing
settings only), sensitivity, and specificity as specified by the user. Results
for each requested objective function (provided in opt.ET, for example) in-
clude the OTC (OTC) and the corresponding vector of individual probabilities
(p.vec), expected number of tests (ET), objective function value per individual
(value), and overall accuracy measures for the algorithm (Accuracy). Similar
to the Config result produced by opChar1() and opChar2(), the OTC result
details the full testing configuration (group sizes for each stage in hierarchical
testing algorithms or row/column sizes for array testing algorithms).
Additionally, the OTC1() function provides results for some configurations
other than the OTC. For algorithms where there is only one configuration for
each initial group size (e.g., non-informative two-stage hierarchical or array
testing), results for each initial group size are provided (Configs). For al-
gorithms where there is more than one possible configuration for each initial
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group size (e.g., informative two-stage hierarchical or three-stage hierarchical
testing), two sets of configurations are provided: 1) the best configuration for
each initial group size (Configs), and 2) the top 10 configurations for each
initial group size (Top.Configs). The summary.OTC() function provides a
concise summary for objects of class OTC returned by OTC1(). Information
displayed includes the optimal testing configuration, expected number of tests,
objective function value per individual, and overall accuracy measures of the
algorithm for each objective function.
Notice that the OTC for the GR2 objective function (with weights of D1 =
10 and D2 = 10) differs from the others. The OTC for GR2 has an initial group
size of 23 with stage 2 group sizes of 11, 5, 4, and 3 and 2.91/23 = 0.1265
expected tests per individual. In contrast, the OTC for all other objective
functions is an initial group size of 28 with stage 2 group sizes of 13, 7, 5, and
3 and 3.51/28 = 0.1254 expected tests per individual. The pooling predictive
values are slightly higher for GR2 than for the other objective functions. All
other accuracy measures are the same as for other objective functions up to
four decimal places.
The optional trace argument determines whether the progress of calcula-
tions should be printed for each initial group size provided by the user. The
optional print.time argument is available for the OTC1() function as well.
3.3.2. Multiplex assays
The OTC2() function finds the OTC for group testing algorithms with a mul-
tiplex assay that tests for two diseases and computes the associated operating
characteristics. Calculations are performed the same as in the opChar2() func-
tion. The required arguments are the same as for OTC1(), except that no list
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of objective functions is provided. The OTC is found only for the expected
number of tests per individual. This simplification was made due to the results
described in Chapter 2. The joint probabilities are specified in the same way
as for opChar2(). Available group testing algorithms include up to three-stage
hierarchical testing and array testing with and without master pooling. We
show below how to find the OTC for non-informative array testing with master
pooling.
> # Example 5 - non -informative array testing
> # with master pooling
> Se <- matrix(data = rep(0.95, 6), nrow = 2, ncol = 3,
dimnames = list(Infection = 1:2, Stage = 1:3))
> Sp <- matrix(data = rep(0.99, 6), nrow = 2, ncol = 3,
dimnames = list(Infection = 1:2, Stage = 1:3))
> results2 <- OTC2(algorithm = "A2M", p.vec = c(0.90, 0.04,
0.04, 0.02), Se = Se, Sp = Sp, ordering = matrix(data =
c(0, 1, 0, 1, 0, 0, 1, 1), nrow = 4, ncol = 2), group.sz =
3:20)
Row/Column Size=3, Array Size=9
Row/Column Size=4, Array Size =16
<< OUTPUT EDITED >>
Row/Column Size=19, Array Size =361
Row/Column Size=20, Array Size =400
Number of minutes running: 0.15
> names(results5)
[1] "algorithm" "prob.vec" "Se" "Sp"
[5] "opt.ET" "Configs"
> names(results5$opt.ET)
[1] "OTC" "p.mat" "ET" "value" "Accuracy"
> names(results5$opt.ET$OTC)
[1] "Array.dim" "Array.sz"
> summary(results5)
Algorithm: Non -informative array testing with master pooling
Optimal testing configuration:
Row/column size Array size
ET 8 64
Expected number of tests:
E(T) Value
ET 34.77 0.5432
E(T) denotes the expected number of tests.
Value denotes the objective function value per individual.
Overall accuracy of the algorithm:
PSe PSp PPPV PNPV
1 0.8919 0.9976 0.9601 0.9931
2 0.8919 0.9976 0.9601 0.9931
PSe denotes the pooling sensitivity.
PSp denotes the pooling specificity.
PPPV denotes the pooling positive predictive value.
PNPV denotes the pooling negative predictive value.
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The sensitivity and specificity values (specified in matrices) are equal for all
stages of testing and all individuals share the same set of joint probabilities.
For array testing algorithms, the group.sz argument specifies the row/column
size for testing. All of the functions described in this chapter consider only
square arrays for array testing algorithms, which is how array testing is usually
applied. Because we have specified a range of row/column sizes over which
to find the OTC, the matrix of joint probabilities for each individual is newly
generated for each array so that the correct number of individuals are specified.
The same operating characteristics are calculated as in OTC1(). Because
the only objective function option available is the expected number of tests
per individual, all OTC results are provided in opt.ET. For array testing al-
gorithms, the OTC results include the row/column size (Array.dim) and the
array size (Array.sz). Similar configurations are provided as well. The
summary.OTC() function is compatible with OTC2() and provides the opti-
mal testing configuration, expected number of tests, expected number of tests
per individual, and overall accuracy measures for the algorithm. Overall ac-
curacy measures for each disease are displayed in a matrix, where each row
corresponds to a disease.
3.4. Calculation details
Calculations of operating characteristics in binGroup2 are performed by uti-
lizing code written for several papers by other authors. New code was also
written for array testing with master pooling. This section provides details
on the mathematical expressions and R functions used for the group testing
algorithms available in OTC1(), OTC2(), opChar1(), and opChar2().
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3.4.1. Single-disease assays
Operating characteristics for hierarchical testing algorithms, with the excep-
tion of informative two-stage hierarchical testing, are calculated based on ex-
pressions provided in Black et al. (2015). The opChar1() and OTC1() functions
utilize the hierarchical.desc() function, which implements up to four-stage
hierarchical testing and was written for the same paper. Informative two-stage
hierarchical testing (Dorfman) is implemented via the pool-specific optimal
Dorfman (PSOD) method described in McMahan et al. (2012a), where the
greedy algorithm proposed for PSOD is replaced by considering all possible
testing configurations. For this algorithm, the opChar1() and OTC1() func-
tions utilize the characteristics.pool() and accuracy.dorf() functions
written for McMahan et al. (2012a). The former function is used to calculate
the expected number of tests and the latter function calculates the individual
accuracy measures for the algorithm.
Operating characteristics for array testing without master pooling are cal-
culated based on expressions provided in McMahan et al. (2012b). Infor-
mative array testing without master pooling is implemented using the gradi-
ent arrangement (the most efficient array design) for the matrix of individ-
ual risk probabilities, where higher-risk individuals are grouped in the left-
most columns of the array. The gradient arrangement is executed with the
informativeArrayProb() function (originally Informative.array.prob())
and operating characteristics are calculated using the Array.Measures() func-
tion written for McMahan et al. (2012b). Operating characteristics for non-
informative array testing with master pooling are calculated based on expres-
sions provided in Kim et al. (2007) using the MasterPool.Array.Measures()
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function written for Chapter 2.
All of the R functions and papers mentioned in this section make the as-
sumption that the sensitivity/specificity values are equal for all stages of test-
ing. In Appendix B, we present derivations that allow the sensitivity/speci-
ficity values to vary across stages of testing for all seven group testing algo-
rithms in the opChar1() and OTC1() functions. The functions written for
Black et al. (2015), McMahan et al. (2012a), McMahan et al. (2012b), and
Chapter 2 have been revised to match the derivations presented in Appendix
B and incorporated into the binGroup2 package.
3.4.2. Multiplex assays
Operating characteristics for hierarchical testing algorithms with multiplex
assays that test for two diseases are calculated by the ET.all.stages.new()
and PSePSpAllStages() functions written for Bilder et al. (2019). These
functions allow the sensitivity/specificity values to vary across stages of testing
for hierarchical testing up to five stages. As a result, no new derivations were
needed. Only minor modifications (e.g., formatting of returned values) were
made to the functions from Bilder et al. (2019) for inclusion in the binGroup2
package.
Operating characteristics for array testing algorithms with multiplex assays
that test for two diseases are calculated based on expressions provided in Hou
et al. (2020). While the derivations presented in that paper allow for the
sensitivity/specificity values to vary across stages of testing, the corresponding
ARRAY() function written for the paper does not. Revisions were made to the
ARRAY() function to allow the sensitivity/specificity to vary across stages of
testing. These revisions involved editing the C++ code that was used for
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ARRAY(). No derivations for array testing algorithms with multiplex assays
are presented in this dissertation.
3.5. Estimation functions
To provide a coherent structure and reconcile the diverse styles present in the
binGroup package, most of the estimation functions were reorganized and their
documentation revised for inclusion in the binGroup2 package. The propCI()
function integrates three functions from binGroup into one to calculate point
estimates and confidence intervals for a single proportion when only group
responses are observed. It provides a number of different methods for point
estimation and confidence interval calculation, and it allows for both equal and
unequal group sizes. The propDiffCI() function calculates point estimates
and confidence intervals for a difference of proportions in a similar setting.
Additional information on methods for estimation of and inference on pro-
portions for group testing algorithms is available in Schaarschmidt (2007), Big-
gerstaff (2008), and Tebbs and Bilder (2004). The expected width of a confi-
dence interval can be calculated using the gtWidth() function. The gtTest()
and gtPower() functions calculate the p-value and power associated with a
hypothesis test, respectively. Minor modifications were made to these three
functions for inclusion in binGroup2. The designPower() function combines
two functions from binGroup that help determine the number of groups or
group size needed to achieve a specified level of power. The designEst()
function helps to find the optimal group size for a design and was included in
binGroup2 with only minor modifications. Additional information on deter-
mining the optimal group testing design is available in Schaarschmidt (2007).
The gtSim() function merges three separate simulation functions from
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binGroup, simulating group testing data for simple pooling (two-stage hier-
archical testing), halving (an S-stage algorithm where each group that tests
positive is split into two subgroups), and array testing designs. The gtReg()
function joins three distinct regression functions from binGroup and fits group
testing regression models for simple pooling, halving, and array testing designs.
Additional information on group testing simulation and regression functions
is available in Zhang (2012). Print and summary method functions were com-
bined, as necessary, so that a single print and/or summary method function
exists for the estimation functions included in the binGroup2 package.
3.6. Additional functions
In addition to the opChar1(), opChar2(), OTC1(), and OTC2() func-
tions discussed in this chapter, we authored 32 functions to perform cal-
culations for each of the group testing algorithms internally. For ex-
ample, NI.Dorf.calc1() and NI.Dorf.calc2() perform calculations for
non-informative two-stage hierarchical (Dorfman) testing to support the
opChar1() and opChar2() functions. Similarly, NI.Dorf.OTC1() and
NI.Dorf.OTC2() support the OTC1() and OTC2() functions by finding the
OTC for non-informative Dorfman testing. Analogous functions provide
support for the other group testing algorithms available in the opChar1(),
opChar2(), OTC1(), and OTC2() functions.
Operating characteristics for the halving protocol can be calculated with
the halving() function written for Black et al. (2012). The Sterrett()
function written for Bilder et al. (2010) performs calculations for the unique
Sterrett (1957) algorithm that was adapted for informative retesting by Bilder
et al. (2010). Functions described by McMahan et al. (2012a) for informa-
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Table 3.1: New functions for binGroup2.
binGroup2
operatingCharacteristics1 (opChar1)
operatingCharacteristics2 (opChar2)
summary.opChar
OTC2
summary.OTC
Sterrett
tive two-stage hierarchical testing implemented via methods other than PSOD
were previously included in the binGroup package but are not included in the
binGroup2 package.
Table 3.1 provides a list of functions that did not exist in the binGroup
package and are new to the binGroup2 package. Table 3.2 illustrates the
mapping of exported functions in the binGroup package to the binGroup2
package. The mapping of internal functions is shown in Table 3.3. Table
3.4 provides a list of binGroup functions without direct counterparts in the
binGroup2 package.
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Table 3.2: Mapping of R functions from binGroup to binGroup2 (exported
functions only).
binGroup binGroup2
p.vec.func* expectOrderBeta
Informative.array.prob* informativeArrayProb
OTC* OTC1
halving* halving
sim.gt
gtSimsim.halving
sim.mp
gtreg
gtReggtreg.halving
gtreg.mp
gt.control gtRegControl
summary.gt
summary.gtReg
summary.gt.mp
print.summary.gt
print.summary.gtReg
print.summary.gt.mp
predict.gt predict.gtReg
bgtCI
propCIbgtvs
pooledBin
summary.poolbin
print.propCI
print.bgtCI
print.bgtvs
print.poolbin
pooledBinDiff propDiffCI
summary.poolbindiff
print.propDiffCI
print.poolbindiff
bgtPower gtPower
bgtTest gtTest
print.bgtTest print.gtTest
bgtWidth gtWidth
estDesign designEst
nDesign
designPower
sDesign
print.nDesign
print.designPower
print.sDesign
*denotes functions that were incorporated into the binGroup package by
myself before the decision to create binGroup2 was made.
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Table 3.3: Mapping of R functions from binGroup to binGroup2 (internal/hid-
den functions).
binGroup binGroup2
beta.dist* (called by
p.vec.func)
beta.dist / beta.dist2 (called
by expectOrderBeta)
NI.Dorf* NI.Dorf.OTC1, NI.Dorf.calc1
Inf.Dorf* Inf.Dorf.OTC1, Inf.Dorf.calc1
NI.D3* NI.D3.OTC1, NI.D3.calc1
Inf.D3* Inf.D3.OTC1, Inf.D3.calc1
NI.Array* NI.Array.OTC1, NI.Array.calc1
Inf.Array*
Inf.Array.OTC1,
Inf.Array.calc1
NI.A2M* NI.A2M.OTC1, NI.A2M.calc1
hierarchical.desc2* (called by
NI.Dorf, NI.D3, Inf.D3)
hierarchical.desc2 (called by
NI.Dorf.OTC1, NI.Dorf.calc1,
NI.D3.OTC1, NI.D3.calc1,
Inf.D3.OTC1, Inf.D3.calc1)
inf.dorf.measures* (called by
Inf.Dorf)
inf.dorf.measures (called by
Inf.Dorf.OTC1, Inf.Dorf.calc1)
characteristics.pool* (called
by inf.dorf.measures)
characteristics.pool (called by
inf.dorf.measures)
accuracy.dorf* (called by
inf.dorf.measures)
accuracy.dorf (called by
inf.dorf.measures)
Array.Measures* (called by
NI.Array, Inf.Array)
Array.Measures (called by
NI.Array.OTC1, NI.Array.calc1,
Inf.Array.OTC1,
Inf.Array.calc1)
MasterPool.Array.Measures*
(called by NI.A2M)
MasterPool.Array.Measures
(called by NI.A2M.OTC1,
NI.A2M.calc1)
bgtAC, bgtBlaker, bgtCP, bgtSOC,
bgtWald, bgtWilson (called by
bgtCI)
bgtAC, bgtBlaker, bgtCP, bgtSOC,
bgtWald, bgtWilson (called by
propCI)
bgtPowerI (called by bgtPower) bgtPowerI (called by gtPower)
bgtWidthI (called by bgtWidth) bgtWidthI (called by gtWidth)
gtreg.fit (called by gtreg) gtreg.fit (called by gtReg)
EM (called by gtreg) EM (called by gtReg)
EM.ret (called by gtreg) EM.ret (called by gtReg)
EM.halving (called by gtreg) EM.halving (called by gtReg)
EM.mp (called by gtreg.mp) EM.mp (called by gtReg)
*denotes functions that were incorporated into the binGroup package by
myself before the decision to create binGroup2 was made.
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Table 3.4: binGroup functions not included in binGroup2
binGroup
opt.info.dorf, pool.specific.dorf, opt.pool.size,
thresh.val.dorf
binCI (binAC, binBlaker, binCP, binSOC, binWald,
binWilson)
plot.poolbin, print.binCI
binDesign
plot.binDesign, print.binDesign
plot.nDesign, plot.sDesign
binPower, binTest, binWidth
print.binTest
print.gt
residuals.gt
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Chapter 4
A Shiny app for pooled testing
4.1. Background
Laboratories around the world frequently need to test a high volume of
clinical specimens for disease. For these situations, a decision needs to be
made about whether group testing will reduce testing loads compared to test-
ing specimens individually. Additionally, laboratories need to determine the
set of group sizes to use. We developed a Shiny application (available at
www.chrisbilder.com/shiny) to assist directors and technicians in laboratories
with making these decisions.
A Shiny application (a.k.a., Shiny app) is an interactive web-based applica-
tion built using the Shiny package in R. The app seeks input via a user-friendly
interface in a web browser. The app then takes those inputs and performs cal-
culations or produces plots by calling functions in R. Our Shiny app utilizes
functions in the binGroup2 package to calculate the expected number of tests
and diagnostic accuracy measures for a wide variety of group testing algorithms
using both one- and two-disease assays. The optimal testing configuration for
an algorithm can be identified with the app as well.
Our app focuses on group testing in homogeneous (i.e., non-informative)
settings because that is how group testing is most often utilized in laboratories.
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While the use of the binGroup2 package requires reading the R documentation
and some prior knowledge of programming, the goal of the Shiny app is to
make this research accessible to those with non-statistical backgrounds who
are using group testing in practice. The Shiny app uses simple questions, fill-in
text boxes, and slider/radio button inputs to elicit the same specifications used
for the binGroup2 functions. We illustrate the use of our app with a simple
example for single-disease assays, and with regard to the Aptima Combo 2
Assay used to test for chlamydia and gonorrhea throughout the United States.
4.2. Methods
Users can calculate operating characteristics for a single testing configuration
or find the optimal testing configuration over a range of initial group sizes for
hierarchical or array testing algorithms by following links available 1) in the
side bar panel, 2) on the Introduction (A Shiny App for Pooled Testing) page
(Figure 4.1), and 3) on the About pooled testing page (Figure 4.2) of the app.
Each of the calculation pages (pages that calculate operating characteristics
or find the OTC) pose questions to draw out the user's testing specifications.
These specifications are:
1. The number of diseases for the assay,
2. The overall disease prevalence for a one-disease assay or a set of joint
probabilities for a two-disease assay,
3. Sensitivity and specificity values for each stage of testing for each disease,
4. The number of stages for the algorithm, and
5. The testing configuration.
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Figure 4.1: Introduction page in the Shiny app.
Like the functions in binGroup2, the Shiny app allows for sensitivity and
specificity values to differ across stages of testing. Examples of the app spec-
ifications are shown in Figures 4.3, 4.4, and 4.5 for hierarchical testing and
Figures 4.6 and 4.7 for array testing. Examples are given for when the op-
erating characteristics of a specific testing configuration are of interest and
for when the optimal testing configuration is to be found. After providing
the required inputs, the user clicks Calculate and the Shiny app uses the
binGroup2 package to perform calculations.
Operating characteristics for a single testing configuration are calculated
using the opChar1() and opChar2() functions in the binGroup2 package.
While the computed results are the same as with using these functions in R,
the testing configuration, expected number of tests, expected number of tests
per individual, and accuracy measures are displayed nicely in paragraph form
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Figure 4.2: About pooled testing page in the Shiny app.
Figure 4.3: Specifications for two-stage hierarchical testing with a one-disease
assay prior to specifications being included.
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Figure 4.4: Specifications for three-stage hierarchical testing with a one-disease
assay prior to specifications being included.
Figure 4.5: Specifications for two-stage hierarchical testing with a two-disease
assay prior to specifications being included.
74
Figure 4.6: Specifications for array testing with a one-disease assay prior to
specifications being included.
Figure 4.7: Specifications for array testing when finding the OTC prior to
specifications being included.
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in the app.
Additionally, the app provides the percent reduction in the number of tests
when compared to individual testing and displays the input values used for
calculations. An algorithm diagram is also produced to illustrate the testing
configuration. When finding the optimal testing configuration, the app dis-
plays operating characteristics corresponding to the best configuration for each
initial group size provided by the user. A plot of the the expected number of
tests per individual for each of these similar configurations is also displayed.
4.3. Examples
4.3.1. Single-disease assays
Consider an example involving a two-stage hierarchical testing algorithm with
an overall prevalence of p = 0.03 and an initial group size of 15. The sensi-
tivity is Se = 0.95 and the specificity is Sp = 0.99 for each stage of testing.
Figure 4.8 displays the specifications. After a user selects Calculate, the
corresponding operating characteristics are displayed as shown in Figure 4.9
and the algorithm diagram is displayed as shown in Figure 4.10.
The expected number of tests per individual is E (T ) /I = 6.32/15 = 0.42.
Thus, two-stage hierarchical testing reduces the expected number of tests by
(1− 0.42)× 100 = 58% when compared to individual testing.
4.3.2. Multiplex assays
Consider an example involving the Aptima Combo 2 Assay that is used to
test for both chlamydia and gonorrhea simultaneously. We focus here on how
the State Hygienic Laboratory (SHL) at the University of Iowa uses the assay,
where details are provided in Hou et al. (2020). While the SHL uses group
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Figure 4.8: Example 1 - Specifications for two-stage hierarchical testing.
Figure 4.9: Example 1 - Operating characteristics for two-stage hierarchical
testing.
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Figure 4.10: Example 1 - Algorithm diagram for two-stage hierarchical testing.
testing for female swab specimens, it uses individual testing for female urine
specimens because they are concerned that the probability of having at least
one disease may be too large for group testing to work well. The purpose
here is to determine if group testing would be beneficial for the female urine
specimens.
Figure 4.11 displays the specifications for a three-stage hierarchical testing
algorithm. The joint probabilities of disease were estimated based on previous
testing results for 5,998 individuals, where the first disease is chlamydia and
the second disease is gonorrhea in our specifications. Sensitivity and specificity
values were obtained from the Aptima Combo 2 Assay product insert (Food
and Drug Administration, 2018), and we assumed these accuracy measures to
be equal for all stages of testing. A maximum group size of 10 is used here
because this is the largest size that we have seen used with group testing for
these diseases (e.g., see Mund et al. (2008)).
Figure 4.12 shows the optimal testing configuration has an initial group
size of 9 individuals with groups of size 3 in the second stage of testing.
The expected number of tests per individual is E (T ) /I = 4.83/9 = 0.54.
Thus, three-stage hierarchical testing reduces the expected number of tests by
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Figure 4.11: Example 2 - Specifications for three-stage hierarchical testing.
(1− 0.54)× 100 = 46% when compared to individual testing. Figure 4.13 dis-
plays the algorithm diagram for the OTC and results for similar configurations
are displayed in Figure 4.14.
The specifications are the same for array testing without master pooling.
Figure 4.15 shows the optimal array is 7×7, with an expected number of tests
per individual of E (T ) /I = 26.50/49 = 0.54. Thus, array testing without
master pooling also reduces the expected number of tests by 46% when com-
pared to individual testing. Figure 4.16 shows the algorithm diagram for the
OTC and results for similar configurations are shown in Figure 4.17. Both
algorithms offer significant savings over the individual testing currently being
used by the SHL to test female urine specimens.
Because both algorithms provide a 46% reduction in the number of tests
compared to individual testing, we can examine the accuracy of each algorithm
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Figure 4.12: Example 2 - OTC and operating characteristics for three-stage
hierarchical testing.
Figure 4.13: Example 2 - Algorithm diagram for three-stage hierarchical test-
ing.
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Figure 4.14: Example 2 - Similar configurations for three-stage hierarchical
testing.
to determine which is best. The overall sensitivity of the algorithm is slightly
higher for both diseases when using array testing. The overall specificity and
positive predictive value of the algorithm is slightly higher for both diseases
when using three-stage hierarchical testing. The overall negative predictive
value corresponding to chlamydia is the same for both diseases and the overall
negative predictive value corresponding to gonorrhea is slightly higher for array
testing. Depending on which overall accuracy measure is considered most
important for these diseases, this information can help to make a decision on
which algorithm is preferred.
Sometimes laboratories face testing constraints and may not be able to im-
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Figure 4.15: Example 2 - Optimal testing configuration and operating charac-
teristics for array testing without master pooling.
Figure 4.16: Example 2 - Algorithm diagram for array testing without master
pooling.
82
Figure 4.17: Example 2 - Similar configurations for array testing without
master pooling.
plement the optimal testing configuration. This may be due to physical limits,
such as a restriction on the group size that can be used in an automated pool-
ing platform, or due to concerns over dilution effects. In these situations, the
results for similar configurations can assist laboratories in choosing a different
set of group sizes as close as possible to the optimal. For example, if the SHL
chooses to utilize three-stage hierarchical testing but an initial group size of 9 is
too large for implementation, an initial group of 6 individuals might be a good
alternative (see Figure 4.17). This configuration allows for a smaller initial
group size and provides similar savings in the number of tests over individual
testing.
83
4.4. Conclusions
There are several additional features in our Shiny app that contribute to a
more user-friendly experience:
 After clicking Calculate, a pop-up indicator bar displays the progress
of the calculations as shown in Figure 4.18. The proportion of calcula-
tions completed is based on the range of initial group sizes provided by
the user.
 An Example button allows users to quickly populate input fields with
sample values to demonstrate the app's capabilities. As the number of
diseases or the testing configuration inputs change, the button can be
clicked again and new sample values will populate as appropriate.
 Popover text provides helpful information about the sensitivity, speci-
ficity, and testing configurations and how to correctly specify their val-
ues. Figure 4.19 illustrates the popover text that appears when the
user's mouse hovers over a fill-in box for the test sensitivity. Helpful ex-
planations also appear over the overall accuracy measures in the results
section.
 The results for similar configurations are displayed in an interactive data
table and can be sorted by any column in increasing or decreasing order.
Additionally, these results are available for download in a .csv file. For
three-stage hierarchical testing, two sets of similar configurations (the
best configuration for each initial group size and the top 10 configurations
for each initial group size) are accessible.
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Figure 4.18: Progress indicator for the three-stage hierarchical testing algo-
rithm in Example 2.
Figure 4.19: Popover text for the test sensitivity in Example 2.
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Our Shiny app implements group testing algorithms for hierarchical and array-
based testing algorithms with one- and two-disease assays over a wide variety
of settings. It performs calculations for specified testing configurations and
finds the optimal testing configuration over a range of initial group sizes. The
app allows laboratories to do an initial investigation and determine if group
testing would be beneficial for their situation, making the binGroup2 functions
available to researchers with no statistical or programming background.
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Chapter 5
Additional Research
While developing this dissertation, we considered some investigations addi-
tional to those already presented in other chapters. We present here a few
of these explorations related to the work in Chapter 2 and Chapter 4. We
then discuss potential topics of future mathematical investigations related to
multiplex assays. Finally, we propose ideas for future work on the binGroup2
package and Shiny app.
5.1. Additional investigations for The objective function contro-
versy for group testing
In an initial effort to find the OTC in Chapter 2, we considered the use of sim-
ulated annealing implemented via the optim() function in the stats package
in R. Simulated annealing is a method for combinatorial optimization that gets
its name from the process of slowly heating and cooling metals. The algorithm,
described in detail within Givens and Hoeting (2013), involves randomly se-
lecting moves and accepting them with a probability dependent on the amount
the solution is worsened and a temperature parameter. Simulated annealing
is best used with large candidate spaces (e.g., the set of all possible configu-
rations for three-stage hierarchical testing); however, it can be extremely slow
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to converge and may require a significant amount of skilled tuning to improve
the performance of the algorithm (Givens and Hoeting, 2013).
We investigated the use of simulated annealing to find the OTC for both
three-stage hierarchical and array testing algorithms. In the end, we discov-
ered that searching over all possible testing configurations is faster in non-
informative settings and in informative settings when the individual probabil-
ities are ordered, which is how informative group testing is applied in practice
(Black et al., 2012). In informative settings where risk probabilities are not
ordered, simulated annealing might provide a benefit.
Expanding on our search for the OTC, we examined much larger preva-
lences than those given in Chapter 2. These investigations ranged up to a value
of p = 0.30. Overall, the patterns discussed in Chapter 2 were similar for these
larger prevalences. In addition, the optimal initial group size decreased as the
overall prevalence increased in most cases. Occasionally, the optimal group
size for larger probabilities was found to be 40 instead, which was the maxi-
mum group size allowed in our investigations. This result coincided with what
Malinovsky et al. (2016) showed, that the optimal initial group size can be
infinite for certain combinations of p, Se, and Sp. For this reason, and because
p > 0.15 rarely occurs in application, we focused on a range of prevalences
from 0.005 to 0.150 by 0.005 in that chapter.
5.2. Additional considerations for the Shiny app
While developing the Shiny app, a significant amount of work was put into two
features of the app: 1) a progress indicator that was only briefly mentioned
in Chapter 4, and 2) a Reset button. In this section, we provide additional
details on the efforts related to these features.
88
In Chapter 4, we introduced the progress indicator available in the Shiny
app. To make this feature available, the app utilizes several functions from
the shiny package to create and update the progress indicator as calculations
are completed. Before any calculations are started, Progress$new() creates a
new progress object and progress$set() is used to initialize the value of the
progress bar to 0. The message argument provides the text to be displayed
on the progress bar, which is Calculation in progress for the app. When the
app calculates operating characteristics for a specified testing configuration,
the progress is set to a value of 0.5 right before the opChar1() or opChar2()
function is called and the progress is set to a value of 1 after the calculations
are complete.
When the app finds the OTC, we are able to provide an additional level
of detail in the progress indicator. Prior to the OTC1() or OTC2() function
being called, a simple progress function is created. This function is passed as
an additional argument to the OTC functions in binGroup2. For every initial
group size in the range provided by the user, the progress bar is incremented
by 1/ (m+ 1), where m is the number of initial group sizes considered. The
text for the progress bar is also updated, displaying the initial group size
(or row/column size) for which calculations were just completed. When all
calculations are completed, the progress is set to a value of 1 and the pop-up
window containing the progress indicator closes. We added code to update
Shiny progress objects in the binGroup2 functions so that the functions would
not have to be revised for use with the Shiny app. This code allows Shiny
to interact with the binGroup2 functions and update the progress indicators
without making binGroup2 dependent on the shiny package.
Previous versions of the Shiny app attempted to provide a Reset button
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to complement the Example and Calculate buttons. The goal of a Reset
button was to clear the specified input values and erase any displayed results.
Issues arose when resetting the specified inputs caused the disabling of the
Calculate button. Additionally, the effects of a Reset button were not
isolated to the page on which the button appeared. For example, resetting
inputs on the calculation page for hierarchical testing disabled the Calculate
button on all pages of the app. While we believe a Reset button could prove
a useful addition to the Shiny app, additional research is needed to implement
this feature successfully.
5.3. Future research
In this dissertation, we focused on calculating operating characteristics and
finding OTCs for a large number of group testing algorithms using one- or
two-disease assays. We presented an R package and Shiny app to this end and
provided derivations to allow diagnostic accuracy to vary across stages of test-
ing. We next describe extensions to our proposed methods and programming
work, and provide recommendations for future research. We discuss addi-
tional mathematical investigations for group testing using multiplex assays,
especially with three or more diseases. Additionally, the binGroup2 package
and Shiny app will continue to be advanced with the goal of enhancing the
user experience. Additions and revisions are proposed to improve the app for
statisticians and researchers who use group testing in practice.
5.3.1. Mathematical investigations
This dissertation focused on the implementation of group testing algorithms
with assays that test for one or two diseases. One of the largest areas for new
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research in group testing is with multiplex assays that test for more diseases.
Closed-form expressions are available to calculate operating characteristics for
hierarchical and array-based group testing algorithms with two-disease assays.
Research could be performed to derive operating characteristics for the same
algorithms using multiplex assays that test for three or more diseases.
At the time of publication, the authors of Bilder et al. (2019) were only
aware of multiplex assays for up to K = 3 diseases being used in practice.
For example, the American Red Cross uses a multiplex assay to screen blood
donations for HBV, HCV, and HIV (American Red Cross, 2020), and the
BD Max CT/GC/TV assay tests for chlamydia, gonorrhea, and trichomonas
(Van Der Pol et al., 2016). However, there exist several multiplex assays to
test for more than three diseases. Rumyantseva et al. (2015) evaluated a
multiplex assay that detects chlamydia, gonorrhea, trichomonas, and M.gen,
and the Tick-Borne Disease Serochip tests for eight major tick-borne pathogens
including Lyme disease, babesiosis, anaplasmosis, and Powassan virus disease
(Tokarz et al., 2018). While the implementation of these tests does not appear
to utilize group testing procedures at this time, it serves as motivation for
developing statistical methodology to show how best to take advantage of
such an assay with group testing. Also, it is of interest to determine at what
point the probability of testing positive for at least one disease becomes too
high for realistic group testing applications.
Bilder et al. (2019) developed algorithms for hierarchical testing with two
or more stages, but their derivations focused primarily on the K = 2 disease
setting. Work is needed to explore settings for K ≥ 3 diseases and to develop
functions that implement the associated calculations. It may be possible to
find closed-form expressions for operating characteristics in the K = 3 disease
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case, but the derivations will likely be cumbersome because there are eight
joint probabilities and many more probability terms to deal with than for the
K = 2 disease setting. In the case that closed-form expressions for K ≥ 3 are
not attainable, a simulation approach could be used instead. It is important
to note that simulation raises questions of whether finding the OTC would
be feasible in regards to the time it takes to find a solution. Additional ex-
plorations potentially involve four-stage hierarchical testing, finding the OTC
using combinatorial algorithms. Overall, further research is needed to deter-
mine how to calculate operating characteristics and find the OTC for K ≥ 3
diseases and to evaluate how well hierarchical testing works as K increases.
Additionally, there are a number of investigations associated with the re-
search in Bilder et al. (2019) that could be valuable. First, the effect of the
correlation between diseases for K > 2 needs to be examined. As the correla-
tion increases, it is more likely that positive responses for diseases will occur
together and, hence, fewer tests should be needed. Investigation is also needed
to determine what happens as the correlation between diseases approaches
zero. Second, research is needed in regards to the pooling sensitivity. With a
higher number of diseases, the pooling sensitivity increases. Work is needed
to determine whether there is a mathematical reason for this phenomenon and
to observe contextually what happens with simulation.
5.3.2. binGroup2
The binGroup2 package is available on CRAN, but development of the package
continues. The OTC and operating characteristic functions make available a
large number of hierarchical and array-based group testing algorithms. The
halving() and Sterrett() functions are available separately in binGroup2,
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but these are only available for single-disease assays and do not allow for
diagnostic accuracy to vary across stages of testing. One potential addition to
the package involves revising these functions to allow sensitivity and specificity
values to differ across stages of testing. These algorithms could also be added
as options to the OTC and operating characteristic functions.
Another possible addition to the package involves a revision to the obj.fn
argument in the OTC1() function. The OTC1() function only calculates oper-
ating characteristics and finds the OTC for a limited set of objective functions.
Rather than use the objective functions currently available, we could allow the
user to provide their own objective function. This capability would require the
user to understand how the OTC1() and associated internal functions operate,
but would allow the user to customize OTC1() for their needs.
The OTC1() and OTC2() functions provide results for configurations similar
to the OTC. For algorithms that have only one testing configuration per initial
group size (i.e., non-informative two-stage hierarchical testing, array testing),
the set of similar configurations includes results for every initial group size
specified by the user. For algorithms that have more than one testing config-
uration per initial group size (i.e., informative two-stage hierarchical testing,
three-stage hierarchical testing), two sets of similar configurations are pro-
vided: 1) the best configuration for each initial group size specified by the
user, and 2) the top 10 configurations for each initial group size specified by
the user. A potential addition to the OTC functions involves a new argument,
say sim.config, that allows the user to specify how many testing configu-
rations to display for each initial group size. Another method for providing
similar configurations could utilize a threshold value , specified by the user.
All configurations where the objective function value per individual is within
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 of the OTC could be displayed by the function.
Currently, the functions for array testing with a two-disease assay do not
allow for individuals with different risk probabilities pi. Once methods for in-
formative array testing with multiplex assays are developed, the corresponding
functions in binGroup2 could be revised to include this option and calculate
individual accuracy measures as appropriate. Additionally, R functions could
be written to perform simulation for hierarchical and array-based testing al-
gorithms using multiplex assays. Bilder et al. (2019) made available R func-
tions to implement simulation using hierarchical testing with multiplex assays
that test for two diseases. These functions could be incorporated into the
binGroup2 package. Additional work could be done to expand these programs
for multiplex assays that test for three or more diseases. New functions that
implement simulation for array testing algorithms could also be included in
binGroup2 when they become available.
5.3.3. Shiny app
The most significant future development for our Shiny app is to incorporate
programs for simulation that were mentioned in Section 5.3.2. However, we
mentioned in Section 5.3.1 that these simulations may not be feasible with
regards to the time required to find the OTC. For incorporation of these simu-
lations in the Shiny app, we could omit the OTC and only calculate E (T ) /I,
the expected number of tests per individual. If it is determined that analytical
derivations for the K ≥ 3 disease case are not possible, the Shiny app could
be limited to K = 2 diseases. Functions for simulation could either be incor-
porated on another page in the existing app or in a completely separate app
that focuses on simulation.
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Our Shiny app currently provides only overall accuracy measures when cal-
culating operating characteristics for a specified testing configuration and only
allows non-informative settings. The corresponding functions in binGroup2
provide overall and individual accuracy measures. Individual accuracy mea-
sures could be added to the results in the Shiny app, particularly for hierarchi-
cal testing. Individual accuracy measures for hierarchical testing algorithms
can vary depending on the set of group sizes used, but accuracy measures
for array testing algorithms will be the same for all individuals. Additionally,
future versions of the Shiny app could incorporate informative group testing
settings. The expansion of the app in this manner would need to be care-
fully implemented though, because laboratory directors and technicians would
need to decide on what risk probabilities to use and/or a distribution of risk
probabilities.
The current version of the Shiny app needs a true disease prevalence(s)
to perform calculations. In practice, laboratories most often won't know this
information. Instead, they will have the proportion of individuals declared as
positive from previous tests. To be more accurate, users of the app could spec-
ify which probability they have. If they provide the positive test proportion,
the app could calculate a maximum likelihood estimate of the true disease
prevalence using this proportion.
Minor revisions could be made to the app pertaining to long running com-
putations and displayed error messages. When performing long running com-
putations (e.g., finding the OTC for three-stage hierarchical testing over a
large range of initial group sizes), the only way to stop calculations is to close
the app and reopen it. To make the app more user-friendly, we could modify
it to allow long running computations to be halted without restarting the app.
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In addition, multiple copies of an error message (e.g., Please specify a sen-
sitivity value for each stage of testing.) are displayed when input values are
incorrectly specified. This occurs because multiple rendered outputs depend
on the calculations and each generates its own copy of the error message. A
simple revision to the app could clean up the display so that only a single
copy of an error message is displayed when necessary. Finally, development
of a phone app would provide an exciting new way for users to access our
research.
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Appendix A
Supporting information for Chapter 2
This appendix provides supporting information for the published manuscript
in Chapter 2: Hitt, B., Bilder, C., Tebbs, J., and McMahan, C., (2019).
The objective function controversy for group testing: Much ado about nothing?
Statistics in Medicine 38(24), 4912-4923. Used with permission.
A.1. Notation for Section 2.2
In Section 2.2, we provided the following expression for the expected number
of tests for three-stage hierarchical testing:
E(T ) = 1 +m11P (G11 = 1) +
c2∑
j=1
m2jP (G11 = 1, G2j = 1).
To help explain the expression's notation, Figure A.1 provides a visual repre-
sentation of this type of algorithm as it is used for HIV testing in San Francisco
(Sherlock et al., 2007). The binary random variable Gsj indicates the positive
(1) or negative (0) outcome for group j at stage s. For the initial group of
50 individuals in the first stage of Figure A.1, there will be a single group
testing result for G11. When G11 = 1, c2 = 5 subgroups of size m11 = 10
are formed for a second stage of testing. These five subgroups have binary
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Figure A.1: Diagram of the three-stage hierarchical testing algorithm used for
HIV testing in San Francisco.
testing outcomes of G21, G22, G23, G24, and G25. If G2j = 1 for some subgroup
j = 1, . . . , 5, m2j = 10 individual tests are performed in the third and final
stage of testing.
A.2. Additional results for Section 2.3.1
We provide additional results to coincide with our investigations in Section
2.3.1. Overall, these additional results continue to show that the OTCs have
the same or very similar operating characteristics when using either objective
function. We also include in our summaries the pooling positive predictive
value, PPPV , and the pooling negative predictive value, PNPV , as additional
accuracy measures. The pooling positive (negative) predictive value is the
probability that an individual who is determined to be positive (negative)
by the testing algorithm is truly positive (negative). Predictive values simply
provide an alternative way of looking at accuracy in comparison to the pooling
sensitivity and pooling specificity. Expressions for all accuracy measures are
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available in Kim et al. (2007), McMahan et al. (2012a,b), and Black et al.
(2015).
Table 2.1 provides a summary of the optimal testing configurations (OTCs)
and their operating characteristics when p = 0.01. This table is reproduced
here as Table A.1 with the addition of the predictive values. Similar tables
for p = 0.05 and p = 0.10 are shown in Tables A.2 and A.3, respectively.
The largest differences between operating characteristics for OTCs are shown
in Table 2.2. Table A.4 displays the same results with the addition of the
predictive values.
A.3. Additional results for Section 2.3.2
A.3.1. Tables
We provide additional results to coincide with our investigations in Section
2.3.2. Once again, these additional results show that the same or very similar
operating characteristics are obtained regardless of which objective function is
used. Table A.5 displays the same results as Table 2.3 but with the addition
of the predictive values. Similar tables for E(Pi) = 0.05 and E(Pi) = 0.10
are provided in Tables A.6 and A.7, respectively. Table A.8 displays the same
findings as Table 2.4 but with the addition of the predictive values.
Because informative group testing results in potentially different accuracy
measures for each individual tested, we formed weighted averages across all in-
dividuals tested to present one overall value for each accuracy measure. These
weighted averages are developed from accuracy definitions given by Altman
and Bland (1994a,b) and were used by Black et al. (2015). The pooling sensi-
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tivity is defined as
PSWe =
∑
i piPSe,i∑
i pi
, (A.3.1)
and the pooling specificity is defined as
PSWp =
∑
i(1− pi)PSp,i∑
i(1− pi)
. (A.3.2)
Similarly, the pooling positive predictive value is defined as
PPPV W =
∑
i piPSe,i∑
i piPSe,i + (1− pi)(1− PSp,i)
, (A.3.3)
and the pooling negative predictive value is defined as
PNPV W =
∑
i(1− pi)PSp,i∑
i(1− pi)PSp,i + pi(1− PSe,i)
. (A.3.4)
Expressions (A.3.1) through (A.3.4) represent weighted averages over all I
individuals within the initial group for a hierarchical algorithm or all I2 indi-
viduals within the array for an array testing algorithm.
A.3.2. OTCs for informative group testing
Due to the lack of available space, Tables A.5, A.6, and A.7 display at most
only the initial (stage 1) group size for the informative hierarchical algorithms.
We display their full algorithms in Tables A.9 - A.14. Define Isj as the size of
group j at stage s. For two-stage hierarchical testing, individuals are assembled
into blocks (McMahan et al., 2012a), where we use a block size of 50. Thus,
we have
∑
j I1j = 50 by design.
To better understand the displayed OTCs in the tables, consider the OTC
given in the first row of results in Table A.12. The algorithm is performed
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over S = 3 stages with an initial group size of I11 = 10 individuals. If this
initial group tests positively, four new groups are formed for the second stage
of testing with sizes I21 = 4, I22 = 3, I23 = 2, and I24 = 1. Informative group
testing always orders individuals by their probabilities of positivity. Therefore,
the first group consists of the individuals with the four smallest probabilities,
and the last group consists of the individual with the largest probability. If
any of these groups test positively and has a size greater than 1, individual
testing is performed upon its group members. For the first group in stage 2,
this means that individual tests would be performed on each of its members in
stage 3 (I31 = I32 = I33 = I34 = 1). For the last group in stage 2, no subsequent
retesting would be performed. Figure A.2 provides a pictorial representation
of this group testing algorithm.
Figure A.2: Diagram of the group testing algorithm described in Section A.3.2.
Group sizes are provided within nodes.
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A.4. Additional results for Section 2.4
We provide additional results to coincide with our investigations in Section
2.4. Tables A.15 and A.16 display the same results as Tables 2.5 and 2.6,
respectively, but with the addition of the predictive values. Due to the lack of
available space, Table A.16 displays at most only the initial (stage 1) group size
for the informative hierarchical algorithms. We display their full algorithms
in Tables A.17 and A.18.
A.5. Additional results for Section 2.5
Graff and Roeloffs (1972) proposed an objective function that is a linear com-
bination of the expected number of tests, the number of misclassified negative
individuals (FN1), and the number of misclassified positive individuals (FP1).
This linear combination can be expressed as
E(T ) +D1 × FN1 +D2 × FP1
= E(T ) +
I∑
i=1
{D1(1− PSp,i)(1− pi) +D2(1− PSe,i)pi} ,
where D1 and D2 are subjectively chosen weights. The OTC is found by
minimizing the value of this linear combination per individual, denoted by
OGR. Because weights are subjectively chosen, there will be weights that
result in an OTC different than what is obtained by using OET or OMAR.
We provide results in Tables A.19 and A.20 to illustrate these differences.
Overall, the value of D1 has a larger effect than the value of D2, because there
are many more individuals who are truly negative than positive due to the
small probability of being positive.
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A.6. R examples
To reproduce the research in this paper, we make available a set of R functions
in the binGroup package that
 Calculate E(T ) and associated accuracy measures for different objective
functions, and
 Find the OTC over a wide variety of settings.
All calculations for the paper were performed in version 3.4.1 of R (R Core
Team, 2017).
The examples provided next show how to use binGroup to reproduce re-
sults from Tables 2.1 and 2.3. Examples 1 and 2 use non-informative group
testing with an overall disease prevalence of p = 0.01. Examples 3 and 4 use
informative group testing with an overall disease prevalence of E(Pi) = 0.01.
Estimated running times for each example were calculated using a computer
with 16 GB of RAM and one core of an Intel i7-6500U processor.
> library(binGroup)
> # Example 1
> # Finding the OTC using non -informative
> # three -stage hierarchical testing , where
> # p denotes the overall prevalence of disease ,
> # Se denotes the sensitivity of the diagnostic test ,
> # Sp denotes the specificity of the diagnostic test ,
> # group.sz denotes the range of initial pool sizes
> # for consideration , and obj.fn specifies
> # the objective functions for which to find results.
> # This example takes approximately 2.5 minutes to run.
> results1 <- OTC(algorithm ="D3", p=0.01, Se=0.99 , Sp=0.99,
group.sz=3:40, obj.fn=c("ET", "MAR"))
You have specified an overall probability of disease.
A probability vector will be generated based on the algorithm
specified.
Algorithm: Non -informative three -stage hierarchical testing
Initial Group Size = 3
Initial Group Size = 4
Initial Group Size = 5
<OUTPUT EDITED >
Initial Group Size = 38
Initial Group Size = 39
Initial Group Size = 40
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Number of minutes running: 2.429667
> # Print the results.
> data.frame("Obj.Fn"=c("O_ET", "O_MAR"),
"OTC"=c(paste(results1$opt.ET$OTC$Stage1 ,
results1$opt.ET$OTC$Stage2 [1], 1, sep="-"),
paste(results1$opt.MAR$OTC$Stage1 ,
results1$opt.MAR$OTC$Stage2 [1], 1, sep="-")),
"ET.I"=c(round(results1$opt.ET$ET /
results1$opt.ET$OTC$Stage1 , 4),
round(results1$opt.MAR$ET/results1$opt.MAR$OTC$Stage1 ,
4)), "PSe"=c(round(results1$opt.ET$PSe , 4),
round(results1$opt.MAR$PSe , 4)),
"PSp"=c(round(results1$opt.ET$PSp , 4),
round(results1$opt.MAR$PSp , 4)))
Obj.Fn OTC ET.I PSe PSp
1 O_ET 25-5-1 0.1354 0.9703 0.9996
2 O_MAR 25-5-1 0.1354 0.9703 0.9996
> # Example 2
> # Finding the OTC using non -informative
> # array testing with master pooling.
> # The OTC differs for the ET and MAR
> # objective functions in this example.
> # This example takes approximately 2 minutes to run.
> results2 <- OTC(algorithm ="A2M", p=0.01 , Se=0.90, Sp=0.90 ,
group.sz=3:30, obj.fn=c("ET", "MAR"))
You have specified an overall probability of disease.
A probability vector will be generated based on the algorithm
specified.
Algorithm: Non -informative square array testing with master
pooling
Row/Column Size = 3, Array Size = 9
Row/Column Size = 4, Array Size = 16
Row/Column Size = 5, Array Size = 25
<OUTPUT EDITED >
Row/Column Size = 28, Array Size = 784
Row/Column Size = 29, Array Size = 841
Row/Column Size = 30, Array Size = 900
Number of minutes running: 1.745667
> # Print the results.
> data.frame("Obj.Fn"=c("O_ET", "O_MAR"),
"OTC"=c(paste(results2$opt.ET$OTC$Array.sz,
results2$opt.ET$OTC$Array.dim , 1, sep="-"),
paste(results2$opt.MAR$OTC$Array.sz,
results2$opt.MAR$OTC$Array.dim , 1, sep="-")),
"ET.I"=c(round(results2$opt.ET$ET /
results2$opt.ET$OTC$Array.sz, 4),
round(results2$opt.MAR$ET/results2$opt.MAR$OTC$Array.sz,
4)), "PSe"=c(round(results2$opt.ET$PSe , 4),
round(results2$opt.MAR$PSe , 4)),
"PSp"=c(round(results2$opt.ET$PSp , 4),
round(results2$opt.MAR$PSp , 4)))
Obj.Fn OTC ET.I PSe PSp
1 O_ET 625-25-1 0.145 0.6562 0.9934
2 O_MAR 576-24-1 0.145 0.6562 0.9937
> # Example 3
> # Finding the OTC using informative two -stage
> # hierarchical testing , implemented via the
> # pool -specific optimal Dorfman (PSOD) method
> # described in McMahan et al. (2012) , where
> # alpha denotes the level of heterogeneity in
> # the beta distribution used to generate the
> # vector of individual probabilities.
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> # Depending on the specified probability , level of
> # heterogeneity , and initial group size , simulation
> # may be necessary in order to generate an ordered
> # vector of individual probabilities. This is done
> # with the beta.dist() function (see Black et al. 2015)
> # using 10,000 simulated data sets. The user will
> # need to set a seed in order to reproduce results.
> # This examples takes approximately 2.5 minutes to run.
> set.seed (1002)
> results3 <- OTC(algorithm ="ID2", p=0.01, Se=0.95 , Sp=0.95,
group.sz=50, obj.fn=c("ET", "MAR"), alpha =2)
You have specified an overall probability of disease.
A probability vector will be generated based on the algorithm
specified.
A single group size was provided. The optimal testing
configuration will be found
over all possible testing configurations for the specified
group size.
NOTE: You have specified a maximum group size of 50 or larger.
This function may take a VERY long time to run.
Press 'ESC ' if you wish to cancel the submitted statements.
Algorithm: Informative Dorfman testing
[1] "Using simulation"
Block Size = 50
[1] "Using simulation"
[1] "Using simulation"
Number of minutes running: 2.617833
> # Print the results.
> data.frame("Obj.Fn"=c("O_ET", "O_MAR"),
"OTC"=c(results3$opt.ET$OTC$Block.sz,
results3$opt.MAR$OTC$Block.sz),
"ET.I"=c(round(results3$opt.ET$ET /
results3$opt.ET$OTC$Block.sz, 4),
round(results3$opt.MAR$ET / results3$opt.MAR$OTC$Block.sz,
4)), "PSe"=c(round(results3$opt.ET$PSe , 4),
round(results3$opt.MAR$PSe , 4)),
"PSp"=c(round(results3$opt.ET$PSp , 4),
round(results3$opt.MAR$PSp , 4)))
Obj.Fn OTC ET.I PSe PSp
1 O_ET 50 0.2264 0.9025 0.9931
2 O_MAR 50 0.2264 0.9025 0.9931
> # Second -stage of OTCs
> results3$opt.ET$OTC$pool.szs
[1] 18 13 11 8
> results3$opt.MAR$OTC$pool.szs
[1] 18 13 11 8
> # Example 4
> # Finding the OTC using non -informative two -stage
> # hierarchical testing
> # This example takes approximately 2.5 minutes to run.
> set.seed (1002)
> results4 <- OTC(algorithm ="ID3", p=0.01, Se=0.95 , Sp=0.95,
group.sz=3:40, obj.fn=c("ET", "MAR"), alpha =0.5)
You have specified an overall probability of disease.
A probability vector will be generated based on the algorithm
specified.
Algorithm: Informative three -stage hierarchical testing
Initial Group Size = 3
Initial Group Size = 4
Initial Group Size = 5
<OUTPUT EDITED >
Initial Group Size = 38
Initial Group Size = 39
Initial Group Size = 40
Number of minutes running: 2.614333
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> # Print the results.
> data.frame("Obj.Fn"=c("O_ET", "O_MAR"),
"OTC"=c(results4$opt.ET$OTC$Stage1 ,
results4$opt.MAR$OTC$Stage1),
"ET.I"=c(round(results4$opt.ET$ET /
results4$opt.ET$OTC$Stage1 , 4), round(results4$opt.MAR$ET
/ results4$opt.MAR$OTC$Stage1 , 4)),
"PSe"=c(round(results4$opt.ET$PSe , 4),
round(results4$opt.MAR$PSe , 4)),
"PSp"=c(round(results4$opt.ET$PSp , 4),
round(results4$opt.MAR$PSp , 4)))
Obj.Fn OTC ET.I PSe PSp
1 O_ET 28 0.1291 0.8574 0.9977
2 O_MAR 28 0.1291 0.8574 0.9977
The next example shows how to use binGroup to reproduce results from Table
A.19.
> # Example 5
> # Finding the OTC using two -stage
> # hierarchical testing with O_GR
> # This example takes less than 1 second to run.
> results5 <- OTC(algorithm ="D2", p=0.01, Se=0.99 , Sp=0.99,
group.sz=3:40, obj.fn="GR", weights=matrix(data=c(1, 1,
1000, 1000), nrow=2, ncol=2, byrow=TRUE))
You have specified an overall probability of disease.
A probability vector will be generated based on the algorithm
specified.
Algorithm: Non -informative two -stage hierarchical (Dorfman)
testing
Initial Group Size = 3
Initial Group Size = 4
Initial Group Size = 5
<OUTPUT EDITED >
Initial Group Size = 38
Initial Group Size = 39
Initial Group Size = 40
Number of minutes running: 0.0001666667
> names(results5)
[1] "prob" "Se" "Sp" "opt.ET" "opt.GR1"
[6] "opt.GR2" "Configs"
> data.frame("Obj.Fn"=c("O_GR", "O_GR"),
"OTC"=c(paste(results5$opt.GR1$OTC$Stage1 , 1, sep="-"),
paste(results5$opt.GR2$OTC$Stage1 , 1, sep="-")),
"ET.I"=c(round(results5$opt.GR1$ET /
results5$opt.GR1$OTC$Stage1 , 4), round(results5$opt.GR2$ET
/ results5$opt.GR2$OTC$Stage1 , 4)),
"PSe"=c(round(results5$opt.GR1$PSe , 4),
round(results5$opt.GR2$PSe , 4)),
"PSp"=c(round(results5$opt.GR1$PSp , 4),
round(results5$opt.GR2$PSp , 4)))
Obj.Fn OTC ET.I PSe PSp
1 O_GR 11-1 0.2035 0.9801 0.9990
2 O_GR 3-1 0.3724 0.9801 0.9997
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Table A.1: OTC summary for p = 0.01 under non-informative group testing.
Equally sized groups are optimal at each stage; thus, an OTC of 24-6-1 means
that stage 1 has a group of size 24, stage 2 has four groups of size 6, and stage
3 has twenty-four groups of size 1. Differences between OET and OMAR are
highlighted.
Objective
Algorithm Se Sp function OTC E(T )/I PSe PSp PPPV PNPV
0.99 0.99
OET 11-1 0.2035 0.9801 0.9990 0.9052 0.9998
OMAR 11-1 0.2035 0.9801 0.9990 0.9052 0.9998
0.95 0.95
OET 11-1 0.2351 0.9025 0.9932 0.5727 0.9990
OMAR 11-1 0.2351 0.9025 0.9932 0.5727 0.9990
Two-stage
0.90 0.90
OET 12-1 0.2742 0.8100 0.9816 0.3081 0.9980
hierarchical OMAR 12-1 0.2742 0.8100 0.9816 0.3081 0.9980
0.99 0.90
OET 11-1 0.2841 0.9801 0.9815 0.3485 0.9998
OMAR 11-1 0.2841 0.9801 0.9815 0.3485 0.9998
0.90 0.99
OET 11-1 0.1941 0.8100 0.9990 0.8959 0.9981
OMAR 11-1 0.1941 0.8100 0.9990 0.8959 0.9981
0.99 0.99
OET 25-5-1 0.1354 0.9703 0.9996 0.9604 0.9997
OMAR 25-5-1 0.1354 0.9703 0.9996 0.9604 0.9997
0.95 0.95
OET 24-6-1 0.1443 0.8574 0.9973 0.7634 0.9986
OMAR 24-6-1 0.1443 0.8574 0.9973 0.7634 0.9986
Three-stage
0.90 0.90
OET 24-6-1 0.1562 0.7290 0.9938 0.5437 0.9973
hierarchical OMAR 24-6-1 0.1562 0.7290 0.9938 0.5437 0.9973
0.99 0.90
OET 24-6-1 0.1708 0.9703 0.9928 0.5780 0.9997
OMAR 24-6-1 0.1708 0.9703 0.9928 0.5780 0.9997
0.90 0.99
OET 25-5-1 0.1229 0.7290 0.9997 0.9564 0.9973
OMAR 25-5-1 0.1229 0.7290 0.9997 0.9564 0.9973
0.99 0.99
OET 25-1 0.1378 0.9703 0.9995 0.9529 0.9997
OMAR 25-1 0.1378 0.9703 0.9995 0.9529 0.9997
0.95 0.95
OET 25-1 0.1475 0.8575 0.9970 0.7456 0.9986
OMAR 24-1 0.1475 0.8575 0.9972 0.7566 0.9986
Array w/o
0.90 0.90
OET 25-1 0.1611 0.7291 0.9926 0.4996 0.9973
master pooling OMAR 24-1 0.1611 0.7291 0.9930 0.5112 0.9973
0.99 0.90
OET 23-1 0.1726 0.9703 0.9923 0.5614 0.9997
OMAR 23-1 0.1726 0.9703 0.9923 0.5614 0.9997
0.90 0.99
OET 27-1 0.1279 0.7292 0.9995 0.9410 0.9973
OMAR 27-1 0.1279 0.7292 0/9995 0.9410 0.9973
0.99 0.99
OET 625-25-1 0.1364 0.9606 0.9995 0.9529 0.9996
OMAR 625-25-1 0.1364 0.9606 0.9995 0.9529 0.9996
0.95 0.95
OET 625-25-1 0.1402 0.8146 0.9972 0.7458 0.9981
OMAR 576-24-1 0.1402 0.8146 0.9974 0.7569 0.9981
Array w/
0.90 0.90
OET 625-25-1 0.1450 0.6562 0.9934 0.4997 0.9965
master pooling OMAR 576-24-1 0.1450 0.6562 0.9937 0.5115 0.9965
0.99 0.90
OET 529-23-1 0.1708 0.9606 0.9924 0.5618 0.9996
OMAR 529-23-1 0.1708 0.9606 0.9924 0.5618 0.9996
0.90 0.99
OET 729-27-1 0.1151 0.6563 0.9996 0.9410 0.9965
OMAR 729-27-1 0.1151 0.6563 0.9996 0.9410 0.9965
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Table A.2: OTC summary for p = 0.05 under non-informative group testing.
Equally sized groups are optimal at each stage; thus, a 24-6-1 means that
stage 1 has a group of size 24, stage 2 has four groups of size 6, and stage 3
has twenty-four groups of size 1. There are no differences between the OTCs.
Objective
Algorithm Se Sp function OTC E(T )/I PSe PSp PPPV PNPV
0.99 0.99
OET 5-1 0.4317 0.9801 0.9981 0.9642 0.9990
OMAR 5-1 0.4317 0.9801 0.9981 0.9642 0.9990
0.95 0.95
OET 5-1 0.4536 0.9025 0.9892 0.8141 0.9948
OMAR 5-1 0.4536 0.9025 0.9892 0.8141 0.9948
Two-stage
0.90 0.90
OET 6-1 0.4786 0.8100 0.9719 0.6027 0.9898
hierarchical OMAR 6-1 0.4786 0.8100 0.9719 0.6027 0.9898
0.99 0.90
OET 5-1 0.5013 0.9801 0.9735 0.6605 0.9989
OMAR 5-1 0.5013 0.9801 0.9735 0.6605 0.9989
0.90 0.99
OET 5-1 0.4113 0.8100 0.9982 0.9605 0.9901
OMAR 5-1 0.4113 0.8100 0.9982 0.9605 0.9901
0.99 0.99
OET 9-3-1 0.3773 0.9703 0.9990 0.9812 0.9984
OMAR 9-3-1 0.3773 0.9703 0.9990 0.9812 0.9984
0.95 0.95
OET 9-3-1 0.3798 0.8574 0.9950 0.8993 0.9925
OMAR 9-3-1 0.3798 0.8574 0.9950 0.8993 0.9925
Three-stage
0.90 0.90
OET 12-4-1 0.3806 0.7290 0.9853 0.7227 0.9857
hierarchical OMAR 12-4-1 0.3806 0.7290 0.9853 0.7227 0.9857
0.99 0.90
OET 9-3-1 0.4227 0.9703 0.9874 0.8023 0.9984
OMAR 9-3-1 0.4227 0.9703 0.9874 0.8023 0.9984
0.90 0.99
OET 12-4-1 0.3409 0.7290 0.9988 0.9701 0.9859
OMAR 12-4-1 0.3409 0.7290 0.9988 0.9701 0.9859
0.99 0.99
OET 10-1 0.3809 0.9705 0.9986 0.9735 0.9984
OMAR 10-1 0.3809 0.9705 0.9986 0.9735 0.9984
0.95 0.95
OET 10-1 0.3852 0.8581 0.9926 0.8597 0.9925
OMAR 10-1 0.3852 0.8581 0.9926 0.8597 0.9925
Array w/o
0.90 0.90
OET 10-1 0.3907 0.7302 0.9842 0.7086 0.9858
master pooling OMAR 10-1 0.3907 0.7302 0.9842 0.7086 0.9858
0.99 0.90
OET 9-1 0.4243 0.9705 0.9839 0.7602 0.9984
OMAR 9-1 0.4243 0.9705 0.9839 0.7602 0.9984
0.90 0.99
OET 11-1 0.3511 0.7301 0.9986 0.9659 0.9860
OMAR 11-1 0.3511 0.7301 0.9986 0.9659 0.9860
0.99 0.99
OET 100-10-1 0.3772 0.9608 0.9986 0.9736 0.9979
OMAR 100-10-1 0.3772 0.9608 0.9986 0.9736 0.9979
0.95 0.95
OET 100-10-1 0.3660 0.8152 0.9930 0.8600 0.9903
OMAR 100-10-1 0.3660 0.8152 0.9930 0.8600 0.9903
Array w/
0.90 0.90
OET 100-10-1 0.3517 0.6572 0.9858 0.7091 0.9820
master pooling OMAR 100-10-1 0.3517 0.6572 0.9858 0.7091 0.9820
0.99 0.90
OET 81-9-1 0.4201 0.9608 0.9842 0.7617 0.9979
OMAR 81-9-1 0.4201 0.9608 0.9842 0.7617 0.9979
0.90 0.99
OET 121-11-1 0.3160 0.6571 0.9988 0.9660 0.9823
OMAR 121-11-1 0.3160 0.6571 0.9988 0.9660 0.9823
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Table A.3: OTC summary for p = 0.10 under non-informative group testing.
Equally sized groups are optimal at each stage; thus, a 24-6-1 means that
stage 1 has a group of size 24, stage 2 has four groups of size 6, and stage
3 has twenty-four groups of size 1. Differences between OET and OMAR are
highlighted.
Objective
Algorithm Se Sp function OTC E(T )/I PSe PSp PPPV PNPV
0.99 0.99
OET 4-1 0.5970 0.9801 0.9972 0.9753 0.9978
OMAR 4-1 0.5970 0.9801 0.9972 0.9753 0.9978
0.95 0.95
OET 4-1 0.6095 0.9025 0.9853 0.8722 0.9891
OMAR 4-1 0.6095 0.9025 0.9853 0.8722 0.9891
Two-stage
0.90 0.90
OET 4-1 0.6251 0.8100 0.9683 0.7396 0.9787
hierarchical OMAR 4-1 0.6251 0.8100 0.9683 0.7396 0.9787
0.99 0.90
OET 4-1 0.6561 0.9801 0.9659 0.7614 0.9977
OMAR 4-1 0.6561 0.9801 0.9659 0.7614 0.9977
0.90 0.99
OET 4-1 0.5661 0.8100 0.9975 0.9728 0.9793
OMAR 4-1 0.5661 0.8100 0.9975 0.9728 0.9793
0.99 0.99
OET 9-3-1 0.5836 0.9703 0.9981 0.9827 0.9967
OMAR 9-3-1 0.5836 0.9703 0.9981 0.9827 0.9967
0.95 0.95
OET 9-3-1 0.5733 0.8574 0.9905 0.9091 0.9843
OMAR 9-3-1 0.5733 0.8574 0.9905 0.9091 0.9843
Three-stage
0.90 0.90
OET 9-3-1 0.5619 0.7290 0.9808 0.8081 0.9702
hierarchical OMAR 9-3-1 0.5619 0.7290 0.9808 0.8081 0.9702
0.99 0.90
OET 9-3-1 0.6295 0.9703 0.9772 0.8254 0.9966
OMAR 6-3-1 0.6295 0.9703 0.9786 0.8345 0.9966
0.90 0.99
OET 9-3-1 0.5188 0.7290 0.9984 0.9809 0.9707
OMAR 9-3-1 0.5188 0.7290 0.9984 0.9809 0.9707
0.99 0.99
OET 7-1 0.5821 0.9705 0.9978 0.9800 0.9967
OMAR 7-1 0.5821 0.9705 0.9978 0.9800 0.9967
0.95 0.95
OET 7-1 0.5776 0.8585 0.9888 0.8950 0.9843
OMAR 7-1 0.5776 0.8585 0.9888 0.8950 0.9843
Array w/o
0.90 0.90
OET 7-1 0.5722 0.7310 0.9772 0.7808 0.9703
master pooling OMAR 7-1 0.5722 0.7310 0.9772 0.7808 0.9703
0.99 0.90
OET 7-1 0.6250 0.9704 0.9732 0.8009 0.9966
OMAR 7-1 0.6250 0.9704 0.9732 0.8009 0.9966
0.90 0.99
OET 7-1 0.5335 0.7324 0.9982 0.9778 0.9711
OMAR 7-1 0.5335 0.7324 0.9982 0.9778 0.9711
0.99 0.99
OET 49-7-1 0.5767 0.9608 0.9978 0.9800 0.9957
OMAR 49-7-1 0.5767 0.9608 0.9978 0.9800 0.9957
0.95 0.95
OET 49-7-1 0.5491 0.8156 0.9894 0.8952 0.9797
OMAR 49-7-1 0.5491 0.8156 0.9894 0.8952 0.9797
Array w/
0.90 0.90
OET 49-7-1 0.5154 0.6579 0.9795 0.7812 0.9626
master pooling OMAR 49-7-1 0.5154 0.6579 0.9795 0.7812 0.9626
0.99 0.90
OET 49-7-1 0.6191 0.9607 0.9735 0.8013 0.9955
OMAR 49-7-1 0.6191 0.9607 0.9735 0.8013 0.9955
0.90 0.99
OET 49-7-1 0.4806 0.6592 0.9983 0.9778 0.9635
OMAR 49-7-1 0.4806 0.6592 0.9983 09778 0.9635
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Table A.4: Largest differences between operating characteristics for OTCs
under non-informative group testing. Values of p range from 0.005 to 0.150
by 0.005. The frequency column denotes the number of times a different
OTC was found for OET and OMAR among these values of p. Differences
between operating characteristics are rounded to four decimal places. Note
that the operating characteristic value for OET is always subtracted from the
operating characteristic value for OMAR. Thus, a negative value (indicated
with parentheses) means that the value for OET was larger than the value for
OMAR.
Largest difference
Algorithm Se Sp Frequency E(T )/I PSe PSp PPPV PNPV
Two-stage
hierarchical
0.99 0.99 0 - - - - -
0.95 0.95 3 0.0018 0.0000 0.0049 0.0262 0.0001
0.90 0.90 4 0.0023 0.0000 0.0054 0.0345 0.0001
0.99 0.90 7 0.0056 0.0000 0.0096 0.0382 0.0000
0.90 0.99 0 - - - - -
Three-stage
hierarchical
0.99 0.99 0 - - - - -
0.95 0.95 1 0.0014 0.0000 0.0051 0.0296 0.0001
0.90 0.90 3 0.0015 0.0000 0.0049 0.0575 0.0001
0.99 0.90 7 0.0041 (0.0098) 0.0136 0.0580 (0.0015)
0.90 0.99 1 0.0000 0.0000 0.0002 0.0097 0.0000
Array w/o
master
pooling
0.99 0.99 0 - - - - -
0.95 0.95 5 0.0010 0.0018 0.0026 0.0195 0.0003
0.90 0.90 8 0.0028 0.0022 0.0054 0.0305 0.0005
0.99 0.90 5 0.0043 0.0005 0.0076 0.0317 0.0001
0.90 0.99 1 0.0000 0.0006 0.0001 0.0042 0.0000
Array w/
master
pooling
0.99 0.99 2 0.0005 0.0006 0.0008 0.0046 0.0001
0.95 0.95 4 0.0012 0.0017 0.0026 0.0198 0.0003
0.90 0.90 8 0.0015 0.0018 0.0051 0.0307 0.0005
0.99 0.90 5 0.0048 0.0005 0.0077 0.0327 0.0001
0.90 0.99 2 0.0003 0.0026 0.0005 0.0048 0.0004
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Table A.8: Largest differences between operating characteristics for OTCs un-
der informative group testing. Values of E(Pi) = p range from 0.005 to 0.150
by 0.005. The frequency column denotes the number of times a different OTC
was found among these values of p. Differences between operating characteris-
tics are rounded to four decimal places. Note that the operating characteristic
value for OET is always subtracted from the operating characteristic value for
OMAR. Thus, a negative value (indicated with parentheses) means that the
value for OET was larger than the value for OMAR.
Largest difference
Algorithm α Se Sp Frequency E(T )/I PS
W
e PS
W
p PPPV
W PNPV W
2
0.99 0.99 0 - - - - -
0.95 0.95 7 0.0006 (0.0023) 0.0011 0.0156 0.0004
0.90 0.90 12 0.0010 (0.0052) 0.0023 0.0160 0.0007
0.99 0.90 12 0.0011 (0.0008) 0.0022 0.0182 (0.0001)
Two-stage 0.90 0.99 2 0.0003 0.0052 0.0000 0.0002 0.0007
hierarchical
0.5
0.99 0.99 0 - - - - -
0.95 0.95 3 0.0003 (0.0035) 0.0011 0.0102 0.0003
0.90 0.90 15 0.0008 (0.0103) 0.0022 0.0277 0.0007
0.99 0.90 16 0.0012 (0.0011) 0.0022 0.0194 (0.0001)
0.90 0.99 11 0.0006 0.0078 (0.0002) (0.0028) 0.0007
2
0.99 0.99 1 0.0000 (0.0019) 0.0002 0.0057 (0.0001)
0.95 0.95 2 0.0035 0.0219 0.0033 0.0270 0.0034
0.90 0.90 6 0.0044 0.0152 0.0062 0.0409 0.0023
0.99 0.90 4 0.0035 0.0006 0.0066 0.0445 0.0001
Three-stage 0.90 0.99 14 0.0180 0.0500 0.0003 0.0046 0.0064
hierarchical
0.5
0.99 0.99 1 0.0000 0.0001 0.0001 0.0018 0.0000
0.95 0.95 0 - - - - -
0.90 0.90 3 0.0010 0.0250 0.0033 0.0296 0.0025
0.99 0.90 5 0.0022 0.0034 0.0070 0.0385 0.0005
0.90 0.99 9 0.0057 0.0355 0.0003 0.0051 0.0030
2
0.99 0.99 1 0.0003 0.0004 0.0005 0.0039 0.0001
0.95 0.95 2 0.0011 0.0012 0.0027 0.0169 0.0002
0.90 0.90 5 0.0016 0.0012 0.0040 0.0265 0.0003
0.99 0.90 4 0.0028 0.0003 0.0053 0.0277 0.0001
Array w/o 0.90 0.99 0 - - - - -
master pooling
0.5
0.99 0.99 0 - - - - -
0.95 0.95 4 0.0003 0.0004 0.0015 0.0129 0.0001
0.90 0.90 14 0.0015 0.0004 0.0032 0.0194 0.0002
0.99 0.90 8 0.0024 0.0001 0.0041 0.0211 0.0000
0.90 0.99 1 0.0003 0.0005 0.0003 0.0027 0.0001
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Table A.9: Full OTCs for E(Pi) = 0.01 under informative two-stage hierarchi-
cal group testing. There are no differences in the OTCs for OET and OMAR.
Objective Block Group sizes
α Se Sp function size E(T )/I I11 I12 I13 I14 I15
2
0.99 0.99
OET 50 0.1947 16 11 9 8 6
OMAR 50 0.1947 16 11 9 8 6
0.95 0.95
OET 50 0.2264 18 13 11 8
OMAR 50 0.2264 18 13 11 8
0.90 0.90
OET 50 0.2657 18 13 11 8
OMAR 50 0.2657 18 13 11 8
0.99 0.90
OET 50 0.2754 18 13 11 8
OMAR 50 0.2754 18 13 11 8
0.90 0.99
OET 50 0.1854 18 13 11 8
OMAR 50 0.1854 18 13 11 8
0.5
0.99 0.99
OET 50 0.1683 25 12 8 5
OMAR 50 0.1683 25 12 8 5
0.95 0.95
OET 50 0.2019 25 12 8 5
OMAR 50 0.2019 25 12 8 5
0.90 0.90
OET 50 0.2439 25 12 8 5
OMAR 50 0.2439 25 12 8 5
0.99 0.90
OET 50 0.2511 25 12 8 5
OMAR 50 0.2511 25 12 8 5
0.90 0.99
OET 50 0.1611 25 12 8 5
OMAR 50 0.1611 25 12 8 5
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Table A.10: Full OTCs for E(Pi) = 0.01 under informative three-stage hi-
erarchical group testing. There are no differences in the OTCs for OET and
OMAR.
Objective Group sizes
α Se Sp function I11 E(T )/I I21 I22 I23 I24 I25
2
0.99 0.99
OET 26 0.1285 9 5 5 4 3
OMAR 26 0.1285 9 5 5 4 3
0.95 0.95
OET 26 0.1375 10 7 5 4
OMAR 26 0.1375 10 7 5 4
0.90 0.90
OET 26 0.1497 10 7 5 4
OMAR 26 0.1497 10 7 5 4
0.99 0.90
OET 26 0.1638 10 7 5 4
OMAR 26 0.1638 10 7 5 4
0.90 0.99
OET 26 0.1168 9 5 5 4 3
OMAR 26 0.1168 9 5 5 4 3
0.5
0.99 0.99
OET 33 0.1197 15 6 5 4 3
OMAR 33 0.1197 15 6 5 4 3
0.95 0.95
OET 28 0.1291 13 7 5 3
OMAR 28 0.1291 13 7 5 3
0.90 0.90
OET 29 0.1422 14 7 5 3
OMAR 29 0.1422 14 7 5 3
0.99 0.90
OET 28 0.1554 13 7 5 3
OMAR 28 0.1554 13 7 5 3
0.90 0.99
OET 37 0.1078 17 7 6 4 3
OMAR 37 0.1078 17 7 6 4 3
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Table A.11: Full OTCs for E(Pi) = 0.05 under informative two-stage hierar-
chical group testing. Differences between OET and OMAR are highlighted.
Objective Block Group sizes
α Se Sp function size E(T )/I I11 I12 I13 I14 I15 I16 I17 I18 I19
2
0.99 0.99
OET 50 0.4101 9 7 6 6 5 5 4 4 4
OMAR 50 0.4101 9 7 6 6 5 5 4 4 4
0.95 0.95
OET 50 0.4321 9 7 6 6 5 5 4 4 4
OMAR 50 0.4321 9 7 6 6 5 5 4 4 4
0.90 0.90
OET 50 0.4586 10 8 7 6 5 5 5 4
OMAR 50 0.4586 10 8 7 6 5 5 5 4
0.99 0.90
OET 50 0.4798 9 7 6 6 5 5 4 4 4
OMAR 50 0.4798 9 7 6 6 5 5 4 4 4
0.90 0.99
OET 50 0.3898 9 7 6 6 5 5 4 4 4
OMAR 50 0.3898 9 7 6 6 5 5 4 4 4
0.99 0.99
OET 50 0.3584 16 9 6 5 4 4 3 3
OMAR 50 0.3584 16 9 6 5 4 4 3 3
0.95 0.95
OET 50 0.3830 16 9 6 5 4 4 3 3
OMAR 50 0.3830 16 9 6 5 4 4 3 3
0.5 0.90 0.90
OET 50 0.4124 17 9 7 5 5 4 3
OMAR 50 0.4124 17 9 7 5 5 4 3
0.99 0.90
OET 50 0.4308 17 9 6 5 5 4 3 1
OMAR 50 0.4311 16 9 6 5 4 4 3 3
0.90 0.99
OET 50 0.3411 16 9 6 5 4 4 3 3
OMAR 50 0.3411 16 9 6 5 4 4 3 3
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Table A.12: Full OTCs for E(Pi) = 0.05 under informative three-stage hierar-
chical group testing. Differences between OET and OMAR are highlighted.
Objective Group sizes
α Se Sp function I11 E(T )/I I21 I22 I23 I24
0.99 0.99
OET 10 0.3687 4 3 2 1
OMAR 10 0.3687 4 3 2 1
0.95 0.95
OET 11 0.3709 5 3 3
OMAR 11 0.3709 5 3 3
2 0.90 0.90
OET 12 0.3724 5 4 3
OMAR 12 0.3724 5 4 3
0.99 0.90
OET 9 0.4136 5 3 1
OMAR 8 0.4140 4 3 1
0.90 0.99
OET 12 0.3315 5 4 3
OMAR 12 0.3336 5 3 3 1
0.99 0.99
OET 11 0.3365 6 3 1 1
OMAR 11 0.3365 6 3 1 1
0.95 0.95
OET 11 0.3433 6 3 1 1
OMAR 11 0.3433 6 3 1 1
0.5 0.90 0.90
OET 10 0.3503 6 3 1
OMAR 10 0.3503 6 3 1
0.99 0.90
OET 10 0.3833 6 3 1
OMAR 10 0.3833 6 3 1
0.90 0.99
OET 15 0.3052 7 4 3 1
OMAR 11 0.3076 6 3 1 1
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Table A.14: Full OTCs for E(Pi) = 0.10 under informative three-stage hierar-
chical group testing. Differences between OET and OMAR are highlighted.
Objective Group sizes
α Se Sp function I11 E(T )/I I21 I22 I23 I24 I25 I26 I27 I28 I29 I2,10
0.99 0.99
OET 5 0.5567 3 1 1
OMAR 5 0.5567 3 1 1
0.95 0.95
OET 8 0.5550 4 3 1
OMAR 8 0.5550 4 3 1
2 0.90 0.90
OET 8 0.5461 4 3 1
OMAR 8 0.5461 4 3 1
0.99 0.90
OET 5 0.6044 3 1 1
OMAR 5 0.6044 3 1 1
0.90 0.99
OET 8 0.5055 4 3 1
OMAR 6 0.5203 3 1 1 1
0.99 0.99
OET 40 0.5074 12 6 5 4 4 3 3 1 1 1
OMAR 40 0.5074 12 6 5 4 4 3 3 1 1 1
0.95 0.95
OET 40 0.5050 12 6 5 4 4 3 3 1 1 1
OMAR 40 0.5050 12 6 5 4 4 3 3 1 1 1
0.5 0.90 0.90
OET 40 0.4994 12 7 5 4 4 3 3 1 1
OMAR 40 0.4994 12 7 5 4 4 3 3 1 1
0.99 0.90
OET 6 0.5611 4 1 1
OMAR 6 0.5611 4 1 1
0.90 0.99
OET 40 0.4442 12 7 5 4 4 3 3 1 1
OMAR 40 0.4445 12 6 5 4 4 3 3 1 1 1
Table A.15: OTC summary for HIV testing using Se = 0.963, Sp = 0.9903,
and p = 0.004 with non-informative group testing. Equally sized groups are
optimal at each stage; thus, an OTC of 24-6-1 means that stage 1 has a
group of size 24, stage 2 has four groups of size 6, and stage 3 has twenty-four
groups of size 1. There are no differences in the OTCs for OET and OMAR.
Objective
Algorithm function OTC E(T )/I PSe PSp PPPV PNPV
Two-stage OET 17-1 0.1313 0.9274 0.9993 0.8478 0.9997
hierarchical OMAR 17-1 0.1313 0.9274 0.9993 0.8478 0.9997
Three-stage OET 49-7-1 0.0732 0.8931 0.9998 0.9402 0.9996
hierarchical OMAR 49-7-1 0.0732 0.8931 0.9998 0.9402 0.9996
Array w/o OET 44-1 0.0749 0.8931 0.9997 0.9348 0.9996
master pooling OMAR 44-1 0.0749 0.8931 0.9997 0.9348 0.9996
Array w/ OET 1936-44-1 0.0721 0.8600 0.9998 0.9348 0.9994
master pooling OMAR 1936-44-1 0.0721 0.8600 0.9998 0.9348 0.9994
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Table A.18: Full OTCs for informative three-stage hierarchical testing sum-
marized in Table A.16. Differences between OET and OMAR are highlighted.
Objective Group sizes
function I11 E(T )/I I21 I22 I23 I24
Female
OET 19 0.4102 7 5 4 3
OMAR 14 0.4113 6 4 3 1
Male
OET 8 0.5081 4 3 1
OMAR 8 0.5081 4 3 1
Table A.19: OTC summary for OGR with p = 0.01 under non-informative
two-stage hierarchical testing. An OTC of 11-1 means that stage 1 has a
group of size 11 and stage 2 consists of individual testing.
Se Sp D1 D2 OTC E(T )/I PSe PSp PPPV PNPV
0.99 0.99
1 1 11-1 0.2035 0.9801 0.9990 0.9052 0.9998
1000 1000 3-1 0.3724 0.9801 0.9997 0.9711 0.9998
1 10 11-1 0.2035 0.9801 0.9990 0.9052 0.9998
1 100 11-1 0.2035 0.9801 0.9990 0.9052 0.9998
10 1 10-1 0.2037 0.9801 0.9991 0.9127 0.9998
100 1 7-1 0.2194 0.9801 0.9993 0.9363 0.9998
0.95 0.95
1 1 11-1 0.2351 0.9025 0.9932 0.5727 0.9990
1000 1000 3-1 0.4101 0.9025 0.9966 0.7286 0.9990
1 10 11-1 0.2351 0.9025 0.9932 0.5727 0.9990
1 100 11-1 0.2351 0.9025 0.9932 0.5727 0.9990
10 1 9-1 0.2389 0.9025 0.9940 0.6040 0.9990
100 1 4-1 0.3355 0.9025 0.9962 0.7038 0.9990
0.90 0.90
1 1 11-1 0.2746 0.8100 0.9824 0.3167 0.9981
1000 1000 3-1 0.4571 0.8100 0.9884 0.4138 0.9981
1 10 11-1 0.2746 0.8100 0.9824 0.3167 0.9981
1 100 11-1 0.2746 0.8100 0.9824 0.3167 0.9981
10 1 8-1 0.2868 0.8100 0.9846 0.3464 0.9981
100 1 3-1 0.4571 0.8100 0.9884 0.4138 0.9981
0.99 0.90
1 1 11-1 0.2841 0.9801 0.9815 0.3485 0.9998
1000 1000 3-1 0.4598 0.9801 0.9882 0.4568 0.9998
1 10 11-1 0.2841 0.9801 0.9815 0.3485 0.9998
1 100 11-1 0.2841 0.9801 0.9815 0.3485 0.9998
10 1 8-1 0.2938 0.9801 0.9840 0.3816 0.9998
100 1 3-1 0.4598 0.9801 0.9882 0.4568 0.9998
0.90 0.99
1 1 11-1 0.1941 0.8100 0.9990 0.8959 0.9981
1000 1000 3-1 0.3698 0.8100 0.9997 0.9672 0.9981
1 10 11-1 0.1941 0.8100 0.9990 0.8959 0.9981
1 100 11-1 0.1941 0.8100 0.9990 0.8959 0.9981
10 1 11-1 0.1941 0.8100 0.9990 0.8959 0.9981
100 1 8-1 0.2038 0.8100 0.9993 0.9207 0.9981
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Table A.20: OTC summary for OGR with p = 0.01 under non-informative
three-stage hierarchical testing. When equally sized groups are optimal, we use
the same notation as given in other tables (e.g., Table A.1). When unequally
sized groups are optimal, we write out each group size for its stage. For
example, an OTC of 21-6,5,5,5-1 means that stage 1 has a group of size 21;
stage 2 has groups of size 6, 5, 5, and 5; and stage 3 has groups of size 1.
Se Sp D1 D2 OTC E(T )/I PSe PSp PPPV PNPV
0.99 0.99
1 1 25-5-1 0.1354 0.9703 0.9996 0.9604 0.9997
1000 1000 14-2-1 0.1614 0.9703 0.9999 0.9889 0.9997
1 10 25-5-1 0.1354 0.9703 0.9996 0.9604 0.9997
1 100 25-5-1 0.1354 0.9703 0.9996 0.9604 0.9997
10 1 25-5-1 0.1354 0.9703 0.9996 0.9604 0.9997
100 1 18-3-1 0.1435 0.9703 0.9998 0.9791 0.9997
0.95 0.95
1 1 25-5-1 0.1444 0.8574 0.9977 0.7907 0.9986
1000 1000 6-2-1 0.2401 0.8574 0.9993 0.9289 0.9986
1 10 25-5-1 0.1444 0.8574 0.9977 0.7907 0.9986
1 100 25-5-1 0.1444 0.8574 0.9977 0.7907 0.9986
10 1 20-4-1 0.1479 0.8574 0.9982 0.8290 0.9986
100 1 12-2-1 0.1841 0.8574 0.9992 0.9166 0.9986
0.90 0.90
1 1 24-6-1 0.1562 0.7290 0.9938 0.5437 0.9973
1000 1000 4-2-1 0.3432 0.7290 0.9980 0.7900 0.9973
1 10 24-6-1 0.1562 0.7290 0.9938 0.5437 0.9973
1 100 24-6-1 0.1562 0.7290 0.9938 0.5437 0.9973
10 1 20-4-1 0.1644 0.7290 0.9955 0.6192 0.9973
100 1 10-2-1 0.2202 0.7290 0.9976 0.7533 0.9973
0.99 0.90
1 1 21-6,5,5,5-1 0.1714 0.9703 0.9937 0.6074 0.9997
1000 1000 4-2-1 0.3486 0.9703 0.9979 0.8204 0.9997
1 10 21-6,5,5,5-1 0.1714 0.9703 0.9937 0.6074 0.9997
1 100 21-6,5,5,5-1 0.1714 0.9703 0.9937 0.6074 0.9997
10 1 16-4-1 0.1785 0.9703 0.9951 0.6684 0.9997
100 1 8-2-1 0.2438 0.9703 0.9975 0.7977 0.9997
0.90 0.99
1 1 25-5-1 0.1229 0.7290 0.9997 0.9564 0.9973
1000 1000 3-1 0.3698 0.8100 0.9997 0.9672 0.9981
1 10 25-5-1 0.1229 0.7290 0.9997 0.9564 0.9973
1 100 11-1 0.1941 0.8100 0.9990 0.8959 0.9981
10 1 25-5-1 0.1229 0.7290 0.9997 0.9564 0.9973
100 1 21-3-1 0.1330 0.7290 0.9998 0.9766 0.9973
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Appendix B
Operating characteristics for group testing algorithms
when testing error is allowed to differ across stages of
testing
Chapter 1 provides reasons why the assumption of equal sensitivity and equal
specificity across stages of testing might be unrealistic. In this appendix, we
present derivations of operating characteristics for hierarchical and array test-
ing algorithms that allow the sensitivity and specificity to each differ across
testing stages. Our derivations pertain only to group testing with a single-
disease assay because Bilder et al. (2019) and Hou et al. (2020) supplied
derivations for the two-disease calculations in the binGroup2 package. It is im-
portant to note that all of our derivations follow those in other papers where
the derivations were performed assuming equal sensitivity and equal speci-
ficity. Throughout our own work, we purposely use the same notation as these
other papers to maintain a consistency in the group testing literature and the
associated R functions. Because of the close correspondence to these other
papers, we do not provide a multitude of details. Rather, we focus on where
unequal sensitivity and specificity values will lead to changes in the operating
characteristics.
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B.1. Hierarchical testing (excluding informative two-stage hierar-
chical)
We closely follow the work of Black et al. (2015) to derive the operating char-
acteristics of hierarchical testing, excluding informative two-stage (Dorfman)
testing. Derivations for informative two-stage testing are provided in Appendix
D. Consider an initial group of size I where the ith individual has probabil-
ity pi, i = 1, ..., I, of being positive for a disease. Let Gs,j = 1 (0) denote a
positive (negative) test result and let G˜s,j = 1 (0) denote a positive (negative)
true status for the jth group at stage s. There are Is,j individuals screened in
the group corresponding to Gs,j, where I1,1 = I. If Gs,j = 0, all members of
the corresponding group are declared negative. If Gs,j = 1, individuals in that
group are split into ms,j groups for the next stage of testing. Let cs be the
total possible groups tested at stage s, where c1 = 1 and cs =
∑cs−1
j=1 ms−1,j
for s = 2, ..., S.
To help explain this notation, consider the following example based on how
HIV testing is performed in Seattle using a three-stage hierarchical testing
algorithm (Sherlock et al., 2007). An initial group size of I = 30 is used
in the first stage of the algorithm. Groups that test positive are split into
three groups of size 10 for the second-stage of testing. Individual testing is
performed on any sub-group that tests positive. In this context, I = I1,1 = 30,
c1 = 1, and m1,1 = 3 for the first stage of testing. For the second stage of
testing, I2,j = 10, c2 = 3, and m2,j = 10 for j = 1, 2, 3. For the third stage,
I3,j = 1, c3 = 30, and m3,j = 0 for j = 1, ..., 30.
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B.1.1. Expected number of tests
Define T as the number of tests needed to decode an initial group of size I.
Black et al. (2012) showed the expected number of tests for an initial group of
size I to be
E (T ) = 1 +
S−1∑
s=1
cs∑
j=1
ms,jP
 ⋂
{(s′,j′):Gs,j=1}
{Gs′,j′ = 1}
 (B.1.1)
for an S-stage algorithm. The probability in equation (B.1.1) is
P
 ⋂
{(s′,j′):Gs,j=1}
{
Gs′,j′ = 1
}
= (1− Sp)s
{
I∏
i=1
(1− pi)
}
+
s−1∑
a=1
Sae (1− Sp)s−a
 ∏
i∈Ba+1,j′
(1− pi)

1− ∏
i∈B¯a+1,j′
(1− pi)
+
Sse
1− ∏
i∈Bs,j
(1− pi)
 , (B.1.2)
where Se = P
(
Gs,j = 1
∣∣∣ G˜s,j = 1) is the test sensitivity and Sp =
P
(
Gs,j = 0
∣∣∣ G˜s,j = 0) is the test specificity. Additionally, i ∈ Bs,j repre-
sents the individuals who belong to the jth group at stage s, and i ∈ B¯s,j
represents the set of individuals within the parent group of Bs,j not including
those in Bs,j itself (e.g., i ∈ B¯2,1 denotes all individuals within the initial group
B1,1 who are in stage 2 groups other than B2,1).
The probability in equation (B.1.2) represents a series of groups testing
positive up to and including Gs,j = 1 (Black et al., 2015). For example,
consider a four-stage hierarchical testing algorithm. One of the probabilities
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that needs to be found to calculate E (T ) is P (G1,1 = 1, G2,1 = 1, G3,1 = 1),
where s = 3 and j = 1. The probability P
(⋂
{(s′,j′):Gs,j=1} {Gs′,j′ = 1}
)
can
be expressed as the sum of the following:
1. The joint probability that groups at each stage test positive and all are
truly negative in status,
2. The joint probabilities that groups at each stage test positive and at
least one, but not all, are truly positive in status, and
3. The joint probability that groups at each stage test positive and all are
truly positive in status.
It is important to note that this probability is expressed under the assumption
of equal sensitivity and equal specificity across all stages of testing. With-
out this assumption, we show in this section that the probability in equation
(B.1.1) becomes
P
 ⋂
{(s′,j′):Gs,j=1}
{Gs′,j′ = 1}

=
{
s∏
k=1
(1− Sp:k)
}{
I∏
i=1
(1− pi)
}
+
s−1∑
a=1
{
a∏
k=1
Se:k
}{
s∏
l=a+1
(1− Sp:l)
}
× ∏
i∈Ba+1,j′
(1− pi)

1− ∏
i∈B¯a+1,j′
(1− pi)
+{
s∏
k=1
Se:k
}1− ∏
i∈Bs,j
(1− pi)
 , (B.1.3)
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where Se:s = P
(
Gs,j = 1
∣∣∣ G˜s,j = 1) and Sp:s = P (Gs,j = 0 ∣∣∣ G˜s,j = 0)
are the test sensitivity and test specificity particular to stage s =
1, ..., S, respectively. Thus, the only difference between equation (B.1.2)
and equation (B.1.3) is the leading sensitivity and specificity prod-
ucts for the three main terms in the expression. To see why these
changes occur, suppose S = 3. For this situation, we need to find
P (G1,1 = 1) and P (G1,1 = 1, G2,1 = 1) , ..., P (G1,1 = 1, G2,c2 = 1). The prob-
ability P (G1,1 = 1) is for the initial group testing positive. It is found by
taking into account the true group statuses,
P (G1,1 = 1)
= P
(
G1,1 = 1, G˜1,1 = 0
)
+ P
(
G1,1 = 1, G˜1,1 = 1
)
= P
(
G1,1 = 1
∣∣∣ G˜1,1 = 0)P (G˜1,1 = 0)+
P
(
G1,1 = 1
∣∣∣ G˜1,1 = 1)P (G˜1,1 = 1)
= (1− Sp:1)
{
I∏
i=1
(1− pi)
}
+ Se:1
{
1−
I∏
i=1
(1− pi)
}
. (B.1.4)
For the probabilities of the first- and second-stage groups testing positive,
consider the derivation for P (G1,1 = 1, G2,1 = 1). This probability can be
written as the sum of three separate terms:
P (G1,1 = 1, G2,1 = 1)
= P
(
G1,1 = 1, G2,1 = 1, G˜1,1 = 0, G˜2,1 = 0
)
+
P
(
G1,1 = 1, G2,1 = 1, G˜1,1 = 1, G˜2,1 = 0
)
+
P
(
G1,1 = 1, G2,1 = 1, G˜1,1 = 1, G˜2,1 = 1
)
, (B.1.5)
which takes into account the three ways that {G1,1 = 1} ∩ {G2,1 = 1} may
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occur with respect to the true statuses. The first joint probability is
P
(
G1,1 = 1, G2,1 = 1, G˜1,1 = 0, G˜2,1 = 0
)
= P
(
G1,1 = 1, G2,1 = 1
∣∣∣ G˜1,1 = 0, G˜2,1 = 0)×
P
(
G˜1,1 = 0, G˜2,1 = 0
)
= P
(
G1,1 = 1
∣∣∣ G˜1,1 = 0)P (G2,1 = 1 ∣∣∣ G˜2,1 = 0)×
P
(
G˜1,1 = 0, G˜2,1 = 0
)
= (1− Sp:1) (1− Sp:2)P
(
G˜1,1 = 0, G˜2,1 = 0
)
= (1− Sp:1) (1− Sp:2)P
(
G˜2,1 = 0
∣∣∣ G˜1,1 = 0)P (G˜1,1 = 0)
= (1− Sp:1) (1− Sp:2)P
(
G˜1,1 = 0
)
= (1− Sp:1) (1− Sp:2)
{
I∏
i=1
(1− pi)
}
, (B.1.6)
where we make the assumption that the test outcomes are conditionally in-
dependent once the true status is known (see Litvak et al. (1994) for more
information). Similarly, the second and third joint probabilities can be shown
to be
P
(
G1,1 = 1, G2,1 = 1, G˜1,1 = 1, G˜2,1 = 0
)
= Se:1 (1− Sp:2)
 ∏
i∈B2,1
(1− pi)

1− ∏
i∈B¯2,1
(1− pi)

and
P
(
G1,1 = 1, G2,1 = 1, G˜1,1 = 1, G˜2,1 = 1
)
= Se:1Se:2
1− ∏
i∈B2,1
(1− pi)
 .
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Combining these results together, the probability in equation (B.1.5) becomes
P (G1,1 = 1, G2,1 = 1)
= (1− Sp:1) (1− Sp:2)
{
I∏
i=1
(1− pi)
}
+
Se:1 (1− Sp:2)
 ∏
i∈B2,1
(1− pi)

1− ∏
i∈B¯2,1
(1− pi)
+
Se:1Se:2
1− ∏
i∈B2,1
(1− pi)

for three-stage hierarchical testing. The patterns shown here for three-stage
hierarchical testing are also observed for S-stage hierarchical testing in gen-
eral. Putting all this information together, one can show that for an S-stage
algorithm, the probability in (B.1.1) becomes
P
 ⋂
{(s′,j′):Gs,j=1}
{Gs′,j′ = 1}

=
{
s∏
k=1
(1− Sp:k)
}{
I∏
i=1
(1− pi)
}
+
s−1∑
a=1
{
a∏
k=1
Se:k
}{
s∏
l=a+1
(1− Sp:l)
}
× ∏
i∈Ba+1,j′
(1− pi)

1− ∏
i∈B¯a+1,j′
(1− pi)
+{
s∏
k=1
Se:k
}1− ∏
i∈Bs,j
(1− pi)
 . (B.1.7)
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B.1.2. Accuracy measures
Define Yi = 1 (0) as the final positive (negative) test outcome based on the
group testing algorithm, and define Y˜i = 1 (0) as the positive (negative) true
status of the ith individual, for i = 1, ..., I. The pooling sensitivity for the
ith individual is the probability of a correct positive diagnosis and is ex-
pressed as PS
(i)
e = P
(
Yi = 1
∣∣∣ Y˜i = 1). The pooling specificity for the ith
individual is the probability of a correct negative diagnosis and is written
as PS
(i)
p = P
(
Yi = 0
∣∣∣ Y˜i = 0). We also define the pooling positive predictive
value and pooling negative predictive value as PPPV (i) = P
(
Y˜i = 1
∣∣∣ Yi = 1)
and PNPV (i) = P
(
Y˜i = 0
∣∣∣ Yi = 0), respectively.
B.1.2.1. Pooling sensitivity
For the ith individual to be diagnosed as positive (Yi = 1), the initial group and
all later groups containing that individual must test positive. This includes
the last group which contains only the ith individual (Black et al., 2015). We
define group j∗ in stage L (L ≤ S) as the group in the final stage of testing
for individual i (i.e., the stage where individual i could be tested individually
with respect to the configuration).
Black et al. (2015) showed the pooling sensitivity for an S-stage algorithm
to be
PS(i)e = P
(
Yi = 1
∣∣∣ Y˜i = 1)
= P
 ⋂
{(s′j′):GL,j∗=1}
{Gs′,j′ = 1}
∣∣∣∣∣∣∣
⋂
{(s′j′):GL,j∗=1}
{
G˜s′,j′ = 1
}
= SLe .
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This derivation uses the conditional independence assumption previously men-
tioned in Section B.1.1 to result in the product of the sensitivities at each stage
of the algorithm. Allowing for unequal sensitivities across the stages, the pool-
ing sensitivity simply becomes
PS(i)e =
L∏
k=1
Se:k.
Thus, the pooling sensitivity is the same for each individual testing positive
within L stages.
B.1.2.2. Pooling specificity
Black et al. (2015) showed the pooling specificity for an S-stage algorithm to
be
PS(i)p = P
(
Yi = 0
∣∣∣ Y˜i = 0)
= 1− P
(
Yi = 1
∣∣∣ Y˜i = 0)
= 1−
P (Yi = 1)− P
(
Yi = 1
∣∣∣ Y˜i = 1)P (Y˜i = 1)
P
(
Y˜i = 0
)
= 1−
P
(⋂
{(s′j′):GL,j∗=1} {Gs′,j′ = 1}
)
− SLe pi
(1− pi) .
Allowing for unequal sensitivities and unequal specificities across stages of
testing, the pooling specificity simply becomes
PS(i)p = 1−
P
(⋂
{(s′j′):GL,j∗=1} {Gs′,j′ = 1}
)
− PS(i)e pi
(1− pi) ,
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where P
(⋂
{(s′j′):GL,j∗=1} {Gs′,j′ = 1}
)
is given by equation (B.1.3) and
PS
(i)
e =
∏L
k=1 Se:k. Notice that the individual pooling specificity is a func-
tion of the individual probabilities, unlike what was found for PS
(i)
e . The
pooling positive and negative predictive values, given in Black et al. (2015),
are then found through applications of Bayes' rule:
PPPV (i) =
piPS
(i)
e
piPS
(i)
e + (1− pi)
(
1− PS(i)p
)
and
PNPV (i) =
(1− pi)PS(i)p
(1− pi)PS(i)p + pi
(
1− PS(i)e
) .
New expressions for PPPV (i) and PNPV (i) (allowing for unequal sensitivity
and unequal specificity across stages of testing) are found by substituting the
derived expressions for PS
(i)
e and PS
(i)
p into the above equations. Overall mea-
sures of pooling sensitivity, pooling specificity, and pooling predictive values
are provided in Appendix A.
B.2. Array testing without master pooling
We closely follow the work of McMahan et al. (2012b) to derive the operating
characteristics for array testing without master pooling. Consider an array
with J > 1 rows and K > 1 columns, and denote the individual assigned
to the (j, k) cell as Ijk, for j = 1, ..., J and k = 1, ..., K. Let Y˜jk denote
the true status of individual Ijk based on the group testing algorithm, so that
pjk = P
(
Y˜jk = 1
)
is the probability of being truly positive. We make the same
assumption as McMahan et al. (2012b) that the true statuses are independent
random variables.
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Define Rj = 1 (0) as the positive (negative) test outcome and R˜j = 1 (0)
as the positive (negative) true status of the jth row for j = 1, ..., J . Likewise,
define Ck as the test outcome and C˜k as the true status of the kth column for
k = 1, ..., K. Note that R˜j = 1 (C˜k = 1) if the jth row (kth column) contains
at least one truly positive individual. Equivalently, R˜j = I
(∑K
k=1 Y˜jk > 0
)
and C˜k = I
(∑J
j=1 Y˜jk > 0
)
, where I(·) represents the indicator function. As
in McMahan et al. (2012b), we assume that diagnostic test outcomes are con-
ditionally independent given the true statuses. We also assume that if a group
contains at least one positive individual, it will test positive with probability
Se (sensitivity) and if a group consists entirely of negative individuals, it will
test negative with probability Sp (specificity). Note that Se and Sp are allowed
to vary across stages of testing (e.g., row/column test, individual test), but we
assume that these accuracy measures do not depend on the size of the group.
Using diagnostic tests with perfect accuracy, Phatarfod and Sudbury (1994)
classified Ijk as negative if Rj = 0 or Ck = 0. Individual retesting for Ijk occurs
when Rj = 1 and Ck = 1. However, diagnostic tests are rarely perfect, so we
need to account for the possibility that one or more row (column) tests are
positive while all column (row) tests are negative (Kim et al., 2007). As a
result of this ambiguity, we use the notation in McMahan et al. (2012b) and
partition all individuals in the algorithm into one of two categories:
M+ =
{
Ijk : I (Rj = 1, Ck = 1) + I
(
Rj = 1,
K∑
k=1
Ck = 0
)
+
I
(
J∑
j=1
Rj = 0, Ck = 1
)
= 1
}
and M_ = M+. Individuals in M+ are classified as positive or negative after
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individual retesting and individuals in M_ are classified as negative without
individual testing.
B.2.1. Expected number of tests
Let T denote the total number of tests required to decode one array. McMahan
et al. (2012b) showed the expected number of tests is
E (T ) = J +K +
J∑
j=1
K∑
k=1
E (Tjk) ,
where Tjk represents the number of tests required to classify Ijk after the
initial stage of testing (i.e., row and column tests). Using the classification
methodology provided by Kim et al. (2007), Tjk can be written as
Tjk =

1, if Rj = 1 and Ck = 1
1, if Rj = 1 and
∑K
k′=1Ck′ = 0
1, if
∑J
j′=1Rj′ = 0 and Ck = 1
0, otherwise.
Then, for the two-dimensional array testing algorithm without master pooling,
E (Tjk) = P (Rj = 1, Ck = 1) +
P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
)
+
P
(
J∑
j′=1
Rj′ = 0, Ck = 1
)
. (B.2.1)
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McMahan et al. (2012b) provided expressions for each of these probabilities.
For the first term in equation (B.2.1),
P (Rj = 1, Ck = 1)
=
{
1− P
(
Rj = 0
∣∣∣ R˜j = 0)}{1− P (Ck = 0 ∣∣∣ C˜k = 0)}×
P
(
R˜j = 0, C˜k = 0
)
+
P
(
Rj = 1
∣∣∣ R˜j = 1){1− P (Ck = 0 ∣∣∣ C˜k = 0)}P (R˜j = 1, C˜k = 0)+{
1− P
(
Rj = 0
∣∣∣ R˜j = 0)}P (Ck = 1 ∣∣∣ C˜k = 1)P (R˜j = 0, C˜k = 1)+
P
(
Rj = 1
∣∣∣ R˜j = 1)P (Ck = 1 ∣∣∣ C˜k = 1)P (R˜j = 1, C˜k = 1) .
When the sensitivity and specificity are unequal across stages of testing, this
becomes
P (Rj = 1, Ck = 1)
= (1− Sp:R) (1− Sp:C)P
(
R˜j = 0, C˜k = 0
)
+
Se:R (1− Sp:C)P
(
R˜j = 1, C˜k = 0
)
+
(1− Sp:R)Se:CP
(
R˜j = 0, C˜k = 1
)
+
Se:RSe:CP
(
R˜j = 1, C˜k = 1
)
, (B.2.2)
where Se:R (Sp:R) and Se:C (Sp:C) represent the sensitivity (specificity) for the
row and column tests, respectively. The jth row and kth column have only
individual, Ijk, in common. Under the assumption that the individual statuses
are independent, R˜j and C˜k are independent, conditional on Y˜jk (McMahan
et al., 2012b). Expressions for the probabilities in equation (B.2.2) consisting
only of R˜j and C˜k do not change from those already given in McMahan et al.
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(2012b). Thus, the first term in equation (B.2.1) can be written as
P (Rj = 1, Ck = 1)
= (1− Sp:R) (1− Sp:C)
{
piR (j) piC (k)
1− pjk
}
+
Se:R (1− Sp:C)
{
piC (k)− piR (j)piC (k)
1− pjk
}
+
(1− Sp:R)Se:C
{
piR (j)− piR (j) piC (k)
1− pjk
}
+
Se:RSe:C
{
1− piR (j)− piC (k) + piR (j)piC (k)
(1− pjk)
}
, (B.2.3)
where piR (j) = P
(
R˜j = 0
)
=
∏K
k′=1 (1− pjk′) and piC (k) = P
(
C˜k = 0
)
=∏J
j′=1 (1− pj′k). The remaining terms in equation (B.2.1) are much more
complicated to derive.
First, we consider the second probability in equation (B.2.1). To find
this probability, we must consider each of the 2K configurations of the true
column statuses; i.e.,
{
C˜1 = c˜1, C˜2 = c˜2, ..., C˜K = c˜K
}
,where c˜k ∈ {0, 1}, for
k = 1, ..., K (McMahan et al., 2012b). By the Law of Total Probability,
P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
)
=
1∑
r˜=0
1∑
c˜1=0
...
1∑
c˜K=0
P
(
Rj = 1,
K⋂
k=1
{Ck = 0}
∣∣∣∣∣ R˜j = r˜,
K⋂
k=1
{
C˜k = c˜k
})
×
P
(
R˜j = r˜,
K⋂
k=1
{
C˜k = c˜k
})
.
Define Bc, for c = 1, ..., K, to be the set of all c-combinations of K0 =
{1, 2, ..., K}, and let B0 = ∅, the empty set. For all B ∈ Bc, c = 0, 1, ..., K,
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define the events
C˜(B) =
K⋂
k=1
{
C˜k = I (k ∈ B)
}
C(B) =
K⋂
k=1
{Ck = I (k ∈ B)} ,
where I(·) is the indicator function. For example, suppose K = 3. We have
K0 = {1, 2, 3}, B0 = ∅, B1 = {{1} , {2} , {3}}, B2 = {{1, 2} , {1, 3} , {2, 3}},
and B3 = {{1, 2, 3}}. The set B = {1, 2} ∈ B2 corresponds to{
C˜1 = 1, C˜2 = 1, C˜3 = 0
}
, the event that columns 1 and 2 are truly positive
and column 3 is truly negative. Using this notation from McMahan et al.
(2012b), the previous probability can be written as
P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
)
=
1∑
r˜=0
K∑
c=0
∑
B∈Bc
P
{
Rj = 1, C(B0)
∣∣∣ R˜j = r˜, C˜(B)}×
P
{
R˜j = r˜, C˜(B)
}
. (B.2.4)
Using the assumptions about test sensitivity and specificity and allowing sen-
sitivity and specificity to differ across stages of testing, for all c ∈ {0, 1, ..., K},
we have
P
{
Rj = 1, C(B0)
∣∣∣ R˜j = 0, C˜(Bc)}
= P
(
Rj = 1
∣∣∣ R˜j = 0)P {C(B0) ∣∣∣ C˜(Bc)}
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=
{
1− P
(
Rj = 0
∣∣∣ R˜j = 0)}×
P
[
K⋂
k=1
{Ck = I (k ∈ B0)}
∣∣∣∣∣
K⋂
k=1
C˜k = I (k ∈ Bc)
]
= (1− Sp:R) (1− Se:C)c (Sp:C)K−c
and
P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 1, C˜ (Bc)}
= P
(
Rj = 1
∣∣∣ R˜j = 1)P {C(B0) ∣∣∣ C˜(Bc)}
= Se:R (1− Se:C)c (Sp:C)K−c .
Substituting back into equation (B.2.4) and changing the order of summation,
we get
P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
)
=
K∑
c=0
∑
B∈Bc
[
P
{
Rj = 1, C(B0)
∣∣∣ R˜j = 0, C˜(B)}P {R˜j = 0, C˜(B)}+
P
{
Rj = 1, C(B0)
∣∣∣ R˜j = 1, C˜(B)}P {R˜j = 1, C˜(B)}]
=
K∑
c=0
∑
B∈Bc
[
(1− Sp:R) (1− Se:C)c (Sp:C)K−c P
{
R˜j = 0, C˜(B)
}
+
Se:R (1− Se:C)c (Sp:C)K−c P
{
R˜j = 1, C˜(B)
}]
. (B.2.5)
Expressions for the probabilities consisting only of R˜j and C˜ (B) do not change
from those already given in McMahan et al. (2012b). The probability expres-
sions in equation (B.2.5) are
P
{
R˜j = 0, C˜(Bc)
}
= piR (j)λC (Bc | K0, j)
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and
P
{
R˜j = 1, C˜(Bc)
}
= λC (Bc | ∅, j)− piR (j)λC (Bc | K0, j) ,
where
λC (Bc | S, j) =
∏
k′∈Bc
{
1− piC (k
′)
(1− pjk′)I(k′∈S)
} ∏
k′∈B¯c
piC (k
′)
(1− pjk′)I(k′∈S)
,
B¯c = K0 \ Bc and products taken over {k′ ∈ ∅} are understood to be equal to
1. Therefore, equation (B.2.5) becomes
P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
)
=
K∑
c=0
∑
B∈Bc
[
(1− Sp:R) (1− Se:C)c (Sp:C)K−c piR (j)λC (B | K0, j)+
Se:R (1− Se:C)c (Sp:C)K−c {λC (B | ∅, j)− piR (j)λC (B | K0, j)}
]
=
K∑
c=0
∑
B∈Bc
{
(1− Se:R − Sp:R) (1− Se:C)c (Sp:C)K−c piR (j)λC (B | K0, j)+
Se:R (1− Se:C)c (Sp:C)K−c λC (B | ∅, j)
}
=
K∑
c=0
∑
B∈Bc
{γ0 (c,K)λC (B | ∅, j) + γ1 (c,K)piR (j)λC (B | K0, j)} , (B.2.6)
where γ0 (c,K) = Se:R (1− Se:C)c (Sp:C)K−c and γ1 (c,K) = (1− Se:R − Sp:R)×
(1− Se:C)c (Sp:C)K−c.
The third probability in equation (B.2.1) is found in a similar manner as
the second probability. Define Ar, for r = 1, 2, ..., J , to be the set of all
r-combinations of J0 = {1, 2, ..., J}, and let A0 = ∅. We define
λR (Ar | S, j) =
∏
j′∈Ar
{
1− piR (j
′)
(1− pj′k)I(j′∈S)
} ∏
j′∈A¯r
piR (j
′)
(1− pj′k)I(j′∈S)
,
where A¯r = J0 \ Ar and products taken over {j′ ∈ ∅} are understood to be
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equal to 1. Then, the third probability in equation (B.2.1) becomes
P
(
J∑
j′=1
Rj′ = 0, Ck = 1
)
=
J∑
r=0
∑
A∈Ar
{γ2 (r, J)λR (A | ∅, k) + γ3 (r, J)λR (A | J0, k) piC (k)} ,
where γ2 (r, J) = Se:C (1− Se:R)r (Sp:R)J−r and γ3 (r, J) = (1− Se:C − Sp:C)×
(1− Se:R)r (Sp:R)J−r. This follows from equation (B.2.6) by treating the rows
as columns and vice versa. This completes the derivation of E (Tjk) in equation
(B.2.1).
B.2.2. Accuracy measures
We now present derivations for the pooling sensitivity and pooling speci-
ficity. Let Se:I (Sp:I) represent the sensitivity (specificity) for individual test-
ing. Let Yjk denote the test outcome for individual Ijk based on individual
testing and let I+jk (I
−
jk) denote the event that individual Ijk is classified as
positive (negative) by the group testing algorithm. Define the pooling sen-
sitivity to be PS
Ijk
e = P
(
I+jk
∣∣∣ Y˜jk = 1) and the pooling specificity to be
PS
Ijk
p = P
(
I−jk
∣∣∣ Y˜jk = 0).
B.2.2.1. Pooling Sensitivity
For array testing without master pooling, individual Ijk is classified as positive
if its corresponding row and/or column tests are positive and the individual
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test is positive. Then, the pooling sensitivity is
PS
Ijk
e = P
(
I+jk
∣∣∣ Y˜jk = 1)
= P
(
Yjk = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 1)+ (B.2.7)
P
(
Yjk = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 1
)
+ (B.2.8)
P
(
Yjk = 1,
J∑
j′=1
Rj′ = 0, Ck = 1
∣∣∣∣∣ Y˜jk = 1
)
. (B.2.9)
If Y˜jk = 1, then R˜j = 1 and C˜k = 1. This fact, together with the conditional
independence assumption, implies that equation (B.2.7) is
P
(
Yjk = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 1)
= P
(
Yjk = 1
∣∣∣ Y˜jk = 1)P (Rj = 1 ∣∣∣ Y˜jk = 1)P (Ck = 1 ∣∣∣ Y˜jk = 1)
= Se:ISe:RSe:C .
Similarly, the probability in equation (B.2.8) can be written as
P
(
Yjk = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 1
)
= Se:ISe:RP
(
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 1
)
.
McMahan et al. (2012b) showed that the probability on the right-hand side of
this expression can be written as
P
(
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 1
)
= (1− Se)
∏
k′ 6=k
P (Ck′ = 0) ,
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where P (Ck′ = 0) = 1− Se − (1− Se − Sp) piC (k′). Allowing the sensitivities
and specificities to differ across stages of testing, we can write
P
(
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 1
)
= (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) ,
where P (Ck′ = 0) = 1 − Se:C − (1− Se:C − Sp:C) piC (k′). Therefore, equation
(B.2.8) can be written as
P
(
Yjk = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 1
)
= Se:ISe:R (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) . (B.2.10)
Finally, equation (B.2.9) can be written as
P
(
Yjk = 1,
J∑
j′=1
Rj′ = 0, Ck = 1
∣∣∣∣∣ Y˜jk = 1
)
= Se:ISe:C (1− Se:R)
∏
j′ 6=j
P (Rj′ = 0) ,
where P (Rj′ = 0) = 1 − Se:R − (1− Se:R − Sp:R) piR (j′). This follows from
equation (B.2.10) by treating the rows as columns and vice versa. Combining
these results, we obtain
PS
Ijk
e = Se:ISe:RSe:C + Se:ISe:R (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) +
Se:ISe:C (1− Se:R)
∏
j′ 6=j
P (Rj′ = 0)
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= Se:I
{
Se:RSe:C + Se:R (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) +
Se:C (1− Se:R)
∏
j′ 6=j
P (Rj′ = 0)
}
.
B.2.2.2. Pooling Specificity
We now turn to the derivation of the pooling specificity, PS
Ijk
p . By definition,
PS
Ijk
p = P
(
I−jk
∣∣∣ Y˜jk = 0)
= 1− P
(
I+jk
∣∣∣ Y˜jk = 0) , (B.2.11)
where
P
(
I+jk
∣∣∣ Y˜jk = 0)
= P
(
Yjk = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)+ (B.2.12)
P
(
Yjk = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
+ (B.2.13)
P
(
Yjk = 1,
J∑
j′=1
Rj′ = 0, Ck = 1
∣∣∣∣∣ Y˜jk = 0
)
. (B.2.14)
Using the conditional independence assumption, McMahan et al. (2012b)
showed that equation (B.2.12) can be written as
P
(
Yjk = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)
= P
(
Yjk = 1
∣∣∣ Y˜jk = 0)P (Rj = 1, Ck = 1 ∣∣∣ Y˜jk = 0)
= (1− Sp:I)P
(
Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0) .
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Using the Law of Total Probability, McMahan et al. (2012b) also showed that
P
(
Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)
=
1∑
r=0
1∑
c=0
{
P
(
R˜j = r, C˜k = c
∣∣∣ Y˜jk = 0)×
P
(
Rj = 1, Ck = 1
∣∣∣ R˜j = r, C˜k = c, Y˜jk = 0)} .
Allowing the sensitivities and specificities to differ across stages of testing, it
can be shown that
P
(
Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)
= (1− Sp:R) (1− Sp:C)P
(
R˜j = 0
∣∣∣ Y˜jk = 0)P (C˜k = 0 ∣∣∣ Y˜jk = 0)+
Se:R (1− Sp:C)P
(
R˜j = 1
∣∣∣ Y˜jk = 0)P (C˜k = 0 ∣∣∣ Y˜jk = 0)+
Se:C (1− Sp:R)P
(
R˜j = 0
∣∣∣ Y˜jk = 0)P (C˜k = 1 ∣∣∣ Y˜jk = 0)+
Se:RSe:CP
(
R˜j = 1
∣∣∣ Y˜jk = 0)P (C˜k = 1 ∣∣∣ Y˜jk = 0) .
Expressions for the probabilities consisting only of R˜j and C˜k conditioned on
Y˜jk do not change from those already given inMcMahan et al. (2012b). After
extensive algebra, equation (B.2.12) becomes
P
(
Yjk = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)
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= (1− Sp:I)
[
(1− Sp:R) (1− Sp:C) piR (j) piC (k)
(1− pjk)2
+
Se:R (1− Sp:C)
{
piC (k)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:C (1− Sp:R)
{
piR (j)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:RSe:C
{
1− piR (j)
1− pjk −
piC (k)
1− pjk +
piR (j) piC (k)
(1− pjk)2
}]
.
Using conditional independence, we can write equation (B.2.13) as
P
(
Yjk = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
= P
(
Yjk = 1
∣∣∣ Y˜jk = 0)P (Rj = 1, K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
= (1− Sp:I)P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
.
Conditioning on the true statuses of the rows and columns, McMahan et al.
(2012b) showed that
P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
=
1∑
r˜=0
K∑
c=0
∑
B∈Bc
P
{
Rj = 1, C (B0)
∣∣∣ R˜j = r˜, C˜ (B) , Y˜jk = 0}×
P
{
R˜j = r˜, C˜ (B)
∣∣∣ Y˜jk = 0} .
Allowing the sensitivities and specificities to differ across stages of testing, it
can be shown that
P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 0, C˜ (Bc) , Y˜jk = 0}
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= (1− Sp:R) (1− Se:C)c (Sp:C)K−c
and
P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 1, C˜ (Bc) , Y˜jk = 0}
= Se:R (1− Se:C)c (Sp:C)K−c .
This allows us to rewrite
P
(
Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
=
K∑
c=0
∑
B∈Bc
[
(1− Sp:R) (1− Se:C)c (Sp:C)K−c P
{
R˜j = 0, C˜ (B)
∣∣∣ Y˜jk = 0}+
Se:R (1− Se:C)c (Sp:C)K−c P
{
R˜j = 1, C˜ (B)
∣∣∣ Y˜jk = 0}] .
Expressions for the probabilities consisting only of R˜j and C˜ (B) conditioned
on Y˜jk do not change from those already given in McMahan et al. (2012b).
Therefore, after extensive algebra, we can write equation (B.2.13) as
P
(
Yjk = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
= (1− Sp:I)
K∑
c=0
∑
B∈Bc
{
γ0 (c,K)λC (B | {k} , j) +
γ1 (c,K)
piR (j)
1− pjkλC (B | K0, j)
}
, (B.2.15)
where γ0 (c,K) and γ1 (c,K) were previously defined in the derivations for
E (Tjk). In a similar manner, equation (B.2.14) can be expressed as
P
(
Yjk = 1,
J∑
j′=1
Rj′ = 0, Ck = 1
∣∣∣∣∣ Y˜jk = 0
)
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= (1− Sp:I)
J∑
r=0
∑
A∈Ar
{
γ2 (r, J)λR (A | {j} , k) +
γ3 (r, J)λR (A | J0, k) piC (k)
1− pjk
}
,
where γ2 (r, J) and γ3 (r, J) were previously defined in the derivations for
E (Tjk). This follows from equation (B.2.15) by treating the rows as columns
and vice versa. Combining the expressions for (B.2.12), (B.2.13), and (B.2.14),
we have
P
(
I+jk
∣∣∣ Y˜jk = 0)
= (1− Sp:I)
[
(1− Sp:R) (1− Sp:C) piR (j) piC (k)
(1− pjk)2
+
Se:R (1− Sp:C)
{
piC (k)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:C (1− Sp:R)
{
piR (j)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:RSe:C
{
1− piR (j)
1− pjk −
piC (k)
1− pjk +
piR (j) piC (k)
(1− pjk)2
}
+
K∑
c=0
∑
B∈Bc
{
γ1 (c,K) piR (j)λC (B | K0, j)
1− pjk +
γ0 (c,K)λC (B | {k} , j)
}
+
J∑
r=0
∑
A∈Ar
{
γ3 (r, J)λR (A | J0, k) piC (k)
1− pjk +
γ2 (r, J)λR (A | {j} , k)
}]
. (B.2.16)
The final expression for PS
Ijk
p follows from equation (B.2.16) substituted into
equation (B.2.11).
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The pooling positive and negative predictive values are defined as
PPPV Ijk = P
(
Y˜jk = 1
∣∣∣ I+jk) and PNPV Ijk = P (Y˜jk = 0 ∣∣∣ I−jk), respec-
tively. Expressions for the pooling predictive values follow directly from
McMahan et al. (2012b, p. 798).
B.3. Array testing with master pooling
We closely follow the work of Kim et al. (2007) to derive the operating char-
acteristics for array testing with master pooling. Their derivations assume
that pi = p for all individuals in the algorithm and that diagnostic accuracy
is the same across stages of testing. We generalize their derivations to allow
for heterogeneous risk probabilities pi, for individuals i = 1, ..., I, and to allow
for unequal sensitivity and unequal specificity values across stages of testing.
For consistency in the group testing literature, we adhere to the notation in
McMahan et al. (2012b) whenever possible.
Consider an array with J > 1 rows and K > 1 columns, and denote the
individual assigned to the (j, k) cell as Ijk, for j = 1, ..., J and k = 1, ..., K. In
array testing with master pooling, we first test a master group of size J×K be-
fore testing rows and columns, and finally proceed to individual testing. Recall
that Yjk, Rj, and Ck denote the test outcome of the individual test, row test,
and column test corresponding to individual Ijk, respectively. Similarly, Y˜jk,
R˜j, and C˜k denote the true status of individual Ijk, the jth row, and the kth
column. We again make the assumption that test outcomes are conditionally
independent given the true statuses. Also recall that Se:R (Sp:R), Se:C (Sp:C),
and Se:I (Sp:I) represent the sensitivity (specificity) for row, column, and indi-
vidual testing, respectively.
160
B.3.1. Expected number of tests
Let the number of tests required to decode the full array be T = T0 + T1 + T2,
where T0 = 1 corresponds to testing the master group, T1 corresponds to
possible row and column testing, and T2 corresponds to possible individual
testing. Let X0 be a random variable that equals 1 if the master group tests
positive and 0 otherwise, such that T1 = JKX0 and E (T1) = JK×P (X0 = 1).
Define X˜0 as the true status of the master group. Let Se:M (Sp:M) represent the
sensitivity (specificity) for the master group. The probability that the master
group tests positive can be written as
P (X0 = 1) = P
(
X0 = 1, X˜0 = 0
)
+ P
(
X0 = 1, X˜0 = 1
)
= P
(
X0 = 1
∣∣∣ X˜0 = 0)P (X˜0 = 0)+
P
(
X0 = 1
∣∣∣ X˜0 = 1)P (X˜0 = 1)
= (1− Sp:M)
∏
j,k
(1− pjk) + Se:M
{
1−
∏
j,k
(1− pjk)
}
.
Thus, the expected number of tests corresponding to possible row and column
testing is
E (T1) = JK
[
(1− Sp:M)
∏
j,k
(1− pjk) + Se:M
{
1−
∏
j,k
(1− pjk)
}]
.
This leads to an expression for the expected number of tests for the whole
array,
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E(T ) = 1 + (J +K)
[
(1− Sp:M)
∏
j,k
(1− pjk) +
Se:M
{
1−
∏
j,k
(1− pjk)
}]
+
∑
j,k
E(T2jk),
where T2jk represents the number of tests required to classify Ijk after the
initial stage of testing (i.e., master group test) and the second stage of testing
(i.e., row and column tests). Using the classification methodology provided by
Kim et al. (2007), T2jk can be written as
T2jk =

1 if X0 = 1, Rj = 1 and Ck = 1
1 if X0 = 1, Rj = 1 and
∑
Ck = 0
1 if X0 = 1,
∑
Rj = 0 and Ck = 1
0 otherwise.
Then, for the two-dimensional array testing algorithm with master pooling,
E(T2jk) = P (X0 = 1, Rj = 1, Ck = 1) +
P
(
X0 = 1, Rj = 1,
∑
k
Ck = 0
)
+
P
(
X0 = 1,
∑
j
Rj = 0, Ck = 1
)
. (B.3.1)
The first probability in equation (B.3.1) can be written as
P (X0 = 1, Rj = 1, Ck = 1)
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= P
(
X0 = 1, Rj = 1, Ck = 1, X˜0 = 0, R˜j = 0, C˜k = 0
)
+
P
(
X0 = 1, Rj = 1, Ck = 1, X˜0 = 1, R˜j = 0, C˜k = 0
)
+
P
(
X0 = 1, Rj = 1, Ck = 1, X˜0 = 1, R˜j = 1, C˜k = 0
)
+
P
(
X0 = 1, Rj = 1, Ck = 1, X˜0 = 1, R˜j = 0, C˜k = 1
)
+
P
(
X0 = 1, Rj = 1, Ck = 1, X˜0 = 1, R˜j = 1, C˜k = 1
)
= P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 0, R˜j = 0, C˜k = 0)×
P
(
X˜0 = 0, R˜j = 0, C˜k = 0
)
+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 0, C˜k = 0)×
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 1, C˜k = 0)×
P
(
X˜0 = 1, R˜j = 1, C˜k = 0
)
+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 0, C˜k = 1)×
P
(
X˜0 = 1, R˜j = 0, C˜k = 1
)
+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 1, C˜k = 1)×
P
(
X˜0 = 1, R˜j = 1, C˜k = 1
)
Using the conditional independence assumption, we can write
P (X0 = 1, Rj = 1, Ck = 1)
= (1− Sp:M) (1− Sp:R) (1− Sp:C)×
P
(
X˜0 = 0, R˜j = 0, C˜k = 0
)
+ (B.3.2)
Se:M (1− Sp:R) (1− Sp:C)P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
+ (B.3.3)
Se:MSe:R (1− Sp:C)P
(
X˜0 = 1, R˜j = 1, C˜k = 0
)
+ (B.3.4)
Se:M (1− Sp:R)Se:CP
(
X˜0 = 1, R˜j = 0, C˜k = 1
)
+ (B.3.5)
Se:MSe:RSe:CP
(
X˜0 = 1, R˜j = 1, C˜k = 1
)
(B.3.6)
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The jth row and kth column have only individual Ijk in common. Under
the assumption that the individual statuses are independent, R˜j and C˜k are
also independent, conditional on Y˜jk. Recall that if any row or column tests
positive, X˜0 = 1. Then, we can write
P
(
X˜0 = 1, R˜j = 1, C˜k = 1
)
= P
(
R˜j = 1, C˜k = 1
)
,
P
(
X˜0 = 1, R˜j = 0, C˜k = 1
)
= P
(
R˜j = 0, C˜k = 1
)
,
and
P
(
X˜0 = 1, R˜j = 1, C˜k = 0
)
= P
(
R˜j = 1, C˜k = 0
)
.
Each of these three probabilities were derived in McMahan et al. (2012b, p.
2 in the web appendix). Next, we'll consider the probability expression in
equation (B.3.3). In order to have X˜0 = 1, at least one individual in the array
must be truly positive. In this probability expression, we have the added
requirement that the truly positive individual(s) is not located in the jth row
or the kth column. Then, we can write equation (B.3.3) as
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
= P
(
X˜0 = 1
)
−
{
P
(
R˜j = 1, C˜k = 0
)
+
P
(
R˜j = 0, C˜k = 1
)
+ P
(
R˜j = 1, C˜k = 1
)}
=
{
1− P
(
X˜0 = 0
)}
− P
(
R˜j = 1, C˜k = 0
)
−
P
(
R˜j = 0, C˜k = 1
)
− P
(
R˜j = 1, C˜k = 1
)
.
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Define piM = P
(
X˜0 = 0
)
=
∏J
j′=1
∏K
k′=1 (1− pj′k′). Then, using substitution
and some algebraic manipulation, we can write
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
=
piR (j) piC (k)
1− pjk − piM .
Note that X˜0 = 0 if all individuals in the array are truly negative and, hence,
all rows and columns are truly negative. Then, the probability expression in
equation (B.3.2) is
P
(
X˜0 = 0, R˜j = 0, C˜k = 0
)
= P
(
X˜0 = 0
)
= piM .
Combining these five probability expressions, we get
P (X0 = 1, Rj = 1, Ck = 1)
= (1− Sp:M) (1− Sp:R) (1− Sp:C) piM +
Se:M (1− Sp:R) (1− Sp:C)
{
piR (j) piC (k)
1− pjk − piM
}
+
Se:MSe:R (1− Sp:C)
{
piC (k)− piR (j)piC (k)
1− pjk
}
+
Se:M (1− Sp:R)Se:C
{
piR (j)− piR (j) piC (k)
1− pjk
}
+
Se:MSe:RSe:C
{
1− piR (j)− piC (k) + piR (j)piC (k)
1− pjk
}
.
Next, we consider the second probability in equation (B.3.1). To find this
probability, recall that the master group must test positive (X0 = 1) in order
for row/column testing to occur. Using the Law of Total Probability and the
notation presented in Section B.2, we can write
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
)
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=
1∑
r˜=0
1∑
c˜1=0
...
1∑
c˜K=0
{
P
(
Rj = 1,
K⋂
k=1
{Ck = 0}
∣∣∣∣∣ X0 = 1, R˜j = r˜,
K⋂
k=1
{
C˜k = c˜k
})
×
P
(
X0 = 1
∣∣∣∣∣ R˜j = r˜,
K⋂
k=1
{
C˜k = c˜k
})
P
(
R˜j = r˜,
K⋂
k=1
{
C˜k = c˜k
})}
.
Using the definitions of C˜ (B) and C (B) in Section B.2, this probability can
be written as
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
)
=
1∑
r˜=0
K∑
c=0
∑
B∈Bc
[
P
{
Rj = 1, C (B0)
∣∣∣ X0 = 1, R˜j = r˜, C˜ (B)}×
P
{
X0 = 1
∣∣∣ R˜j = r˜, C˜ (B)}P {R˜j = r˜, C˜ (B)}] . (B.3.7)
Since a master group must test positive for a row to be tested, we have
P
{
Rj = 1, C (B0)
∣∣∣ X0 = 1, R˜j = 0, C˜ (Bc)}
= P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 0, C˜ (Bc)}
and
P
{
Rj = 1, C (B0)
∣∣∣ X0 = 1, R˜j = 1, C˜ (Bc)}
= P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 1, C˜ (Bc)} .
Derivations for both of these resulting probability expressions were shown in
Section B.2.1. Note that P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 1, C˜ (B0)} = 0 because we
cannot have a truly positive row when all columns are truly negative.
From Section B.2, we recall that
P
{
R˜j = 0, C˜ (Bc)
}
= piR (j)λC (Bc | K0, j)
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and
P
{
R˜j = 1, C˜ (Bc)
}
= λC (Bc | ∅, j)− piR (j)λC (Bc | K0, j) . (B.3.8)
Now, we consider the middle probability expression in equation (B.3.7). We
have two cases:
1. When c = 0,
P
{
X0 = 1
∣∣∣ R˜j = 0, C˜ (B0)} = P (X0 = 1 ∣∣∣ X˜0 = 0)
= 1− P
(
X0 = 0
∣∣∣ X˜0 = 0)
= 1− Sp:M
and
P
{
X0 = 1
∣∣∣ R˜j = 1, C˜ (B0)} = 0.
2. When c = 1, ..., K (i.e., at least one column in the array is truly positive),
we see that
P
{
X0 = 1
∣∣∣ R˜j = 0, C˜ (Bc)} = P (X0 = 1 ∣∣∣ X˜0 = 1) = Se:M
and
P
{
X0 = 1
∣∣∣ R˜j = 1, C˜ (Bc)} = P (X0 = 1 ∣∣∣ X˜0 = 1) = Se:M .
Substituting back into equation (B.3.7), we get
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
)
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=
K∑
c=0
∑
B∈Bc
[
(1− Sp:R) (1− Se:C)c (Sp:C)K−c×
P
{
X0 = 1
∣∣∣ R˜j = 0, C˜ (B)}piR (j)λC (B | K0, j) +
Se:R (1− Se:C)c (Sp:C)K−c P
{
X0 = 1
∣∣∣ R˜j = 1, C˜ (B)}×
{λC (B | ∅, j)− piR (j)λC (B | K0, j)}
]
.
After extensive algebra, we can write the second probability in equation (B.3.1)
as
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
)
= (1− Sp:M − Se:M) (1− Sp:R) (Sp:C)K piR (j)λC (B0 | K0, j) +
Se:M
K∑
c=0
∑
B∈Bc
{γ0 (c,K)λC (B | ∅, j) +
γ1 (c,K) piR (j)λC (B | K0, j)} , (B.3.9)
where γ0 (c,K) and γ1 (c,K) are as defined in Section B.2.
In a similar manner, the third probability in equation (B.3.1) can be ex-
pressed as
P
(
X0 = 1,
J∑
j′=1
Rj′ = 0, Ck = 1
)
= Se:M
J∑
r=0
∑
A∈Ar
{γ2 (r, J)λR (A | ∅, k) +
γ3 (r, J)piC (k)λR (A | J0, k)} ,
where γ2 (r, J) and γ3 (r, J) are as defined in Section B.2. This follows from
equation (B.3.9) by treating the rows as columns and vice versa. This com-
pletes the derivation of E (T2jk) in equation (B.3.1).
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B.3.2. Accuracy measures
Recall from Section B.2 that I+jk
(
I−jk
)
denotes the event that individual Ijk is
classified as positive (negative) by the group testing algorithm.
B.3.2.1. Pooling sensitivity
For array testing with master pooling, individual Ijk is classified as positive if
the master group test is positive, the corresponding row and/or column tests
are positive, and the individual test is positive. Then, the pooling sensitivity
is
PS
Ijk
e = P
(
I+jk
∣∣∣ Y˜jk = 1)
= P
(
X0 = 1, Rj = 1, Ck = 1, Yjk = 1
∣∣∣ Y˜jk = 1)+ (B.3.10)
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck = 0, Yjk = 1
∣∣∣∣∣ Y˜jk = 1
)
+ (B.3.11)
P
X0 = 1, J∑
j′=1
Rj = 0, Ck = 1, Yjk = 1
∣∣∣∣∣∣ Y˜jk = 1
 . (B.3.12)
If Y˜jk = 1, then R˜j = 1, C˜k = 1, and X˜0 = 1. This fact, together with the
conditional independence assumption, implies that equation (B.3.10) is
P
(
X0 = 1, Rj = 1, Ck = 1, Yjk = 1
∣∣∣ Y˜jk = 1)
= P
(
X0 = 1
∣∣∣ Y˜jk = 1)P (Rj = 1 ∣∣∣ Y˜jk = 1)×
P
(
Ck = 1
∣∣∣ Y˜jk = 1)P (Yjk = 1 ∣∣∣ Y˜jk = 1)
= Se:MSe:RSe:CSe:I .
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Similarly, equation (B.3.11) can be written as
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck = 0, Yjk = 1
∣∣∣∣∣ Y˜jk = 1
)
= P
(
X0 = 1
∣∣∣ Y˜jk = 1)P (Rj = 1 ∣∣∣ Y˜jk = 1)×
P
(
K∑
k′=1
Ck = 0
∣∣∣∣∣ Y˜jk = 1
)
P
(
Yjk = 1
∣∣∣ Y˜jk = 1)
= Se:MSe:RSe:IP
(
K∑
k′=1
Ck = 0
∣∣∣∣∣ C˜k = 1
)
.
Because Ck is independent of Ck′ for all k 6= k′, we can write
P
(
K∑
k′=1
Ck = 0
∣∣∣∣∣ C˜k = 1
)
= P
(
K⋂
k=1
{Ck = 0}
∣∣∣∣∣ C˜k = 1
)
= P
(
Ck = 0
∣∣∣ C˜k = 1)P (⋂
k′ 6=k
{Ck = 0}
)
= (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) ,
where P (Ck′ = 0) was derived in Section B.2 to allow for unequal sensitivities
and unequal specificities across stages of testing. Therefore, equation (B.3.11)
can be written as
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck = 0, Yjk = 1
∣∣∣∣∣ Y˜jk = 1
)
= Se:MSe:RSe:I (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) . (B.3.13)
Finally, equation (B.3.12) can be written as
P
(
X0 = 1,
J∑
j′=1
Rj = 0, Ck = 1, Yjk = 1
∣∣∣∣∣ Y˜jk = 1
)
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= Se:MSe:CSe:I (1− Se:R)
∏
j′ 6=j
P (Rj′ = 0) .
This follows from equation (B.3.13) by treating the rows as columns and vice
versa. Combining these results, we obtain
PS
Ijk
e = Se:MSe:RSe:CSe:I + Se:MSe:RSe:I (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) +
Se:MSe:CSe:I (1− Se:R)
∏
j′ 6=j
P (Rj′ = 0)
= Se:MSe:I
{
Se:RSe:C + Se:R (1− Se:C)
∏
k′ 6=k
P (Ck′ = 0) +
Se:C (1− Se:R)
∏
j′ 6=j
P (Rj′ = 0)
}
.
B.3.2.2. Pooling specificity
We now turn to the derivation of the pooling specificity, PS
Ijk
p . By definition,
PS
Ijk
p = P
(
I−jk
∣∣∣ Y˜jk = 0)
= 1− P
(
I+jk
∣∣∣ Y˜jk = 0) ,
where
P
(
I+jk
∣∣∣ Y˜jk = 0)
= P
(
X0 = 1, Rj = 1, Ck = 1, Yjk = 1
∣∣∣ Y˜jk = 0)+ (B.3.14)
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck = 0, Yjk = 1
∣∣∣∣∣ Y˜jk = 0
)
+ (B.3.15)
P
(
X0 = 1,
J∑
j′=1
Rj = 0, Ck = 1, Yjk = 1
∣∣∣∣∣ Y˜jk = 0
)
. (B.3.16)
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Using the conditional independence assumption, equation (B.3.14) can be writ-
ten as
P
(
X0 = 1, Rj = 1, Ck = 1, Yjk = 1
∣∣∣ Y˜jk = 0)
= P
(
Yjk = 1
∣∣∣ Y˜jk = 0)P (X0 = 1, Rj = 1, Ck = 1 ∣∣∣ Y˜jk = 0)
= (1− Sp:I)P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0) . (B.3.17)
Using the Law of Total Probability, the probability expression on the right-
hand side of equation (B.3.17) can be written as
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)
= P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 0, R˜j = 0, C˜k = 0, Y˜jk = 0)×
P
(
X˜0 = 0, R˜j = 0, C˜k = 0
∣∣∣ Y˜jk = 0)+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 0, C˜k = 0, Y˜jk = 0)×
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
∣∣∣ Y˜jk = 0)+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 1, C˜k = 0, Y˜jk = 0)×
P
(
X˜0 = 1, R˜j = 1, C˜k = 0
∣∣∣ Y˜jk = 0)+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 0, C˜k = 1, Y˜jk = 0)×
P
(
X˜0 = 1, R˜j = 0, C˜k = 1
∣∣∣ Y˜jk = 0)+
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ X˜0 = 1, R˜j = 1, C˜k = 1, Y˜jk = 0)×
P
(
X˜0 = 1, R˜j = 1, C˜k = 1
∣∣∣ Y˜jk = 0) .
Recall that X˜0 = 0 if all individuals in the array are truly negative and, hence,
all rows and columns are truly negative. Additionally, X˜0 = 1 if at least one
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row or at least one column is truly positive. Then, we have
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)
= P
(
X0 = 1
∣∣∣ X˜0 = 0)P (Rj = 1 ∣∣∣ R˜j = 0)×
P
(
Ck = 1
∣∣∣ C˜k = 0)P (X˜0 = 0 ∣∣∣ Y˜jk = 0)+
P
(
X0 = 1
∣∣∣ X˜0 = 1)P (Rj = 1 ∣∣∣ R˜j = 0)P (Ck = 1 ∣∣∣ C˜k = 0)×
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
∣∣∣ Y˜jk = 0)+
P
(
X0 = 1
∣∣∣ X˜0 = 1)P (Rj = 1 ∣∣∣ R˜j = 1)P (Ck = 1 ∣∣∣ C˜k = 0)×
P
(
R˜j = 1
∣∣∣ Y˜jk = 0)P (C˜k = 0 ∣∣∣ Y˜jk = 0)+
P
(
X0 = 1
∣∣∣ X˜0 = 1)P (Rj = 1 ∣∣∣ R˜j = 0)P (Ck = 1 ∣∣∣ C˜k = 1)×
P
(
R˜j = 0
∣∣∣ Y˜jk = 0)P (C˜k = 1 ∣∣∣ Y˜jk = 0)+
P
(
X0 = 1
∣∣∣ X˜0 = 1)P (Rj = 1 ∣∣∣ R˜j = 1)P (Ck = 1 ∣∣∣ C˜k = 1)×
P
(
R˜j = 1
∣∣∣ Y˜jk = 0)P (C˜k = 1 ∣∣∣ Y˜jk = 0)
= (1− Sp:M) (1− Sp:R) (1− Sp:C)P
(
X˜0 = 0
∣∣∣ Y˜jk = 0)+
Se:M (1− Sp:R) (1− Sp:C)P
(
X˜0 = 1, R˜j = 0, C˜k = 0
∣∣∣ Y˜jk = 0)+
Se:MSe:R (1− Sp:C)
{
1− P
(
R˜j = 0
∣∣∣ Y˜jk = 0)}×
P
(
C˜k = 0
∣∣∣ Y˜jk = 0)+
Se:M (1− Sp:R)Se:CP
(
R˜j = 0
∣∣∣ Y˜jk = 0)×{
1− P
(
C˜k = 0
∣∣∣ Y˜jk = 0)}+
Se:MSe:RSe:C
{
1− P
(
R˜j = 0
∣∣∣ Y˜jk = 0)}×{
1− P
(
C˜k = 0
∣∣∣ Y˜jk = 0)} . (B.3.18)
Expressions for P
(
R˜j = 0
∣∣∣ Y˜jk = 0) and P (C˜k = 0 ∣∣∣ Y˜jk = 0) were pre-
sented by McMahan et al. (2012b) and utilized in derivations presented in
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Section B.2. Recall that piM = P
(
X˜0 = 0
)
=
∏
j′,k′ (1− pj′k′). Then, we have
P
(
X˜0 = 0
∣∣∣ Y˜jk = 0) = P
(
X˜0 = 0, Y˜jk = 0
)
P
(
Y˜jk = 0
) = P
(
X˜0 = 0
)
P
(
Y˜jk = 0
) = piM
1− pjk .
For the remaining probability expression in equation (B.3.18), Bayes' theorem
allows us to write
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
∣∣∣ Y˜jk = 0)
=
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
P
(
Y˜jk = 0
∣∣∣ X˜0 = 1, R˜j = 0, C˜k = 0)
P
(
Y˜jk = 0
)
=
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
P
(
Y˜jk = 0
) .
From Section B.2, we have
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
=
piR (j) piC (k)
1− pjk − piM .
Thus, we can write
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
∣∣∣ Y˜jk = 0)
=
P
(
X˜0 = 1, R˜j = 0, C˜k = 0
)
P
(
Y˜jk = 0
)
=
1
1− pjk
{
piR (j) piC (k)
1− pjk − piM
}
=
piR (j) piC (k)
(1− pjk)2
− piM
1− pjk .
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Substituting back into the probability expression on the right-hand side of
equation (B.3.17), we get
P
(
X0 = 1, Rj = 1, Ck = 1
∣∣∣ Y˜jk = 0)
= (1− Sp:M) (1− Sp:R) (1− Sp:C) piM
1− pjk +
Se:M (1− Sp:R) (1− Sp:C)
{
piR (j) piC (k)
(1− pjk)2
− piM
1− pjk
}
+
Se:MSe:R (1− Sp:C)
{
piC (k)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:M (1− Sp:R)Se:C
{
piR (j)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:MSe:RSe:C
{
1− piR (j)
1− pjk −
piC (k)
1− pjk +
piR (j)piC (k)
(1− pjk)2
}
.
Thus, equation (B.3.14) can be written as
P
(
X0 = 1, Rj = 1, Ck = 1, Yjk = 1
∣∣∣ Y˜jk = 0)
= (1− Sp:I)
[
(1− Sp:M) (1− Sp:R) (1− Sp:C) piM
1− pjk+
Se:M (1− Sp:R) (1− Sp:C)
{
piR (j) piC (k)
(1− pjk)2
− piM
1− pjk
}
+
Se:MSe:R (1− Sp:C)
{
piC (k)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:M (1− Sp:R)Se:C
{
piR (j)
1− pjk −
piR (j) piC (k)
(1− pjk)2
}
+
Se:MSe:RSe:C
{
1− piR (j)
1− pjk −
piC (k)
1− pjk +
piR (j) piC (k)
(1− pjk)2
}]
.
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Using conditional independence, we can write equation (B.3.15) as
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0, Yjk = 1
∣∣∣∣∣ Y˜jk = 0
)
= P
(
Yjk = 1
∣∣∣ Y˜jk = 0)P (X0 = 1, Rj = 1, K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
= (1− Sp:I)P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
.
Conditioning on the true statuses of the rows and columns, the probability
expression on the right-hand side becomes
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
=
1∑
r˜=0
K∑
c=0
∑
B∈Bc
P
{
Rj = 1, C (B0)
∣∣∣ X0 = 1, R˜j = r˜, C˜ (B) , Y˜jk = 0}×
P
(
X0 = 1
∣∣∣ R˜j = r˜, C˜ (B) , Y˜jk = 0)×
P
(
R˜j = r˜, C˜ (B)
∣∣∣ Y˜jk = 0) . (B.3.19)
Note that
P
{
Rj = 1, C (B0)
∣∣∣ X0 = 1, R˜j = 0, C˜ (Bc) , Y˜jk = 0}
= P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 0, C˜ (Bc) , Y˜jk = 0}
and
P
{
Rj = 1, C (B0)
∣∣∣ X0 = 1, R˜j = 1, C˜ (Bc) , Y˜jk = 0}
= P
{
Rj = 1, C (B0)
∣∣∣ R˜j = 1, C˜ (Bc) , Y˜jk = 0} .
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Expressions for both of these probabilities were provided in Section B.2. Ex-
pressions for the probabilities consisting only of R˜j and C˜ (B) conditioned on
Y˜jk are the same as those given by McMahan et al. (2012b). Now, we con-
sider the middle probability expression in equation (B.3.19). We have two
different cases:
1. When c = 0, we have
P
{
X0 = 1
∣∣∣ R˜j = 0, C˜ (B0) , Y˜jk = 0} = P (X0 = 1 ∣∣∣ X˜0 = 0)
= 1− Sp:M
and
P
{
X0 = 1
∣∣∣ R˜j = 1, C˜ (B0) , Y˜jk = 0} = 0.
2. When c = 1, ..., K (i.e., at least one column in the array is truly positive),
we see that
P
(
X0 = 1
∣∣∣ R˜j = 0, C˜ (Bc) , Y˜jk = 0) = P (X0 = 1 ∣∣∣ X˜0 = 1)
= Se:M
and
P
(
X0 = 1
∣∣∣ R˜j = 1, C˜ (Bc) , Y˜jk = 0) = P (X0 = 1 ∣∣∣ X˜0 = 1)
= Se:M .
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Substituting back into equation (B.3.19) and performing a significant amount
of algebraic manipulation gives us
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0
∣∣∣∣∣ Y˜jk = 0
)
= (1− Sp:M) (1− Sp:R) (Sp:C)K piR (j)
1− pjkλC (B0 | K0, j) +
Se:M
K∑
c=1
∑
B∈Bc
{
γ0 (c,K)λC (B | {k} , j) +
γ1 (c,K)
piR (j)
1− pjkλC (B | K0, j)
}
,
where γ0 (c,K) and γ1 (c,K) are as defined previously. Then, the expression
for equation (B.3.15) is
P
(
X0 = 1, Rj = 1,
K∑
k′=1
Ck′ = 0, Yjk = 1
∣∣∣∣∣ Y˜jk = 0
)
= (1− Sp:I)
[
(1− Sp:M) (1− Sp:R) (Sp:C)K piR (j)
1− pjkλC (B0 | K0, j) +
Se:M
K∑
c=1
∑
B∈Bc
{
γ0 (c,K)λC (B | {k} , j) +
γ1 (c,K)
piR (j)
1− pjkλC (B | K0, j)
}]
. (B.3.20)
In a similar manner, equation (B.3.16) can be written as
P
(
X0 = 1,
J∑
j′=1
Rj′ = 0, Ck = 1, Yjk = 1
∣∣∣∣∣ Y˜jk = 0
)
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= (1− Sp:I)
[
(1− Sp:M) (Sp:R)J (1− Sp:C)λR (A0 | J0, k) piC (k)
1− pjk+
Se:M
J∑
r=1
∑
A∈Ar
{
γ2 (r, J)λR (A | {j} , k) +
γ3 (r, J)λR (A | J0, k) piC (k)
1− pjk
}]
,
where γ2 (r, J) and γ3 (r, J) are as previously defined. This follows from equa-
tion (B.3.20) by treating the rows as columns and vice versa. This concludes
the derivations for PS
Ijk
p .
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Appendix C
R function documentation
This appendix contains important parts of the documentation for the
binGroup2 package. Included are 1) the help page for the package as a
whole, 2) the index of available functions, and 3) the help documents for
the opChar1(), opChar2(), OTC1(), and OTC2() functions.
binGroup2 {binGroup2} R Documentation 
binGroup2: Identification and Estimation 
using Group Testing 
Description 
Methods for the group testing identification and estimation problems. 
Details 
Methods for identification of positive items in group testing designs: Operating characteristics (e.g., 
expected number of tests) are calculated for commonly used hierarchical and array-based algorithms. 
Optimal testing configurations for an algorithm can be found as well. Please see Hitt et al. (2019) for 
specific details. 
Methods for estimation and inference for proportions in group testing designs: For estimating one 
proportion or the difference of proportions, confidence interval methods are included that account for 
different pool sizes. Functions for hypothesis testing of proportions, calculation of power, and calculation 
of the expected width of confidence intervals are also included. Furthermore, regression methods and 
simulation of group testing data are implemented for simple pooling, halving, and array testing designs. 
The binGroup2 package is based upon the binGroup package that was originally designed for the 
group testing estimation problem. Over time, additional functions for estimation and for the group testing 
identification problem were included. Due to the diverse styles resulting from these additions, we have 
created binGroup2 as a way to unify functions in a coherent structure and incorporate additional 
functions for identification. The name “binGroup” originates from the assumption in basic estimation for 
group testing that the number of positive groups has a binomial distribution. While more advanced 
estimation methods no longer make this assumption, we continue with the binGroup name for 
consistency. 
Bilder (2019a,b) provide introductions to group testing. These papers and additional details about group 
testing are available at http://chrisbilder.com/grouptesting. 
This research was supported by the National Institutes of Health under grant R01 AI121351. 
Identification 
The binGroup2 package focuses on the group testing identification problem using hierarchical and array-
based group testing algorithms. 
The OTC1 function implements a number of group testing algorithms, described in Hitt et al. (2019), 
which calculate the operating characteristics and find the optimal testing configuration over a range of 
possible initial group sizes and/or testing configurations (sets of subsequent group sizes). 
The OTC2 function does the same with a multiplex assay that tests for two diseases. 
The operatingCharacteristics1 (opChar1) and operatingCharacteristics2(opChar2) functions 
calculate operating characteristics for a specified testing configuration with assays that test for one and 
two diseases, respectively. 
These functions allow the sensitivity and specificity to differ across stages of testing. This means that the 
accuracy of the diagnostic test can differ for stages in a hierarchical testing algorithm or between 
row/column testing and individual testing in an array testing algorithm. 
Estimation 
The binGroup2 package also provides functions for estimation and inference for proportions in group 
testing designs. 
The propCI function calculates the point estimate and confidence intervals for a single proportion from 
group testing data. The propDiffCI function does the same for the difference of proportions. A number of 
confidence interval methods are available for groups of equal or different sizes. 
The gtWidth function calculates the expected width of confidence intervals in group testing. 
The gtTest function calculates p-values for hypothesis tests of single proportions. ThegtPower function 
calculates power to reject a hypothesis. 
The designPower function iterates either the number of groups or group size in a one-parameter group 
testing design until a pre-specified power level is achieved. The designEstfunction finds the optimal 
group size corresponding to the minimal mean-squared error of the point estimator. 
The gtReg function implements regression methods and the gtSim function simulates group testing data 
for simple pooling, halving, and array testing designs. 
Author(s) 
Maintainer: Brianna Hitt brianna.hitt@huskers.unl.edu (ORCID) 
Authors: 
 Christopher Bilder (ORCID) 
 Frank Schaarschmidt (ORCID) 
 Brad Biggerstaff (ORCID) 
 Christopher McMahan (ORCID) 
 Joshua Tebbs (ORCID) 
Other contributors: 
 Boan Zhang [contributor] 
 Michael Black [contributor] 
 Peijie Hou [contributor] 
 Peng Chen [contributor] 
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Examples 
# Estimated running time for all examples was calculated  
#   using a computer with 16 GB of RAM and one core of  
#   an Intel i7-6500U processor. Please take this into  
#   account when interpreting the run times given. 
 
# 1) Identification using hierarchical and array-based group testing  
#   algorithms with an assay that tests for one disease. 
 
# 1.1) Find the optimal testing configuration over a range of initial  
#   group sizes, using informative three-stage hierarchical testing, where  
#   p denotes the overall prevalence of disease; 
#   Se denotes the sensitivity of the diagnostic test;  
#   Sp denotes the specificity of the diagnostic test; 
#   group.sz denotes the range of initial pool sizes for consideration; and 
#   obj.fn specifies the objective functions for which to find results. 
 
# This example takes approximately 25 seconds to run. 
 
set.seed(1002) 
results1 <- OTC1(algorithm="ID3", p=0.01, Se=0.95, Sp=0.95,  
                 group.sz=3:30, obj.fn=c("ET", "MAR"), alpha=2) 
summary(results1) 
 
# 1.2) Find the optimal testing configuration using non-informative 
# array testing without master pooling. 
# The sensitivity and specificity differ for row/column testing and  
#   individual testing. 
 
# This example takes approximately 15 seconds to run. 
 
results2 <- OTC1(algorithm="A2", p=0.05, Se=c(0.95, 0.99),  
                 Sp=c(0.95, 0.98), group.sz=3:20, obj.fn=c("ET", "MAR")) 
summary(results2) 
 
# 1.3) Calculate the operating characteristics using informative 
#   two-stage hierarchical (Dorfman) testing, implemented via the  
#   pool-specific optimal Dorfman (PSOD) method described in  
#   McMahan et al. (2012a). 
# Hierarchical testing configurations are specified by a matrix  
#   in the hier.config argument. The rows of the matrix correspond  
#   to the stages of the hierarchical testing algorithm, the columns  
#   correspond to the individuals to be tested, and the cell values  
#   correspond to the group number of each individual at each stage. 
config.mat <- matrix(data=c(rep(1, 5), rep(2, 4), 3, 1:10),  
                     nrow=2, ncol=10, byrow=TRUE) 
set.seed(8791) 
results3 <- opChar1(algorithm="ID2", p=0.02, Se=0.95, Sp=0.99,  
                    hier.config=config.mat, alpha=0.5) 
summary(results3) 
 
# 1.4) Calculate the operating characteristics using non-informative 
#   four-stage hierarchical testing.  
config.mat <- matrix(data=c(rep(1, 15), rep(c(1, 2, 3), each=5),  
                            rep(1, 3), rep(2, 2), rep(3, 3), rep(4, 2),  
                            rep(5, 4), 6, 1:15),  
                     nrow=4, ncol=15, byrow=TRUE) 
results4 <- opChar1(algorithm="D4", p=0.008, Se=0.96, Sp=0.98,  
                    hier.config=config.mat, a=c(1, 4, 6, 9, 11, 15)) 
summary(results4) 
 
 
# 2) Identification using hierarchical and array-based group testing  
#   algorithms with a multiplex assay that tests for two diseases. 
 
# 2.1) Find the optimal testing configuration using non-informative  
#   two-stage hierarchical testing, given 
#   p.vec, a vector of overall joint probabilities of disease;  
#   Se, a vector of sensitivity values for each disease; and  
#   Sp, a vector of specificity values for each disease.  
# Se and Sp can also be specified as a matrix, where one value  
#   is specified for each disease at each stage of testing. 
results5 <- OTC2(algorithm="D2", p.vec=c(0.90, 0.04, 0.04, 0.02),  
                 Se=c(0.99, 0.99), Sp=c(0.99, 0.99), group.sz=3:50) 
summary(results5) 
 
# 2.2) Calculate the operating characteristics for informative 
#   five-stage hierarchical testing, given 
#   alpha.vec, a vector of shape parameters for the Dirichlet distribution;  
#   Se, a matrix of sensitivity values; and  
#   Sp, a matrix of specificity values. 
Se <- matrix(data=rep(0.95, 10), nrow=2, ncol=5, byrow=TRUE) 
Sp <- matrix(data=rep(0.99, 10), nrow=2, ncol=5, byrow=TRUE) 
config.mat <- matrix(data=c(rep(1, 24), rep(1, 18), rep(2, 6),  
                            rep(1, 9), rep(2, 9), rep(3, 4), 4, 5,  
                            rep(1, 6), rep(2, 3), rep(3, 5), rep(4, 4),  
                            rep(5, 3), 6, rep(NA, 2), 1:21, rep(NA, 3)),  
                     nrow=5, ncol=24, byrow=TRUE) 
results6 <- opChar2(algorithm="ID5", alpha=c(18.25, 0.75, 0.75, 0.25), 
                    Se=Se, Sp=Sp, hier.config=config.mat) 
summary(results6) 
 
# 3) Estimation of the overall disease prevalence and calculation  
#   of confidence intervals. 
 
# 3.1) Suppose 3 groups out of 24 test positively.  
#   Each group has a size of 7. 
propCI(x=3, m=7, n=24, ci.method="CP") 
propCI(x=3, m=7, n=24, ci.method="Blaker") 
propCI(x=3, m=7, n=24, ci.method="score") 
propCI(x=3, m=7, n=24, ci.method="soc") 
 
# 3.2) Consider the following situation: 
#   0 out of 5 groups test positively with groups  
#   of size 1 (individual testing),  
#   0 out of 5 groups test positively with groups of size 5, 
#   1 out of 5 groups test positively with groups of size 10,  
#   2 out of 5 groups test positively with groups of size 50 
propCI(x=c(0,0,1,2), m=c(1,5,10,50), n=c(5,5,5,5),  
       pt.method="Gart", ci.method="skew-score") 
        
# 4) Estimate a group testing regression model. 
 
# 4.1) Fit a group testing regression model with  
#   simple pooling using the "hivsurv" dataset. 
data(hivsurv) 
fit1 <- gtReg(type="sp", formula = groupres ~ AGE + EDUC.,  
              data = hivsurv, groupn = gnum, sens = 0.9,  
              spec = 0.9, method = "Xie") 
summary(fit1) 
 
# 4.2) Simulate data for the halving protocol, and  
#   fit a group testing regression model. 
set.seed(46) 
gt.data <- gtSim(type="halving", par=c(-6, 0.1),  
                 gshape=17, gscale=1.4, size1=1000,  
                 size2=5, sens=0.95, spec=0.95) 
fit2 <- gtReg(type="halving", formula=gres~x,  
              data=gt.data, groupn=groupn, subg=subgroup, 
              retest=retest, sens=0.95, spec=0.95,  
              start=c(-6, 0.1), trace=TRUE) 
summary(fit2) 
 
# This example takes approximately 20 seconds to run. 
# 4.3) Simulate data in 5x6 array testing form, and  
#   fit a group testing regression model. 
set.seed(9128) 
array.sim <- gtSim(type="array", par=c(-7, 0.1),  
                   size1=c(5,6), size2=c(4,5), sens=0.95, spec=0.95) 
set1 <- array.sim$dframe 
 
fit3 <- gtReg(type="array",  
              formula=cbind(col.resp, row.resp)~x,  
              data=set1, coln=coln, rown=rown,  
              arrayn=arrayn, sens=0.95, spec=0.95,  
              tol=0.005, n.gibbs=2000, trace=TRUE) 
summary(fit3) 
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operatingCharacteristics1 {binGroup2} R Documentation 
Calculate operating characteristics for 
group testing algorithms that use a single-
disease assay 
Description 
Calculate operating characteristics, such as the expected number of tests, for a specified testing 
configuration using non-informative and informative hierarchical and array-based group testing 
algorithms. Single-disease assays are used at each stage of the algorithms. 
Usage 
operatingCharacteristics1( 
  algorithm, 
  p = NULL, 
  probabilities = NULL, 
  Se = 0.99, 
  Sp = 0.99, 
  hier.config = NULL, 
  rowcol.sz = NULL, 
  alpha = 2, 
  a = NULL, 
  print.time = TRUE, 
  ... 
) 
 
opChar1( 
  algorithm, 
  p = NULL, 
  probabilities = NULL, 
  Se = 0.99, 
  Sp = 0.99, 
  hier.config = NULL, 
  rowcol.sz = NULL, 
  alpha = 2, 
  a = NULL, 
  print.time = TRUE, 
  ... 
) 
Arguments 
algorithm character string defining the group testing algorithm to be used. Non-informative 
testing options include two-stage hierarchical ("D2"), three-stage hierarchical ("D3"), 
four-stage hierarchical ("D4"), square array testing without master pooling ("A2"), and 
square array testing with master pooling ("A2M"). Informative testing options include 
two-stage hierarchical ("ID2"), three-stage hierarchical ("ID3"), four-stage 
hierarchical ("ID4"), and square array testing without master pooling ("IA2"). 
p overall probability of disease that will be used to generate a vector/matrix of individual 
probabilities. For non-informative algorithms, a homogeneous set of probabilities will 
be used. For informative algorithms, the expectOrderBeta function will be used to 
generate a heterogeneous set of probabilities. Further details are given under 
'Details'. Either p or probabilities should be specified, but not both. 
probabilities a vector of individual probabilities, which is homogeneous for non-informative testing 
algorithms and heterogeneous for informative testing algorithms. 
Either p or probabilities should be specified, but not both. 
Se a vector of sensitivity values, where one value is given for each stage of testing (in 
order). If a single value is provided, sensitivity values are assumed to be equal to this 
value for all stages of testing. Further details are given under 'Details'. 
Sp a vector of specificity values, where one value is given for each stage of testing (in 
order). If a single value is provided, specificity values are assumed to be equal to this 
value for all stages of testing. Further details are given under 'Details'. 
hier.config a matrix specifying the configuration for a hierarchical testing algorithm. The rows 
correspond to the stages of testing, the columns correspond to each individual to be 
tested, and the cell values specify the group number of each individual at each stage. 
Further details are given under 'Details'. For array testing algorithms, this argument 
will be ignored. 
rowcol.sz the row/column size for array testing algorithms. For hierarchical testing algorithms, 
this argument will be ignored. 
alpha a shape parameter for the beta distribution that specifies the degree of heterogeneity 
for the generated probability vector (for informative testing only). 
a a vector containing indices indicating which individuals to calculate individual 
accuracy measures for. If NULL, individual accuracy measures will be displayed for all 
individuals in the algorithm. 
print.time a logical value indicating whether the length of time for calculations should be printed. 
The default is TRUE. 
... arguments to be passed to the expectOrderBeta function, which generates a 
vector of probabilities for informative testing algorithms. Further details are given 
under 'Details'. 
Details 
This function computes the operating characteristics for group testing algorithms with an assay that tests 
for one disease, as described in Hitt et al. (2019). 
Available algorithms include two-, three-, and four-stage hierarchical testing and array testing with and 
without master pooling. Both non-informative and informative group testing settings are allowed for each 
algorithm, except informative array testing with master pooling is unavailable because this method has 
not appeared in the group testing literature. Operating characteristics calculated are expected number of 
tests, pooling sensitivity, pooling specificity, pooling positive predictive value, and pooling negative 
predictive value for each individual. 
For informative algorithms where the p argument is specified, the expected value of order statistics from a 
beta distribution are found. These values are used to represent disease risk probabilities for each 
individual to be tested. The beta distribution has two parameters: a mean parameter p (overall disease 
prevalence) and a shape parameter alpha(heterogeneity level). Depending on the specified p, alpha, 
and overall group size, simulation may be necessary to generate the vector of individual probabilities. 
This is done using expectOrderBeta and requires the user to set a seed to reproduce results. 
Informative two-stage hierarchical (Dorfman) testing is implemented via the pool-specific optimal Dorfman 
(PSOD) method described in McMahan et al. (2012a), where the greedy algorithm proposed for PSOD is 
replaced by considering all possible testing configurations. Informative array testing is implemented via 
the gradient method (the most efficient array design), where higher-risk individuals are grouped in the left-
most columns of the array. For additional details on the gradient arrangement method for informative 
array testing, see McMahan et al. (2012b). 
The sensitivity/specificity values are allowed to vary across stages of testing. For hierarchical testing, a 
different sensitivity/specificity value may be used for each stage of testing. For array testing, a different 
sensitivity/specificity value may be used for master pool testing (if included), row/column testing, and 
individual testing. The values must be specified in order of the testing performed. For example, values are 
specified as (stage 1, stage 2, stage 3) for three-stage hierarchical testing or (master pool testing, 
row/column testing, individual testing) for array testing with master pooling. A single sensitivity/specificity 
value may be specified instead. In this situation, sensitivity/specificity values for all stages are assumed to 
be equal. 
The matrix specified by hier.config defines the hierarchical group testing algorithm for Iindividuals. 
The rows of the matrix correspond to the stages s=1,...,S in the testing algorithm, and the columns 
correspond to individuals i=1,...I. The cell values within the matrix represent the group number of 
individual i at stage s. For three-stage, four-stage, and non-informative two-stage hierarchical testing, the 
first row of the matrix consists of all ones. This indicates that all individuals in the algorithm are tested 
together in a single group in the first stage of testing. For informative two-stage hierarchical testing, the 
initial group (block) is not tested. Thus, the first row of the matrix consists of the group numbers for each 
individual in the first stage of testing. For all hierarchical algorithms, the final row of the matrix denotes 
individual testing. Individuals who are not tested in a particular stage are represented by "NA" (e.g., an 
individual tested in a group of size 1 in the second stage of testing would not be tested again in a third 
stage of testing). It is important to note that this matrix represents the testing that could be performed if 
each group tests positively at each stage prior to the last. For more details on this matrix (called a group 
membership matrix), see Bilder et al. (2019). 
For array testing without master pooling, the rowcol.sz specified represents the row/column size for 
initial (stage 1) testing. For array testing with master pooling, the rowcol.sz specified represents the 
row/column size for stage 2 testing. This is because the master pool size is the overall array size, given 
by the square of the row/column size. 
The displayed overall pooling sensitivity, pooling specificity, pooling positive predictive value, and pooling 
negative predictive value are weighted averages of the corresponding individual accuracy measures for 
all individuals within the initial group (or block) for a hierarchical algorithm, or within the entire array for an 
array-based algorithm. Expressions for these averages are provided in the Supplementary Material for 
Hitt et al. (2019). These expressions are based on accuracy definitions given by Altman and Bland 
(1994a, 1994b). 
The operatingCharacteristics1 function accepts additional arguments, namely num.sim, to be 
passed to the expectOrderBeta function, which generates a vector of probabilities for informative 
group testing algorithms. The num.sim argument specifies the number of simulations from the beta 
distribution when simulation is used. By default, 10,000 simulations are used. 
Value 
A list containing: 
algorithm the group testing algorithm used for calculations. 
prob the probability of disease or the vector of individual probabilities, as specified by the user. 
alpha level of heterogeneity for the generated probability vector (for informative testing only). 
Se the vector of sensitivity values for each stage of testing. 
Sp the vector of specificity values for each stage of testing. 
Config a list specifying elements of the specified testing configuration, which may include: 
Stage1 
group size for the first stage of hierarchical testing, if applicable. 
Stage2 
group sizes for the second stage of hierarchical testing, if applicable. 
Stage3 
group sizes for the third stage of hierarchical testing, if applicable. 
Block.sz 
the block size/initial group size for informative Dorfman testing, which is not tested. 
pool.szs 
group sizes for the first stage of testing for informative Dorfman testing. 
Array.dim 
the row/column size for array testing. 
Array.sz 
the overall array size for array testing (the square of the row/column size). 
p.vec the sorted vector of individual probabilities, if applicable. 
p.mat the sorted matrix of individual probabilities in gradient arrangement, if applicable. Further 
details are given under 'Details'. 
ET the expected testing expenditure to decode all individuals in the algorithm; this includes all 
individuals in all groups for hierarchical algorithms or in the entire array for array testing. 
value the value of the expected number of tests per individual. 
Accuracy a list containing: 
Individual 
a matrix of accuracy measures for each individual specified in a. The rows 
correspond to each unique set of accuracy measures in the algorithm. Individuals 
with the same set of accuracy measures are displayed together in a single row of the 
matrix. The columns correspond to the pooling sensitivity, pooling specificity, pooling 
positive predictive value, pooling negative predictive value, and the indices for the 
individuals in each row of the matrix. 
Overall 
a matrix of overall accuracy measures for the algorithm. The columns correspond to 
the pooling sensitivity, pooling specificity, pooling positive predictive value, and 
pooling negative predictive value for the overall algorithm. Further details are given 
under 'Details'. 
Note 
This function returns the pooling positive and negative predictive values for all individuals even though 
these measures are diagnostic specific; e.g., the pooling positive predictive value should only be 
considered for those individuals who have tested positive. 
Additionally, only stage dependent sensitivity and specificity values are allowed within the program (no 
group within stage dependent values are allowed). See Bilder et al. (2019) for additional information. 
Author(s) 
Brianna D. Hitt 
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See Also 
Other operating characteristic functions: Sterrett(), halving(),operatingCharacteristics2() 
Examples 
# Calculate the operating characteristics for non-informative 
#   two-stage hierarchical (Dorfman) testing. 
config.mat <- matrix(data = c(rep(1, 10), 1:10),  
                     nrow = 2, ncol = 10, byrow = TRUE) 
opChar1(algorithm="D2", p=0.05, Se=0.99, Sp=0.99,  
        hier.config=config.mat) 
opChar1(algorithm="D2", p=0.05, Se=0.99, Sp=0.99,  
        hier.config=config.mat, a=c(1,4), print.time=FALSE) 
 
# Calculate the operating characteristics for informative 
#   two-stage hierarchical (Dorfman) testing. 
# A vector of individual probabilities is generated using 
#   the expected value of order statistics from a beta 
#   distribution with p = 0.01 and a heterogeneity level 
#   of alpha = 0.5. 
config.mat <- matrix(data = c(rep(1:3, each = 10), 1:30),  
                     nrow = 2, ncol = 30, byrow = TRUE) 
set.seed(52613) 
opChar1(algorithm="ID2", p=0.01, Se=0.95, Sp=0.95,  
        hier.config=config.mat, alpha=0.5, num.sim=10000) 
# Equivalent code using a heterogeneous vector of  
#   probabilities 
set.seed(52613) 
probs <- expectOrderBeta(p=0.01, alpha=0.5, grp.sz=30) 
opChar1(algorithm="ID2", probabilities=probs, Se=0.95, Sp=0.95,  
        hier.config=config.mat) 
 
# Calculate the operating characteristics for 
#   non-informative three-stage hierarchical testing. 
config.mat <- matrix(data = c(rep(1, 18), rep(1:3, each = 5),  
                              rep(4, 3), 1:18),  
                    nrow = 3, ncol = 18, byrow = TRUE) 
opChar1(algorithm="D3", p=0.001, Se=0.95, Sp=0.95,  
        hier.config=config.mat) 
opChar1(algorithm="D3", p=0.001, Se=c(0.95, 0.95, 0.99),  
        Sp=c(0.96, 0.96, 0.98), hier.config=config.mat) 
 
# Calculate the operating characteristics for  
#   informative three-stage hierarchical testing,  
#   given a heterogeneous vector of probabilities. 
config.mat <- matrix(data = c(rep(1, 6), rep(1:2, each = 3),  
                              1:6), nrow = 3, ncol = 6,  
                     byrow = TRUE) 
set.seed(52613) 
opChar1(algorithm="ID3",  
         probabilities=c(0.012, 0.014, 0.011, 0.012, 0.010, 0.015),  
         Se=0.99, Sp=0.99, hier.config=config.mat,  
         alpha=0.5, num.sim=5000) 
 
# Calculate the operating characteristics for  
#   non-informative four-stage hierarchical testing. 
config.mat <- matrix(data = c(rep(1, 12), rep(1, 8),  
                              rep(2, 2), 3, 4, rep(1, 5),  
                              rep(2, 3), 3, 4, rep(NA, 2),  
                              1:8, rep(NA, 4)), nrow = 4,  
                     ncol = 12, byrow = TRUE) 
opChar1(algorithm="D4", p=0.041, Se=0.99, Sp=0.90,  
        hier.config=config.mat) 
         
# Calculate the operating characteristics for  
#   informative four-stage hierarchical testing.  
# A vector of individual probabilities is generated using 
#   the expected value of order statistics from a beta 
#   distribution with p = 0.041 and a heterogeneity level 
#   of alpha = 0.5. 
config.mat <- matrix(data = c(rep(1, 12), rep(1, 8),  
                              rep(2, 2), 3, 4, rep(1, 5),  
                              rep(2, 3), 3, 4, rep(NA, 2),  
                              1:8, rep(NA, 4)), nrow = 4,  
                     ncol = 12, byrow = TRUE) 
set.seed(5678) 
opChar1(algorithm="ID4", p=0.041, Se=0.99, Sp=0.90, 
        hier.config=config.mat, alpha=0.5) 
 
# Calculate the operating characteristics for 
#   non-informative array testing without master pooling. 
opChar1(algorithm="A2", p=0.005, Se=c(0.95, 0.99),  
        Sp=c(0.95, 0.99), rowcol.sz=8, a=1) 
 
# Calculate the operating characteristics for  
#   informative array testing without master pooling. 
# A vector of individual probabilities is generated using 
#   the expected value of order statistics from a beta 
#   distribution with p = 0.03 and a heterogeneity level 
#   of alpha = 2. 
set.seed(1002) 
opChar1(algorithm="IA2", p=0.03, Se=0.95, Sp=0.95, 
         rowcol.sz=8, alpha=2, a=1:10) 
 
# Calculate the operating characteristics for  
#   non-informative array testing with master pooling. 
opChar1(algorithm="A2M", p=0.02, Se=c(0.95,0.95,0.99),  
        Sp=c(0.98,0.98,0.99), rowcol.sz=5) 
 
[Package binGroup2 version 1.0.2 Index] 
 
operatingCharacteristics2 {binGroup2} R Documentation 
Calculate operating characteristics for 
group testing algorithms that use a 
multiplex assay for two diseases 
Description 
Calculate operating characteristics, such as the expected number of tests, for a specified testing 
configuration using non-informative and informative hierarchical and array-based group testing 
algorithms. Multiplex assays for two diseases are used at each stage of the algorithms. 
Usage 
operatingCharacteristics2( 
  algorithm, 
  p.vec = NULL, 
  probabilities = NULL, 
  alpha = NULL, 
  Se, 
  Sp, 
  hier.config = NULL, 
  rowcol.sz = NULL, 
  ordering = matrix(data = c(0, 1, 0, 1, 0, 0, 1, 1), nrow = 4, ncol = 2), 
  a = NULL, 
  print.time = TRUE, 
  ... 
) 
 
opChar2( 
  algorithm, 
  p.vec = NULL, 
  probabilities = NULL, 
  alpha = NULL, 
  Se, 
  Sp, 
  hier.config = NULL, 
  rowcol.sz = NULL, 
  ordering = matrix(data = c(0, 1, 0, 1, 0, 0, 1, 1), nrow = 4, ncol = 2), 
  a = NULL, 
  print.time = TRUE, 
  ... 
) 
Arguments 
algorithm character string defining the group testing algorithm to be used. Non-informative 
testing options include two-stage hierarchical ("D2"), three-stage hierarchical ("D3"), 
four-stage hierarchical ("D4"), five-stage hierarchical ("D5"), square array testing 
without master pooling ("A2"), and square array testing with master pooling ("A2M"). 
Informative testing options include two-stage hierarchical ("ID2"), three-stage 
hierarchical ("ID3"), four-stage hierarchical ("ID4"), and five-stage hierarchical 
("ID5") testing. 
p.vec vector of overall joint probabilities. The joint probabilities are assumed to be equal for 
all individuals in the algorithm (non-informative testing only). There are four joint 
probabilities to consider: p_00, the probability that an individual tests negative for 
both diseases; p_10, the probability that an individual tests positive only for the first 
disease; p_01, the probability that an individual tests positive only for the second 
disease; and p_11, the probability that an individual tests positive for both diseases. 
The joint probabilities must sum to 1. Only one of p.vec, probabilities, 
or alpha should be specified. 
probabilities matrix of joint probabilities for each individual, where rows correspond to the four joint 
probabilities and columns correspond to each individual in the algorithm. Only one 
of p.vec, probabilities, or alpha should be specified. 
alpha a vector containing positive shape parameters of the Dirichlet distribution (for 
informative testing only). The vector will be used to generate a heterogeneous matrix 
of joint probabilities for each individual. The vector must have length 4. Further details 
are given under 'Details'. Only one of p.vec, probabilities, or alpha should be 
specified. 
Se matrix of sensitivity values, where one value is given for each disease (or infection) at 
each stage of testing. The rows of the matrix correspond to each disease k=1,...,K, 
and the columns of the matrix correspond to each stage of testing s=1,...,S. If a 
vector of K values is provided, the sensitivity values associated with disease k are 
assumed to be equal to the kth value in the vector for all stages of testing. Further 
details are given under 'Details'. 
Sp a matrix of specificity values, where one value is given for each disease (or infection) 
at each stage of testing. The rows of the matrix correspond to each disease k=1,...,K, 
and the columns of the matrix correspond to each stage of testing s=1,...,S. If a 
vector of K values is provided, the specificity values associated with disease k are 
assumed to be equal to the kth value in the vector for all stages of testing. Further 
details are given under 'Details'. 
hier.config a matrix specifying the configuration for a hierarchical testing algorithm. The rows 
correspond to the stages of testing, the columns correspond to each individual to be 
tested, and the cell values specify the group number of each individual at each stage. 
Further details are given under 'Details'. For array testing algorithms, this argument 
will be ignored. 
rowcol.sz the row/column size for array testing algorithms. For hierarchical testing algorithms, 
this argument will be ignored. 
ordering a matrix detailing the ordering for the binary responses of the diseases. The columns 
of the matrix correspond to each disease and the rows of the matrix correspond to 
each of the 4 sets of binary responses for two diseases. This ordering is used with 
the joint probabilities. The default ordering is (p_00, p_10, p_01, p_11). 
a a vector containing indices indicating which individuals to calculate individual 
accuracy measures for. If NULL, individual accuracy measures will be displayed for all 
individuals in the algorithm. 
print.time a logical value indicating whether the length of time for calculations should be printed. 
The default is TRUE. 
... additional arguments to be passed to functions for hierarchical testing with multiplex 
assays for two diseases. 
Details 
This function computes the operating characteristics for standard group testing algorithms with a multiplex 
assay that tests for two diseases. Calculations for hierarchical group testing algorithms are performed as 
described in Bilder et al. (2019) and calculations for array-based group testing algorithms are performed 
as described in Hou et al. (2019). 
Available algorithms include two-, three-, four-, and five-stage hierarchical testing and array testing with 
and without master pooling. Both non-informative and informative group testing settings are allowed for 
hierarchical algorithms. Only non-informative group testing settings are allowed for array testing 
algorithms. Operating characteristics calculated are expected number of tests, pooling sensitivity, pooling 
specificity, pooling positive predictive value, and pooling negative predictive value for each individual. 
For informative algorithms where the alpha argument is specified, a heterogeneous matrix of joint 
probabilities for each individual is generated using the Dirichlet distribution. This is done 
using rBeta2009::rdirichlet and requires the user to set a seed to reproduce results. See Bilder et 
al. (2019) for additional details on the use of the Dirichlet distribution for this purpose. 
The sensitivity/specificity values are allowed to vary across stages of testing. For hierarchical testing, a 
different sensitivity/specificity value may be used for each stage of testing. For array testing, a different 
sensitivity/specificity value may be used for master pool testing (if included), row/column testing, and 
individual testing. The values must be specified in the order of the testing performed. For example, values 
are specified as (stage 1, stage 2, stage 3) for three-stage hierarchical testing or (master pool testing, 
row/column testing, individual testing) for array testing with master pooling. A vector 
of K sensitivity/specificity values may be specified, and sensitivity/specificity values for all stages of 
testing are assumed to be equal. The first value in the vector will be used at each stage of testing for the 
first disease, and the second value in the vector will be used at each stage of testing for the second 
disease. 
The matrix specified by hier.config defines the hierarchical group testing algorithm for Iindividuals. 
The rows of the matrix correspond to the stages s=1,...,S in the testing algorithm, and the columns 
correspond to individuals i=1,...I. The cell values within the matrix represent the group number of 
individual i at stage s. For three-stage, four-stage, five-stage, and non-informative two-stage hierarchical 
testing, the first row of the matrix consists of all ones. This indicates that all individuals in the algorithm 
are tested together in a single group in the first stage of testing. For informative two-stage hierarchical 
testing, the initial group (block) is not tested. Thus, the first row of the matrix consists of the group 
numbers for each individual in the first stage of testing. For all hierarchical algorithms, the final row of the 
matrix denotes individual testing. Individuals who are not tested in a particular stage are represented by 
"NA" (e.g., an individual tested in a group of size 1 in the second stage of testing would not be tested 
again in a third stage of testing). It is important to note that this matrix represents the testing that could be 
performed if each group tests positively at each stage prior to the last. For more details on this matrix 
(called a group membership matrix), see Bilder et al. (2019). 
For array testing without master pooling, the rowcol.sz specified represents the row/column size for 
initial (stage 1) testing. For array testing with master pooling, the rowcol.sz specified represents the 
row/column size for stage 2 testing. This is because the master pool size is the overall array size, given 
by the square of the row/column size. 
The displayed overall pooling sensitivity, pooling specificity, pooling positive predictive value, and pooling 
negative predictive value are weighted averages of the corresponding individual accuracy measures for 
all individuals within the initial group (or block) for a hierarchical algorithm, or within the entire array for an 
array-based algorithm. Expressions for these averages are provided in the Supplementary Material for 
Hitt et al. (2019). These expressions are based on accuracy definitions given by Altman and Bland 
(1994a, 1994b). 
Value 
A list containing: 
algorithm the group testing algorithm used for calculations. 
prob.vec the vector of joint probabilities provided by the user, if applicable (for non-informative 
algorithms only). 
joint.p the matrix of joint probabilities for each individual provided by the user, if applicable. 
alpha.vec the alpha vector provided by the user, if applicable (for informative algorithms only). 
Se the matrix of sensitivity values for each disease at each stage of testing. 
Sp the matrix of specificity values for each disease at each stage of testing. 
Config a list specifying elements of the specified testing configuration, which may include: 
Stage1 
group size for the first stage of hierarchical testing, if applicable. 
Stage2 
group sizes for the second stage of hierarchical testing, if applicable. 
Stage3 
group sizes for the third stage of hierarchical testing, if applicable. 
Stage4 
group sizes for the fourth stage of hierarchical testing, if applicable. 
Block.sz 
the block size/initial group size for informative Dorfman testing, which is not tested. 
pool.szs 
group sizes for the first stage of testing for informative Dorfman testing. 
Array.dim 
the row/column size for array testing. 
Array.sz 
the overall array size for array testing (the square of the row/column size). 
p.mat the matrix of joint probabilities for each individual in the algorithm. Each row corresponds to 
one of the four joint probabilities. Each column corresponds to an individual in the testing 
algorithm. 
ET the expected testing expenditure for the OTC. 
value the value of the expected number of tests per individual. 
Accuracy a list containing: 
Disease 1 Individual 
a matrix of accuracy measures, pertaining to the first disease, for each individual 
specified in a. The rows correspond to each unique set of accuracy measures in the 
algorithm. Individuals with the same set of accuracy measures are displayed 
together in a single row of the matrix. The columns correspond to the pooling 
sensitivity, pooling specificity, pooling positive predictive value, pooling negative 
predictive value, and the indices for the individuals in each row of the matrix. 
Individual accuracy measures are not displayed for array testing algorithms. 
Disease 2 Individual 
a matrix of accuracy measures, pertaining to the second disease, for each individual 
specified in a. The rows correspond to each unique set of accuracy measures in the 
algorithm. Individuals with the same set of accuracy measures are displayed 
together in a single row of the matrix. The columns correspond to the pooling 
sensitivity, pooling specificity, pooling positive predictive value, pooling negative 
predictive value, and the indices for the individuals in each row of the matrix. 
Individual accuracy measures are not displayed for array testing algorithms. 
Overall 
a matrix of overall accuracy measures for the algorithm. The rows correspond to 
each disease. The columns correspond to the pooling sensitivity, pooling specificity, 
pooling positive predictive value, and pooling negative predictive value for the overall 
algorithm. Further details are given under 'Details'. 
Note 
This function returns the pooling positive and negative predictive values for all individuals even though 
these measures are diagnostic specific; e.g., the pooling positive predictive value should only be 
considered for those individuals who have tested positive. 
Additionally, only stage dependent sensitivity and specificity values are allowed within the program (no 
group within stage dependent values are allowed). See Bilder et al. (2019) for additional information. 
Author(s) 
This function was written by Brianna D. Hitt. It calls ET.all.stages.new and PSePSpAllStages, 
which were originally written by Christopher Bilder for Bilder et al. (2019), and ARRAY, which was 
originally written by Peijie Hou for Hou et al. (2020). The 
functions ET.all.stages.new, PSePSpAllStages, and ARRAY were obtained 
from http://chrisbilder.com/grouptesting. Minor modifications were made to the functions for inclusion in 
the binGroup2 package. 
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See Also 
Other operating characteristic functions: Sterrett(), halving(),operatingCharacteristics1() 
Other multiplex testing functions: OTC2() 
Examples 
# Calculate the operating characteristics for  
#   non-informative two-stage hierarchical  
#   (Dorfman) testing. 
config.mat <- matrix(data = c(rep(1, 24), 1:24),  
                     nrow = 2, ncol = 24, byrow = TRUE) 
Se <- matrix(data=c(0.95, 0.95, 0.95, 0.95), 
             nrow=2, ncol=2, 
             dimnames=list(Infection=1:2, Stage=1:2)) 
Sp <- matrix(data=c(0.99, 0.99, 0.99, 0.99), 
             nrow=2, ncol=2, 
             dimnames=list(Infection=1:2, Stage=1:2)) 
opChar2(algorithm="D2", p.vec=c(0.90, 0.04, 0.04, 0.02), 
         Se=Se, Sp=Sp, hier.config=config.mat) 
opChar2(algorithm="D2", p.vec=c(0.90, 0.04, 0.04, 0.02), 
         Se=Se, Sp=Sp, hier.config=config.mat, a=c(1, 13, 24),  
         print.time = FALSE) 
                             
# Calculate the operating characteristics for informative  
#   two-stage hierarchical (Dorfman) testing. 
# A matrix of joint probabilities for each individual is  
#   generated using the Dirichlet distribution. 
config.mat <- matrix(data = c(rep(1, 5), rep(2, 4), 3, 1:9, NA),  
                     nrow = 2, ncol = 10, byrow = TRUE) 
Se <- matrix(data=c(0.95, 0.95, 0.99, 0.99), 
             nrow=2, ncol=2, 
             dimnames=list(Infection=1:2, Stage=1:2)) 
Sp <- matrix(data=c(0.96, 0.96, 0.98, 0.98), 
             nrow=2, ncol=2, 
             dimnames=list(Infection=1:2, Stage=1:2)) 
set.seed(8791) 
opChar2(algorithm="ID2", alpha=c(18.25, 0.75, 0.75, 0.25), 
         Se=Se, Sp=Sp, hier.config=config.mat) 
# Equivalent code using a heterogeneous matrix of joint 
#   probabilities for each individual 
set.seed(8791) 
p.unordered <- t(rBeta2009::rdirichlet(n = 10,  
                            shape = c(18.25, 0.75, 0.75, 0.25))) 
p.ordered <- p.unordered[, order(1 - p.unordered[1,])] 
opChar2(algorithm="ID2", probabilities=p.ordered, 
        Se=Se, Sp=Sp, hier.config=config.mat) 
          
# Calculate the operating characteristics for  
#   non-informative three-stage hierarchical testing. 
config.mat <- matrix(data = c(rep(1, 10), rep(1, 5),  
                              rep(2, 4), 3, 1:9, NA),  
                     nrow = 3, ncol = 10, byrow = TRUE) 
Se <- matrix(data=rep(0.95, 6), nrow=2, ncol=3, 
             dimnames=list(Infection=1:2, Stage=1:3)) 
Sp <- matrix(data=rep(0.99, 6), nrow=2, ncol=3, 
             dimnames=list(Infection=1:2, Stage=1:3)) 
opChar2(algorithm="D3", p.vec=c(0.95, 0.02, 0.02, 0.01), 
         Se=Se, Sp=Sp, hier.config=config.mat) 
opChar2(algorithm="D3", p.vec=c(0.95, 0.02, 0.02, 0.01), 
         Se=Se, Sp=Sp, hier.config=config.mat, a=c(1, 6, 10)) 
     
# Calculate the operating characteristics for informative  
#   three-stage hierarchical testing.  
# A matrix of joint probabilities for each individual is  
#   generated using the Dirichlet distribution. 
config.mat <- matrix(data = c(rep(1, 15),  
                              rep(c(1, 2, 3), each = 5), 1:15),  
                     nrow = 3, ncol = 15, byrow = TRUE) 
Se <- matrix(data=rep(0.95, 6), nrow=2, ncol=3, 
             dimnames=list(Infection=1:2, Stage=1:3)) 
Sp <- matrix(data=rep(0.99, 6), nrow=2, ncol=3, 
             dimnames=list(Infection=1:2, Stage=1:3)) 
opChar2(algorithm="ID3", alpha=c(18.25, 0.75, 0.75, 0.25), 
         Se=Se, Sp=Sp, hier.config=config.mat) 
          
# Calculate the operating characteristics for  
#   non-informative four-stage hierarchical testing.  
config.mat <- matrix(data = c(rep(1, 12), rep(1, 6), rep(2, 6),  
                              rep(1, 4), rep(2, 2), rep(3, 3),  
                              rep(4, 3), 1:12),  
                     nrow = 4, ncol = 12, byrow = TRUE) 
Se <- matrix(data=rep(0.95, 8), nrow=2, ncol=4, 
             dimnames=list(Infection=1:2, Stage=1:4)) 
Sp <- matrix(data=rep(0.99, 8), nrow=2, ncol=4, 
             dimnames=list(Infection=1:2, Stage=1:4)) 
opChar2(algorithm="D4", p.vec=c(0.92, 0.05, 0.02, 0.01), 
         Se=Se, Sp=Sp, hier.config=config.mat) 
 
# Calculate the operating characteristics for informative  
#   five-stage hierarchical testing.  
# A matrix of joint probabilities for each individual is  
#   generated using the Dirichlet distribution. 
config.mat <- matrix(data = c(rep(1, 20), rep(1, 10), rep(2, 10), 
                              rep(c(1, 2, 3, 4), each = 5),  
                              rep(1, 3), rep(2, 2), rep(3, 3),  
                              rep(4, 2), rep(5, 3), rep(6, 2), 
                              rep(7, 3), rep(8, 2), 1:20),  
                     nrow = 5, ncol = 20, byrow = TRUE) 
Se <- matrix(data=rep(0.95, 10), nrow=2, ncol=5, 
             dimnames=list(Infection=1:2, Stage=1:5)) 
Sp <- matrix(data=rep(0.99, 10), nrow=2, ncol=5, 
             dimnames=list(Infection=1:2, Stage=1:5)) 
opChar2(algorithm="ID5", alpha=c(18.25, 0.75, 0.75, 0.25), 
        Se=Se, Sp=Sp, hier.config=config.mat) 
 
# Calculate the operating characteristics for  
#   non-informative array testing without master pooling. 
Se <- matrix(data=rep(0.95, 4), nrow=2, ncol=2, 
             dimnames=list(Infection=1:2, Stage=1:2)) 
Sp <- matrix(data=rep(0.99, 4), nrow=2, ncol=2, 
             dimnames=list(Infection=1:2, Stage=1:2)) 
opChar2(algorithm="A2", p.vec=c(0.90, 0.04, 0.04, 0.02), 
         Se=Se, Sp=Sp, rowcol.sz=12) 
                   
# Calculate the operating characteristics for  
#   non-informative array testing with master pooling. 
Se <- matrix(data=rep(0.95, 6), nrow=2, ncol=3, 
             dimnames=list(Infection=1:2, Stage=1:3)) 
Sp <- matrix(data=rep(0.99, 6), nrow=2, ncol=3, 
             dimnames=list(Infection=1:2, Stage=1:3)) 
opChar2(algorithm="A2M", p.vec=c(0.90, 0.04, 0.04, 0.02), 
         Se=Se, Sp=Sp, rowcol.sz=10) 
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OTC1 {binGroup2} R Documentation 
Find the optimal testing configuration for 
group testing algorithms that use a single-
disease assay 
Description 
Find the optimal testing configuration (OTC) using non-informative and informative hierarchical and array-
based group testing algorithms. Single-disease assays are used at each stage of the algorithms. 
Usage 
OTC1( 
  algorithm, 
  p = NULL, 
  probabilities = NULL, 
  Se = 0.99, 
  Sp = 0.99, 
  group.sz, 
  obj.fn = c("ET", "MAR"), 
  weights = NULL, 
  alpha = 2, 
  trace = TRUE, 
  print.time = TRUE, 
  ... 
) 
Arguments 
algorithm character string defining the group testing algorithm to be used. Non-informative 
testing options include two-stage hierarchical ("D2"), three-stage hierarchical ("D3"), 
square array testing without master pooling ("A2"), and square array testing with 
master pooling ("A2M"). Informative testing options include two-stage hierarchical 
("ID2"), three-stage hierarchical ("ID3"), and square array testing without master 
pooling ("IA2"). 
p overall probability of disease that will be used to generate a vector/matrix of individual 
probabilities. For non-informative algorithms, a homogeneous set of probabilities will 
be used. For informative algorithms, the expectOrderBeta function will be used to 
generate a heterogeneous set of probabilities. Further details are given under 
'Details'. Either p or probabilities should be specified, but not both. 
probabilities a vector of individual probabilities, which is homogeneous for non-informative testing 
algorithms and heterogeneous for informative testing algorithms. 
Either p or probabilities should be specified, but not both. 
Se a vector of sensitivity values, where one value is given for each stage of testing (in 
order). If a single value is provided, sensitivity values are assumed to be equal to this 
value for all stages of testing. Further details are given under 'Details'. 
Sp a vector of specificity values, where one value is given for each stage of testing (in 
order). If a single value is provided, specificity values are assumed to be equal to this 
value for all stages of testing. Further details are given under 'Details'. 
group.sz a single group size or range of group sizes for which to calculate operating 
characteristics and/or find the OTC. The details of group size specification are given 
under 'Details'. 
obj.fn a list of objective functions which are minimized to find the OTC. The expected 
number of tests per individual, "ET", will always be calculated. Additional options 
include "MAR" (the expected number of tests divided by the expected number of 
correct classifications, described in Malinovsky et al. (2016)), and "GR" (a linear 
combination of the expected number of tests, the number of misclassified negatives, 
and the number of misclassified positives, described in Graff & Roeloffs (1972)). See 
Hitt et al. (2019) for additional details. The first objective function specified in this list 
will be used to determine the results for the top configurations. Further details are 
given under 'Details'. 
weights a matrix of up to six sets of weights for the GR function. Each set of weights is 
specified by a row of the matrix. 
alpha a shape parameter for the beta distribution that specifies the degree of heterogeneity 
for the generated probability vector (for informative testing only). 
trace a logical value indicating whether the progress of calculations should be printed for 
each initial group size provided by the user. The default is TRUE. 
print.time a logical value indicating whether the length of time for calculations should be printed. 
The default is TRUE. 
... arguments to be passed to the expectOrderBeta function, which generates a 
vector of probabilities for informative testing algorithms. Further details are given 
under 'Details'. 
Details 
This function finds the OTC for group testing algorithms with an assay that tests for one disease and 
computes the associated operating characteristics, as described in Hitt et al. (2019). 
Available algorithms include two- and three-stage hierarchical testing and array testing with and without 
master pooling. Both non-informative and informative group testing settings are allowed for each 
algorithm, except informative array testing with master pooling is unavailable because this method has 
not appeared in the group testing literature. Operating characteristics calculated are expected number of 
tests, pooling sensitivity, pooling specificity, pooling positive predictive value, and pooling negative 
predictive value for each individual. 
For informative algorithms where the p argument is specified, the expected value of order statistics from a 
beta distribution are found. These values are used to represent disease risk probabilities for each 
individual to be tested. The beta distribution has two parameters: a mean parameter p (overall disease 
prevalence) and a shape parameter alpha(heterogeneity level). Depending on the specified p, alpha, 
and overall group size, simulation may be necessary to generate the vector of individual probabilities. 
This is done using expectOrderBeta and requires the user to set a seed to reproduce results. 
Informative two-stage hierarchical (Dorfman) testing is implemented via the pool-specific optimal Dorfman 
(PSOD) method described in McMahan et al. (2012a), where the greedy algorithm proposed for PSOD is 
replaced by considering all possible testing configurations. Informative array testing is implemented via 
the gradient method (the most efficient array design), where higher-risk individuals are grouped in the left-
most columns of the array. For additional details on the gradient arrangement method for informative 
array testing, see McMahan et al. (2012b). 
The sensitivity/specificity values are allowed to vary across stages of testing. For hierarchical testing, a 
different sensitivity/specificity value may be used for each stage of testing. For array testing, a different 
sensitivity/specificity value may be used for master pool testing (if included), row/column testing, and 
individual testing. The values must be specified in order of the testing performed. For example, values are 
specified as (stage 1, stage 2, stage 3) for three-stage hierarchical testing or (master pool testing, 
row/column testing, individual testing) for array testing with master pooling. A single sensitivity/specificity 
value may be specified instead. In this situation, sensitivity/specificity values for all stages are assumed to 
be equal. 
The value(s) specified by group.sz represent the initial (stage 1) group size for hierarchical testing and 
the row/column size for array testing. For informative two-stage hierarchical testing, 
the group.sz specified represents the block size used in the pool-specific optimal Dorfman (PSOD) 
method, where the initial group (block) is not tested. For more details on informative two-stage 
hierarchical testing implemented via the PSOD method, see Hitt et al. (2019) and McMahan et al. 
(2012a). 
If a single value is provided for group.sz with array testing or non-informative two-stage hierarchical 
testing, operating characteristics will be calculated and no optimization will be performed. If a single value 
is provided for group.sz with three-stage hierarchical or informative two-stage hierarchical, the OTC will 
be found over all possible configurations. If a range of group sizes is specified, the OTC will be found over 
all group sizes. 
In addition to the OTC, operating characteristics for some of the other configurations corresponding to 
each initial group size provided by the user will be displayed. These additional configurations are only 
determined for whichever objective function ("ET", "MAR", or "GR") is specified first in the function call. If 
"GR" is the objective function listed first, the first set of corresponding weights will be used. For algorithms 
where there is only one configuration for each initial group size (non-informative two-stage hierarchical 
and all array testing algorithms), results for each initial group size are provided. For algorithms where 
there is more than one possible configuration for each initial group size (informative two-stage 
hierarchical and all three-stage hierarchical algorithms), two sets of configurations are provided: 1) the 
best configuration for each initial group size, and 2) the top 10 configurations for each initial group size 
provided by the user. If a single value is provided for group.szwith array testing or non-informative two-
stage hierarchical testing, operating characteristics will not be provided for configurations other than that 
specified by the user. Results are sorted by the value of the objective function per individual, value. 
The displayed overall pooling sensitivity, pooling specificity, pooling positive predictive value, and pooling 
negative predictive value are weighted averages of the corresponding individual accuracy measures for 
all individuals within the initial group (or block) for a hierarchical algorithm, or within the entire array for an 
array-based algorithm. Expressions for these averages are provided in the Supplementary Material for 
Hitt et al. (2019). These expressions are based on accuracy definitions given by Altman and Bland 
(1994a, 1994b). Individual accuracy measures can be calculated using 
the operatingCharacteristics1(opChar1) function. 
The OTC1 function accepts additional arguments, namely num.sim, to be passed to 
the expectOrderBeta function, which generates a vector of probabilities for informative group testing 
algorithms. The num.sim argument specifies the number of simulations from the beta distribution when 
simulation is used. By default, 10,000 simulations are used. 
Value 
A list containing: 
algorithm the group testing algorithm used for calculations. 
prob the probability of disease or the vector of individual probabilities, as specified by the 
user. 
alpha level of heterogeneity for the generated probability vector (for informative testing only). 
Se the vector of sensitivity values for each stage of testing. 
Sp the vector of specificity values for each stage of testing. 
opt.ET, 
opt.MAR, 
opt.GR 
a list of results for each objective function specified by the user, containing: 
OTC 
a list specifying elements of the optimal testing configuration, which may 
include: 
Stage1 
group size for the first stage of hierarchical testing, if applicable. 
Stage2 
group sizes for the second stage of hierarchical testing, if applicable. 
Block.sz 
the block size/initial group size for informative Dorfman testing, which is not 
tested. 
pool.szs 
group sizes for the first stage of testing for informative Dorfman testing. 
Array.dim 
the row/column size for array testing. 
Array.sz 
the overall array size for array testing (the square of the row/column size). 
p.vec 
the sorted vector of individual probabilities, if applicable. 
p.mat 
the sorted matrix of individual probabilities in gradient arrangement, if 
applicable. Further details are given under 'Details'. 
ET 
the expected testing expenditure to decode all individuals in the algorithm; this 
includes all individuals in all groups for hierarchical algorithms or in the entire 
array for array testing. 
value 
the value of the objective function per individual. 
Accuracy 
a matrix of overall accuracy measures for the algorithm. The columns 
correspond to the pooling sensitivity, pooling specificity, pooling positive 
predictive value, and pooling negative predictive value for the overall 
algorithm. Further details are given under 'Details'. 
Configs a data frame containing results for the best configuration for each initial group size 
provided by the user. The columns correspond to the initial group size, configuration (if 
applicable), overall array size (if applicable), expected number of tests, value of the 
objective function per individual, pooling sensitivity, pooling specificity, pooling positive 
predictive value, and pooling negative predictive value. No results are displayed if a 
single group.sz is provided. Further details are given under 'Details'. 
Top.Configs a data frame containing results for some of the top configurations for each initial group 
size provided by the user. The columns correspond to the initial group size, 
configuration, expected number of tests, value of the objective function per individual, 
pooling sensitivity, pooling specificity, pooling positive predictive value, and pooling 
negative predictive value. No results are displayed for non-informative two-stage 
hierarchical testing or for array testing algorithms. Further details are given under 
'Details'. 
Note 
This function returns the pooling positive and negative predictive values for all individuals even though 
these measures are diagnostic specific; e.g., the pooling positive predictive value should only be 
considered for those individuals who have tested positive. 
Additionally, only stage dependent sensitivity and specificity values are allowed within the program (no 
group within stage dependent values are allowed). See Bilder et al. (2019) for additional information. 
Author(s) 
Brianna D. Hitt 
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See Also 
Other OTC functions: OTC2() 
Examples 
# Estimated running time for all examples was calculated  
#   using a computer with 16 GB of RAM and one core of  
#   an Intel i7-6500U processor. Please take this into  
#   account when interpreting the run times given. 
 
# Find the OTC for non-informative 
#   two-stage hierarchical (Dorfman) testing. 
OTC1(algorithm="D2", p=0.05, Se=0.99, Sp=0.99,  
     group.sz=3:100, obj.fn=c("ET", "MAR"),  
     trace=TRUE, print.time=TRUE) 
 
# Find the OTC for informative two-stage hierarchical  
#   (Dorfman) testing. 
# A vector of individual probabilities is generated using 
#   the expected value of order statistics from a beta 
#   distribution with p = 0.01 and a heterogeneity level 
#   of alpha = 0.5. 
# This example takes approximately 2.5 minutes to run. 
 
set.seed(52613) 
OTC1(algorithm="ID2", p=0.01, Se=0.95, Sp=0.95, group.sz=50, 
     obj.fn=c("ET", "MAR", "GR"), 
     weights=matrix(data=c(1, 1, 10, 10, 0.5, 0.5), 
     nrow=3, ncol=2, byrow=TRUE), alpha=0.5,  
     trace=FALSE, print.time=TRUE, num.sim=10000) 
 
# Find the OTC over all possible testing configurations  
#   for non-informative three-stage hierarchical testing  
#   with a specified group size. 
OTC1(algorithm="D3", p=0.001, Se=0.95, Sp=0.95, group.sz=18, 
     obj.fn=c("ET", "MAR", "GR"), 
     weights=matrix(data=c(1, 1), nrow=1, ncol=2, byrow=TRUE),  
     trace=FALSE, print.time=FALSE) 
 
# Find the OTC for non-informative three-stage  
#   hierarchical testing. 
# This example takes approximately 20 seconds to run. 
 
OTC1(algorithm="D3", p=0.06, Se=0.90, Sp=0.90, 
     group.sz=3:30, obj.fn=c("ET", "MAR", "GR"), 
     weights=matrix(data=c(1, 1, 10, 10, 100, 100), 
     nrow=3, ncol=2, byrow=TRUE)) 
 
# Find the OTC over all possible configurations 
#   for informative three-stage hierarchical testing  
#   with a specified group size and a heterogeneous  
#   vector of probabilities. 
set.seed(1234) 
OTC1(algorithm="ID3",  
     probabilities=c(0.012, 0.014, 0.011, 0.012, 0.010, 0.015),  
     Se=0.99, Sp=0.99, group.sz=6, obj.fn=c("ET","MAR","GR"),  
     weights=matrix(data=c(1, 1), nrow=1, ncol=2, byrow=TRUE),  
     alpha=0.5, num.sim=5000, trace=FALSE) 
 
# Calculate the operating characteristics for  
#   non-informative array testing without master pooling  
#   with a specified array size. 
OTC1(algorithm="A2", p=0.005, Se=0.95, Sp=0.95, group.sz=8, 
     obj.fn=c("ET", "MAR"), trace=FALSE) 
 
# Find the OTC for informative array testing without 
#   master pooling. 
# A vector of individual probabilities is generated using 
#   the expected value of order statistics from a beta 
#   distribution with p = 0.03 and a heterogeneity level 
#   of alpha = 2. The probabilities are then arranged in 
#   a matrix using the gradient method. 
# This example takes approximately 30 seconds to run. 
 
set.seed(1002) 
OTC1(algorithm="IA2", p=0.03, Se=0.95, Sp=0.95, 
     group.sz=3:20, obj.fn=c("ET", "MAR", "GR"), 
     weights=matrix(data=c(1, 1, 10, 10, 100, 100),  
                    nrow=3, ncol=2, byrow=TRUE), alpha=2) 
 
# Find the OTC for non-informative array testing 
#   with master pooling. 
# This example takes approximately 20 seconds to run. 
 
OTC1(algorithm="A2M", p=0.02, Se=0.90, Sp=0.90, 
     group.sz=3:20, obj.fn=c("ET", "MAR", "GR"), 
     weights=matrix(data=c(1, 1, 10, 10, 0.5, 0.5, 2, 2, 100, 100,  
                           10, 100), nrow=6, ncol=2, byrow=TRUE)) 
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OTC2 {binGroup2} R Documentation 
Find the optimal testing configuration for 
group testing algorithms that use a 
multiplex assay for two diseases 
Description 
Find the optimal testing configuration (OTC) using non-informative and informative hierarchical and array-
based group testing algorithms. Multiplex assays for two diseases are used at each stage of the 
algorithms. 
Usage 
OTC2( 
  algorithm, 
  p.vec = NULL, 
  probabilities = NULL, 
  alpha = NULL, 
  Se, 
  Sp, 
  ordering = matrix(data = c(0, 1, 0, 1, 0, 0, 1, 1), nrow = 4, ncol = 2), 
  group.sz, 
  trace = TRUE, 
  print.time = TRUE, 
  ... 
) 
Arguments 
algorithm character string defining the group testing algorithm to be used. Non-informative 
testing options include two-stage hierarchical ("D2"), three-stage hierarchical ("D3"), 
square array testing without master pooling ("A2"), and square array testing with 
master pooling ("A2M"). Informative testing options include two-stage hierarchical 
("ID2") and three-stage hierarchical ("ID3") testing. 
p.vec vector of overall joint probabilities. The joint probabilities are assumed to be equal for 
all individuals in the algorithm (non-informative testing only). There are four joint 
probabilities to consider: p_00, the probability that an individual tests negative for 
both diseases; p_10, the probability that an individual tests positive only for the first 
disease; p_01, the probability that an individual tests positive only for the second 
disease; and p_11, the probability that an individual tests positive for both diseases. 
The joint probabilities must sum to 1. Only one of p.vec, probabilities, 
or alpha should be specified. 
probabilities matrix of joint probabilities for each individual, where rows correspond to the four joint 
probabilities and columns correspond to each individual in the algorithm. Only one 
of p.vec, probabilities, or alpha should be specified. 
alpha vector containing positive shape parameters of the Dirichlet distribution (for 
informative testing only). The vector will be used to generate a heterogeneous matrix 
of joint probabilities for each individual. The vector must have length 4. Further details 
are given under 'Details'. Only one of p.vec, probabilities, or alpha should be 
specified. 
Se matrix of sensitivity values, where one value is given for each disease (or infection) at 
each stage of testing. The rows of the matrix correspond to each disease k=1,...,K, 
and the columns of the matrix correspond to each stage of testing s=1,...,S. If a 
vector of K values is provided, the sensitivity values associated with disease k are 
assumed to be equal to the kth value in the vector for all stages of testing. Further 
details are given under 'Details'. 
Sp matrix of specificity values, where one value is given for each disease (or infection) at 
each stage of testing. The rows of the matrix correspond to each disease k=1,...,K, 
and the columns of the matrix correspond to each stage of testing s=1,...,S. If a 
vector of K values is provided, the specificity values associated with disease k are 
assumed to be equal to the kth value in the vector for all stages of testing. Further 
details are given under 'Details'. 
ordering matrix detailing the ordering for the binary responses of the diseases. The columns of 
the matrix correspond to each disease and the rows of the matrix correspond to each 
of the 4 sets of binary responses for two diseases. This ordering is used with the joint 
probabilities. The default ordering is (p_00, p_10, p_01, p_11). 
group.sz single group size or range of group sizes for which to calculate operating 
characteristics and/or find the OTC. The details of group size specification are given 
under 'Details'. 
trace a logical value indicating whether the progress of calculations should be printed for 
each initial group size provided by the user. The default is TRUE. 
print.time a logical value indicating whether the length of time for calculations should be printed. 
The default is TRUE. 
... additional arguments to be passed to functions for hierarchical testing with multiplex 
assays for two diseases. 
Details 
This function finds the OTC for standard group testing algorithms with a multiplex assay that tests for two 
diseases and computes the associated operating characteristics. Calculations for hierarchical group 
testing algorithms are performed as described in Bilder et al. (2019) and calculations for array-based 
group testing algorithms are performed as described in Hou et al. (2019). 
Available algorithms include two- and three-stage hierarchical testing and array testing with and without 
master pooling. Both non-informative and informative group testing settings are allowed for hierarchical 
algorithms. Only non-informative group testing settings are allowed for array testing algorithms. Operating 
characteristics calculated are expected number of tests, pooling sensitivity, pooling specificity, pooling 
positive predictive value, and pooling negative predictive value for each individual. 
For informative algorithms where the alpha argument is specified, a heterogeneous matrix of joint 
probabilities for each individual is generated using the Dirichlet distribution. This is done 
using rBeta2009::rdirichlet and requires the user to set a seed to reproduce results. See Bilder et 
al. (2019) for additional details on the use of the Dirichlet distribution for this purpose. 
The sensitivity/specificity values are allowed to vary across stages of testing. For hierarchical testing, a 
different sensitivity/specificity value may be used for each stage of testing. For array testing, a different 
sensitivity/specificity value may be used for master pool testing (if included), row/column testing, and 
individual testing. The values must be specified in the order of the testing performed. For example, values 
are specified as (stage 1, stage 2, stage 3) for three-stage hierarchical testing or (master pool testing, 
row/column testing, individual testing) for array testing with master pooling. A vector 
of K sensitivity/specificity values may be specified, and sensitivity/specificity values for all stages of 
testing are assumed to be equal. The first value in the vector will be used at each stage of testing for the 
first disease, and the second value in the vector will be used at each stage of testing for the second 
disease. 
The value(s) specified by group.sz represent the initial (stage 1) group size for hierarchical testing and 
the row/column size for array testing. If a single value is provided for group.szwith two-stage 
hierarchical or array testing, operating characteristics will be calculated and no optimization will be 
performed. If a single value is provided for group.sz with three-stage hierarchical, the OTC will be found 
over all possible configurations with this initial group size. If a range of group sizes is specified, the OTC 
will be found over all group sizes. 
In addition to the OTC, operating characteristics for some of the other configurations corresponding to 
each initial group size provided by the user are displayed. For algorithms where there is only one 
configuration for each initial group size (non-informative two-stage hierarchical and all array testing 
algorithms), results for each initial group size are provided. For algorithms where there is more than one 
possible configuration for each initial group size (informative two-stage hierarchical and all three-stage 
hierarchical algorithms), two sets of configurations are provided: 1) the best configuration for each initial 
group size, and 2) the top 10 configurations for each initial group size provided by the user. If a single 
value is provided for group.sz with array testing or non-informative two-stage hierarchical testing, 
operating characteristics will not be provided for configurations other than that specified by the user. 
Results are sorted by the value of the objective function per individual, value. 
The displayed overall pooling sensitivity, pooling specificity, pooling positive predictive value, and pooling 
negative predictive value are weighted averages of the corresponding individual accuracy measures for 
all individuals within the initial group (or block) for a hierarchical algorithm, or within the entire array for an 
array-based algorithm. Expressions for these averages are provided in the Supplementary Material for 
Hitt et al. (2019). These expressions are based on accuracy definitions given by Altman and Bland 
(1994a, 1994b). Individual accuracy measures can be calculated using 
the operatingCharacteristics2(opChar2) function. 
Value 
A list containing: 
algorithm the group testing algorithm used for calculations. 
prob.vec the vector of joint probabilities provided by the user, if applicable (for non-informative 
algorithms only). 
joint.p the matrix of joint probabilities for each individual provided by the user, if applicable. 
alpha.vec the alpha vector provided by the user, if applicable (for informative algorithms only). 
Se the matrix of sensitivity values for each disease at each stage of testing. 
Sp the matrix of specificity values for each disease at each stage of testing. 
opt.ET a list containing: 
OTC 
a list specifying elements of the optimal testing configuration, which may include: 
Stage1 
group size for the first stage of hierarchical testing, if applicable. 
Stage2 
group sizes for the second stage of hierarchical testing, if applicable. 
Block.sz 
the block size/initial group size for informative Dorfman testing, which is not 
tested. 
pool.szs 
group sizes for the first stage of testing for informative Dorfman testing. 
Array.dim 
the row/column size for array testing. 
Array.sz 
the overall array size for array testing (the square of the row/column size). 
p.mat 
the matrix of joint probabilities for each individual in the algorithm. Each row 
corresponds to one of the four joint probabilities. Each column corresponds to an 
individual in the testing algorithm. 
ET 
the expected testing expenditure for the OTC. 
value 
the value of the expected number of tests per individual. 
Accuracy 
the matrix of overall accuracy measures for the algorithm. The rows correspond to 
each disease. The columns correspond to the pooling sensitivity, pooling 
specificity, pooling positive predictive value, and pooling negative predictive value 
for the overall algorithm. Further details are given under 'Details'. 
Configs a data frame containing results for the best configuration for each initial group size 
provided by the user. The columns correspond to the initial group size, configuration (if 
applicable), overall array size (if applicable), expected number of tests, value of the 
objective function per individual, and accuracy measures for each disease. Accuracy 
measures include the pooling sensitivity, pooling specificity, pooling positive predictive 
value, and pooling negative predictive value. No results are displayed if a 
single group.sz is provided. Further details are given under 'Details'. 
Top.Configs a data frame containing results for some of the top configurations for each initial group 
size provided by the user. The columns correspond to the initial group size, configuration, 
expected number of tests, value of the objective function per individual, and accuracy 
measures for each disease. Accuracy measures include the pooling sensitivity, pooling 
specificity, pooling positive predictive value, and pooling negative predictive value. No 
results are displayed for non-informative two-stage hierarchical testing or for array testing 
algorithms. Further details are given under 'Details'. 
Note 
This function returns the pooling positive and negative predictive values for all individuals even though 
these measures are diagnostic specific; e.g., the pooling positive predictive value should only be 
considered for those individuals who have tested positive. 
Additionally, only stage dependent sensitivity and specificity values are allowed within the program (no 
group within stage dependent values are allowed). See Bilder et al. (2019) for additional information. 
Author(s) 
This function was written by Brianna D. Hitt. It calls ET.all.stages.new and PSePSpAllStages, 
which were originally written by Christopher Bilder for Bilder et al. (2019), and ARRAY, which was 
originally written by Peijie Hou for Hou et al. (2020). The 
functions ET.all.stages.new, PSePSpAllStages, and ARRAY were obtained 
from http://chrisbilder.com/grouptesting. Minor modifications were made to the functions for inclusion in 
the binGroup2 package. 
References 
Altman, D., Bland, J. (1994). “Diagnostic tests 1: Sensitivity and specificity.” BMJ, 308, 1552. 
Altman, D., Bland, J. (1994). “Diagnostic tests 2: Predictive values.” BMJ, 309, 102. 
Bilder, C., Tebbs, J., McMahan, C. (2019). “Informative group testing for multiplex assays.”Biometrics, 75, 
278–288. doi: 10.1111/biom.12988. 
Hitt, B., Bilder, C., Tebbs, J., McMahan, C. (2019). “The objective function controversy for group testing: 
Much ado about nothing?” Statistics in Medicine, 38, 4912–4923. doi: 10.1002/sim.8341. 
Hou, P., Tebbs, J., Wang, D., McMahan, C., Bilder, C. (2020). “Array testing with multiplex assays.” To 
appear in Biostatistics. 
McMahan, C., Tebbs, J., Bilder, C. (2012a). “Informative Dorfman Screening.” Biometrics, 68, 287–296. 
doi: 10.1111/j.1541-0420.2011.01644.x. 
See Also 
Other OTC functions: OTC1() 
Other multiplex testing functions: operatingCharacteristics2() 
Examples 
# Estimated running time for all examples was calculated  
#   using a computer with 16 GB of RAM and one core of  
#   an Intel i7-6500U processor. Please take this into  
#   account when interpreting the run times given. 
 
# Find the OTC for non-informative two-stage  
#   hierarchical (Dorfman) testing 
Se <- matrix(data = c(0.95, 0.95, 0.99, 0.99), nrow = 2, ncol = 2, 
             dimnames = list(Infection = 1:2, Stage = 1:2)) 
Sp <- matrix(data = c(0.96, 0.96, 0.98, 0.98), nrow = 2, ncol = 2, 
             dimnames = list(Infection = 1:2, Stage = 1:2)) 
OTC2(algorithm = "D2", p.vec=c(0.90, 0.04, 0.04, 0.02), 
     Se = Se, Sp = Sp, group.sz = 3:30) 
 # Find the OTC over all possible testing configurations  
#   for informative two-stage hierarchical (Dorfman)  
#   testing with a specified group size. 
# A matrix of joint probabilities for each individual is  
#   generated using the Dirichlet distribution. 
# This examples takes approximately 25 seconds to run. 
Se <- matrix(data = rep(0.95, 4), nrow = 2, ncol = 2, 
             dimnames = list(Infection = 1:2, Stage = 1:2)) 
Sp <- matrix(data = rep(0.99, 4), nrow = 2, ncol = 2, 
             dimnames = list(Infection = 1:2, Stage = 1:2)) 
 
set.seed(1002) 
OTC2(algorithm = "ID2", alpha=c(18.25, 0.75, 0.75, 0.25), 
     Se = Se, Sp = Sp, group.sz = 10:20) 
      
# Find the OTC for non-informative three-stage  
#   hierarchical testing. 
# This example takes approximately 1 minute to run. 
Se <- matrix(data = rep(0.95, 6), nrow = 2, ncol = 3, 
             dimnames = list(Infection = 1:2, Stage = 1:3)) 
Sp <- matrix(data = rep(0.99, 6), nrow = 2, ncol = 3, 
             dimnames = list(Infection = 1:2, Stage = 1:3)) 
 
OTC2(algorithm = "D3", p.vec=c(0.95, 0.02, 0.02, 0.01), 
     Se = Se, Sp = Sp, group.sz = 3:20) 
      
# Find the OTC over all possible configurations  
#   for informative three-stage hierarchical  
#   testing with a specified group size  
#   and a heterogeneous matrix of joint  
#   probabilities for each individual.  
set.seed(8791) 
Se <- matrix(data = rep(0.95, 6), nrow = 2, ncol = 3, 
             dimnames = list(Infection = 1:2, Stage = 1:3)) 
Sp <- matrix(data = rep(0.99, 6), nrow = 2, ncol = 3, 
             dimnames = list(Infection = 1:2, Stage = 1:3)) 
p.unordered <- t(rBeta2009::rdirichlet(n = 12,  
                            shape = c(18.25, 0.75, 0.75, 0.25))) 
p.ordered <- p.unordered[, order(1 - p.unordered[1,])] 
OTC2(algorithm="ID3", probabilities = p.ordered, 
         Se=Se, Sp=Sp, group.sz = 12,  
         trace=FALSE, print.time=FALSE) 
                             
# Find the OTC for non-informative array testing  
#   without master pooling. 
Se <- matrix(data = rep(0.95, 4), nrow = 2, ncol = 2, 
             dimnames = list(Infection = 1:2, Stage = 1:2)) 
Sp <- matrix(data = rep(0.99, 4), nrow = 2, ncol = 2, 
             dimnames = list(Infection = 1:2, Stage = 1:2)) 
OTC2(algorithm = "A2", p.vec=c(0.90, 0.04, 0.04, 0.02), 
     Se = Se, Sp = Sp, group.sz = 3:12) 
                   
# Find the OTC for non-informative array testing  
#   with master pooling. 
Se <- matrix(data = rep(0.95, 6), nrow = 2, ncol = 3, 
             dimnames = list(Infection = 1:2, Stage = 1:3)) 
Sp <- matrix(data = rep(0.99, 6), nrow = 2, ncol = 3, 
             dimnames = list(Infection = 1:2, Stage = 1:3)) 
OTC2(algorithm = "A2M", p.vec=c(0.90, 0.04, 0.04, 0.02), 
     Se = Se, Sp = Sp, group.sz = 10,  
     trace=FALSE, print.time=FALSE) 
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Appendix D
Operating characteristics for informative two-stage
hierarchical testing
In Appendix B, we presented derivations of operating characteristics for S-
stage hierarchical testing with the exception of informative two-stage hierar-
chical testing. In this section, we provide derivations for the expected number
of tests and accuracy measures for informative two-stage hierarchical testing.
While this dissertation focuses on the implementation of this algorithm via the
pool-specific optimal Dorfman (PSOD) method described in McMahan et al.
(2012a), the derivations presented here are easily generalizable to other infor-
mative two-stage hierarchical algorithms presented in McMahan et al. (2012a).
McMahan et al. (2012a) presented derivations of operating characteristics
for informative two-stage hierarchical testing. The authors make the assump-
tion that the sensitivity and specificity are not dependent on group size and
use the same diagnostic accuracy for both stages of the testing algorithm.
In the derivations presented here, we allow unequal sensitivity and unequal
specificity values across stages of testing. For consistency in the group testing
literature and associated R functions, we use the same notation and derivation
path as McMahan et al. (2012a) whenever possible.
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D.1. Expected number of tests
Consider an initial block of size N individuals to be tested for a disease. As
in McMahan et al. (2012a), we initially assume that the true probabilities for
each individual are known. The individuals are ordered from lowest to highest
probability of disease and divided into groups of size cj, j = 1, ..., J , so that
group Pj contains the cj lowest risk individuals which remain after constructing
the first j − 1 groups. Let Ij(k) denote the kth ordered individual in the jth
group, for j = 1, ..., J and k = 1, ..., cj, with corresponding probabilities pj(k).
Further, let Gj = 1 (0) denote the positive (negative) test result and let
G˜j = 1(0) denote the positive (negative) true status of the jth group. If
Gj = 0, all individuals in the corresponding group are declared negative. If
Gj = 1, individuals in the corresponding group are individually retested in
the second and final stage of testing. Define Se:1 = P
(
Gj = 1
∣∣∣ G˜j = 1) and
Sp:1 = P
(
Gj = 0
∣∣∣ G˜j = 0) as the test sensitivity and the test specificity
corresponding to the group tests performed in the first stage of the algorithm.
We still assume that the sensitivity and specificity are not dependent on cj.
The probability the jth group is truly positive is
P
(
G˜j = 1
)
= 1−
cj∏
k=1
(
1− pj(k)
)
.
Using the Law of Total Probability, McMahan et al. (2012a) expressed the
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probability of the jth group testing positive as
P (Gj = 1) = P
(
Gj = 1
∣∣∣ G˜j = 0)P (G˜j = 0)+
P
(
Gj = 1
∣∣∣ G˜j = 1)P (G˜j = 1)
= Se + (1− Se − Sp)
cj∏
k=1
(
1− pj(k)
)
.
Substituting Se:1 (Sp:1) for Se (Sp) in the above expression, we can write
P (Gj = 1) = Se:1 + (1− Se:1 − Sp:1)
cj∏
k=1
(
1− pj(k)
)
. (D.1.1)
Let TPj denote the number of tests needed to identify all positive individuals
in group Pj. If cj > 1, then P
(
TPj = 1
)
= P (Gj = 0) and P
(
TPj = cj + 1
)
=
P (Gj = 1). If cj = 1, then P
(
TPj = 1
)
= 1. Using these facts, McMahan
et al. (2012a) expressed the expected number of tests for a block of size N as
E (T ) =
J∑
j=1
E
(
TPj
)
= J +
J∑
j=1
cjI (cj > 1)P (Gj = 1) , (D.1.2)
where I (·) represents the indicator function. Substituting equation (D.1.1)
into equation (D.1.2) gives
E (T ) = J +
J∑
j=1
cjI (cj > 1)
{
Se:1 + (1− Se:1 − Sp:1)
cj∏
k=1
(
1− pj(k)
)}
.
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D.2. Accuracy measures
Let Yj(k) denote the second-stage test outcome and Y˜j(k) denote the true
status of individual Ij(k), so that P
(
Y˜j(k) = 1
)
= pj(k). As in McMahan
et al. (2012a), we adopt the assumption that true individual statuses are
independent random variables. Define Se:2 = P
(
Yj(k) = 1
∣∣∣ Y˜j(k) = 1) and
Sp:2 = P
(
Yj(k) = 0
∣∣∣ Y˜j(k) = 0) as the test sensitivity and the test speci-
ficity corresponding to the individual testing conducted in the second stage
of the algorithm. Let I+j(k)
(
I−j(k)
)
denote the event that individual Ij(k) is
classified as positive (negative) by the PSOD algorithm. The pooling sen-
sitivity for individual Ij(k) is the probability of a correct positive diagnosis,
PS
Ij(k)
e = P
(
I+j(k)
∣∣∣ Y˜j(k) = 1). The pooling specificity for individual Ij(k) is
the probability of a correct negative diagnosis, PS
Ij(k)
p = P
(
I−j(k)
∣∣∣ Y˜j(k) = 0).
We derive expressions for PS
Ij(k)
e and PS
Ij(k)
p when cj > 1, and we assume that
the diagnostic test results are independent, conditional on the true status of
the group (or individual) being tested (McMahan et al., 2012a). Additional
discussion of the conditional independence assumption is available in Litvak
et al. (1994).
D.2.1. Pooling sensitivity
For informative Dorfman testing, individual Ij(k) is categorized as positive
when both its group test and individual test are positive. McMahan et al.
(2012a) showed that an individual's pooling sensitivity can be rewritten as
PS
Ij(k)
e = P
(
Gj = 1
∣∣∣ Y˜j(k) = 1)P (Yj(k) = 1 ∣∣∣ Gj = 1, Y˜j(k) = 1)
= S2e .
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This derivation uses the conditional independence assumption previously men-
tioned in Section D.1 to result in the product of the sensitivities at each stage
of the algorithm. Allowing for Se to differ across the stages of the algorithm,
the pooling sensitivity simply becomes
PS
Ij(k)
e = Se:1Se:2.
D.2.2. Pooling specificity
We now consider the pooling specificity. Individual Ij(k) can be categorized as
negative in two situations: 1) its group test is negative, or 2) its group test is
positive but its individual test is negative. McMahan et al. (2012a) expressed
the pooling specificity for an individual as
PS
Ij(k)
p = P
(
Gj = 0
∣∣∣ Y˜j(k) = 0)+
P
(
Gj = 1, Yj(k) = 0
∣∣∣ Y˜j(k) = 0) . (D.2.1)
Using the Law of Total Probability, McMahan et al. (2012a) wrote the first
term in equation (D.2.1) as
P
(
Gj = 0
∣∣∣ Y˜j(k) = 0)
= P
(
Gj = 0
∣∣∣ G˜j = 0)P (G˜j = 0 ∣∣∣ Y˜j(k) = 0)+
P
(
Gj = 0
∣∣∣ G˜j = 1)P (G˜j = 1 ∣∣∣ Y˜j(k) = 0) .
Using the definitions for Se:1 and Sp:1, we can write
P
(
Gj = 0
∣∣∣ Y˜j(k) = 0)
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= Sp:1
{
1− P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0)}+
(1− Se:1)P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0)
Sp:1 + (1− Se:1 − Sp:1)P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0) . (D.2.2)
Note that P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0) represents the probability that at least one
individual in the jth group, other than the kth ordered individual, is truly
positive. This can be written as
P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0) = 1− ∏
k′∈A(k)j
(
1− pj(k′)
)
, (D.2.3)
where A
(k)
j = {1, ..., k − 1, k + 1, ..., cj}. Substituting equation (D.2.3) into
equation (D.2.2) gives
P
(
Gj = 0
∣∣∣ Y˜j(k) = 0)
= Sp:1 + (1− Se:1 − Sp:1)
1−
∏
k′∈A(k)j
(
1− pj(k′)
)
= (1− Se:1)− (1− Se:1 − Sp:1)
∏
k′∈A(k)j
(
1− pj(k′)
)
. (D.2.4)
McMahan et al. (2012a) expressed the second term in equation (D.2.1) as
P
(
Gj = 1, Yj(k) = 0
∣∣∣ Y˜j(k) = 0)
= P
(
Gj = 1
∣∣∣ Y˜j(k) = 0)P (Yj(k) = 0 ∣∣∣ Gj = 1, Y˜j(k) = 0) .
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Allowing for unequal sensitivity and unequal specificity values across stages of
testing, we can write
P
(
Gj = 1, Yj(k) = 0
∣∣∣ Y˜j(k) = 0)
= P
(
Gj = 1
∣∣∣ Y˜j(k) = 0)Sp:2
= Sp:2
{
P
(
Gj = 1
∣∣∣ G˜j = 0)P (G˜j = 0 ∣∣∣ Y˜j(k) = 0)+
P
(
Gj = 1
∣∣∣ G˜j = 1)P (G˜j = 1 ∣∣∣ Y˜j(k) = 0)}
= Sp:2
[
(1− Sp:1)
{
1− P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0)}+
Se:1P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0)]
= Sp:2
[
(1− Sp:1)− (1− Se:1 − Sp:1)P
(
G˜j = 1
∣∣∣ Y˜j(k) = 0)] .
Substituting equation (D.2.3) into the above equation gives
P
(
Gj = 1, Yj(k) = 0
∣∣∣ Y˜j(k) = 0)
= Sp:2
(1− Sp:1)− (1− Se:1 − Sp:1)×
1−
∏
k′∈A(k)j
(
1− pj(k′)
)

= Se:1Sp:2 + (1− Se:1 − Sp:1)Sp:2
∏
k′∈A(k)j
(
1− pj(k′)
)
. (D.2.5)
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Substituting equations (D.2.4) and (D.2.5) into equation (D.2.1), we get
PS
Ij(k)
p = (1− Se:1)− (1− Se:1 − Sp:1)
∏
k′∈A(k)j
(
1− pj(k′)
)
+
Se:1Sp:2 + (1− Se:1 − Sp:1)Sp:2
∏
k′∈A(k)j
(
1− pj(k′)
)
= 1− (1− Sp:2)
Se:1 +
(1− Se:1 − Sp:1)
∏
k′∈A(k)j
(
1− pj(k′)
) .
The pooling positive predictive value is defined as PPPV Ij(k) =
P
(
Y˜j(k) = 1
∣∣∣ I+j(k)) and the pooling negative predictive value is defined as
PNPV Ij(k) = P
(
Y˜j(k) = 0
∣∣∣ I−j(k)). Expressions for these values follow from
those given in McMahan et al. (2012a).
